Title: Spiro-compounds as SIP modulators

The invention relates to spiro compounds with affinity to SIP receptors, pharmaceutical compositions comprising such compounds, the use of such compounds in the treatment or alleviation of diseases and disorders in which an SIP receptor is involved or in which modulation of the endogenous SIP signaling system via an SIP receptor is involved and the preparation of a medicament for treating or alleviating such diseases and disorders. Background of the invention

Sphingosine-l-phosphate (SIP) is part of the sphingolipid class of molecules. SIP is a bioactive sphingolipid that mediates a wide variety of cellular responses, such as proliferation, autophagy, blockade of apoptosis, cell

differentiation, blockade of cell senescence, cytoskeletal organization and migration, adherence- and tight junction assembly, and morphogenesis. Moreover, SIP is a modulator of APP processing via BACE1 regulation as well as lipid raft formation and can interact with ABC transporters thereby modulating cellular in- and efflux. SIP can bind with members of the endothelial cell differentiation gene family (EDG receptors) of plasma membrane-localized G protein-coupled receptors. To date, five members of this family have been identified as SIP receptors in different cell types, SlPl (EDG-1), S1P2 (EDG-5), S1P3 (EDG-3), S1P4 (EDG-6) and S1P5 (EDG-8). SIP can produce cytoskeletal re-arrangements in many cell types to regulate immune cell trafficking, vascular homeostasis and cell

communication in the central nervous system (CNS) and in peripheral organ systems. The above mentioned actions of SIP are mediated by interaction with its receptors. Therefore, SIP receptors are therapeutic targets for the treatment of, for example, neoplastic diseases, diseases of the central and peripheral nervous system, autoimmune disorders and tissue rejection in transplantation.

It is known that SIP is secreted by vascular endothelium and is present in blood at concentrations of 200-900 nanomolar and is bound by albumin and other plasma proteins. This provides both a stable reservoir in extracellular fluids and efficient delivery to high-affinity cell-surface receptors. SIP binds with low nanomolar affinity to the five receptors S1P1-5. In addition, platelets also contain SIP and may be locally released to cause e.g. vasoconstriction. The receptor subtypes S1P1, S1P2 and S1P3 are widely expressed and represent dominant receptors in the cardiovascular system. Further, S1P1 is also a receptor on lymphocytes. S1P4 receptors are almost exclusively in the haematopoietic and lymphoid system. S1P5 is primarily (though not exclusively) expressed in central nervous system (CNS; brain and spinal cord). Other tissues with S1P5 expression are skin and spleen. Moreover, S1P5 is expressed on NK cells. Early study showed that the CNS expression in mice appeared restricted to oligodendrocytes, while in men and rats expression was more diverse. Recent evidence has shown a broader distribution in all species: S1P5 expression is shown at the level of astrocytes, endothelial cells, glial cells, oligodendrocytes and to a lesser extent neurons.

The present invention relates to modulators of the S1P5 receptor, in particular agonists, and preferably to agonists with selectivity over S1P1, S1P3 and/or S1P4 receptors, in view of unwanted cardiovascular and/or peripheral immune- modulatory effects. It has now been found that S1P5 agonists can be used in the treatment of cognitive disorders, in particular age-related cognitive decline. Moreover, evidence has shown an impact on amyloid 6 (protein) processing, ABC transporter expression, blood-brain-barrier integrity, neuro-inflammatory processes, and (sphingo)lipid content in the CNS.

The latter is of high relevance as an altered sphingolipid metabolism is strongly implicated in several neurodegenerative and cognitive diseases. A comparison of CNS gene expression profiles of normal and Alzheimer's Disease (AD) patients indicated that genes responsible for SIP degradation were strongly upregulated, including the phosphatidic acid phosphatase PPAP2A and SIP lyase genes, while genes for ceramide production (apoptotic sphingolipid) were upregulated (Katsel et al, 2007, Neurochem Res, 32, 845-856). These gene expression data are predictive of actual changes in enzyme and lipid levels in the brain and cerebrospinal fluid (CSF): compared to normal subjects, AD brain are characterized by higher levels of ceramide and cholesterol as well as decreased levels of SIP. These changes also correlate with disease severity of the patients and are related to levels of Amyloid 6 and Tau, two hallmarks of Alzheimer's Disease (Cutler et al, 2004, PNAS, 101, 2070-2075; He et al, 2010, Neurobiol. Aging, 31, 398-408; Koal et al, 2015, J. Alz Disease, 44, 1193-1201). The same changes have been reported in brain tissues (and CSF) from patients suffering HIV dementia, Amyotrophic Lateral Sclerosis (ALS), Parkinson's Disease, Parkison's Disease with Lewy Bodies, Multiple Sclerosis, Huntington's Disease, and several

sphingolipdidosis disorders (Lysosomal Storage Disorders) such as Niemann Pick Disease and Gauchers (Cutler et al, 2002, Ann Neurol, 52, 448-457; Haughey et al, 2004, Ann Neurol, 55, 257-267; Cutler et al, 2010, Neurol, 63, 636-630; Mielke et al, 2013, PLOS ONE, 8; Bras et al, 2008, FEBS Journal, 275, 5767-5773; Vidaurre et al, 2014, Brain, 137, 2271-2286; Fan et al, 2013, J Lipid Research, 54, 2800- 2814). Modulating the activity of the S1P5 receptor in the central nervous system may be a therapeutic method for such neurodegenerative or cognitive disorders by shifting the ceramide/SlP balance towards SIP effects and away from ceramide- mediated cell death.

Soluble 6-amyloid (A6) oligomers are considered the proximate effectors of synaptic injury and neuronal death occurring in AD. A6 induces increased ceramide levels and oxidative stress in neuronal cultures, leading to apoptosis and cell death. SIP is a potent neuroprotective factor against this A6-induced damage, consistent with its role as ceramide's counterpart (Cutler et al, 2004, PNAS, 101, 2070-2075, Malaplate-Armand, 2006, Neurobiol. Dis, 23, 178-189). A6 is also proinflammatory, inducing the migration of monocytes to sites of injury, and the S1P1, S1P3, S1P4, S1P5 agonist FTY720/Fingolimod inhibits such migration. A6 is known to induce expression of S1P2 and S1P5, but not of S1P1, S1P3 and S1P4 (Kaneider et al, 2004, FASEB). The actions of FTY720/FIngolimod and those expressed by monocytes suggest these effects are mediated by the S1P5 receptor. The same applies to more recent findings that FTY720/Fingolimod is able to modulate A6-induced memory deficits (Fukumoto et al, 2014, Beh Brain Res, 268, 88-93).

Additional studies suggest a role for SIP in modulating pain signals. In example, SIP modulates action potentials in capsaicin-sensitive sensory neurons (Zhang et al, 2006, J Physiol, 575, 101-113) and SIP levels are known to be decreased in CSF in acute and inflammatory pain models (Coste et al, 2008, J Biol Chem, 283, 32442-32451). The S1P1, S1P3, S1P4, S1P5 receptor agonist

FTY720/Fingolimod is indeed able to reduce nociceptive behavior in neuropathic pain models (Coste et al, 2008, 12, 995-1004), while the selective S1P1 agonist SEW2817 fails to have an effect. Given the high CNS expression of S1P5 and lack of effects of SIP 1 agonism, the effects can be contributed to effects on the S1P5 receptor.

In summary, potent and selective agents that are agonists of the S1P5 receptor will be beneficial for the treatment of cognitive disorders,

neurodegenerative disorders and pain. In particular, SlP5-selective ligands would be beneficial for these diseases by not engaging the S1P1, S1P3 and/or S1P4 receptor ensuring a lack of peripheral immune suppression and cardiovascular side-effects.

WO 2012/004373 describes SIP receptor modulators containing a fused heterocyclic core. This fused heterocyclic core structurally differs from the compounds of the present invention in the size and position of the rings

constituting the core and the type and number of heteroatoms present in the rings.

WO 2012/004378 also describes SIP receptor modulators containing a core comprising a fused bicyclic ring structure. These compounds structurally differ from the compounds of the present invention in the position of the ring structures relative to each other, resulting in differences in overall three-dimensional configuration of the chemical structure. Other differences are in the size of the ring structures and the heteroatoms present in the ring structure.

Currently, there is still a need for new, potent SIP receptor modulators, in particular selective S1P5 receptor modulators.

Summary of the invention

It is an object of the present invention to provide S1P5 receptor modulators, in particular agonists, preferably to agonists with selectivity over in particular S1P1, S1P3 and/or S1P4 receptors to avoid unwanted cardiovascular and/or immunomodulatory effects. It is a further object of the invention to provide a method for treatment or alleviation of a variety of CNS disorders, such as cognitive disorders, in particular age-related cognitive decline. The invention therefor provides a compound of formula (I):

or a pharmaceutically acceptable salt thereof, wherein

X is CH ₂ or O;

m and n are independently 0 or 1;

Rl is selected from the group consisting of -(Cl-4)alkylene-R2, -(C3- 6)cycloalkylene-R2, -(Cl-3)alkylene-(C3-6)cycloalkylene-R2 and -(C3- 6)cycloalkylene-(Cl-3)alkylene-R2, wherein the (Cl-4)alkylene is optionally substituted with up to 3 carbon atoms, with (CH2)2 to form a cyclopropyl moiety or with (CH2)3 to form a cyclobutyl moiety and wherein R2 is selected from the group consisting of -COOH, -OH, -OPO3H2, -PO3H2, -COO(Cl-4)alkyl and tetrazol-5-yl;

L is attached to atom 1, 2, 3 or 4 and is a group -W-(CH2)p-T- wherein:

W is attached to the phenylene moiety and selected from the group consisting of -0-, -CO-, -S-, -SO-, -SO2-, -NH-, -CH ₂ -CH2-,-CF2-CH ₂ -, -CH2-CF2-, -CH=CH- , -C(CF ₃ )=CH-, -CH=C(CF ₃ )-, -C≡C-, phenyl, -(C3-7)cycloalkyl-, -pyridyl-, - thienyl- and -thiazolyl-, wherein the phenyl, (C3-7)cycloalkyl, pyridyl, thienyl or thiazolyl is optionally substituted with one or more substituents

independently selected from the group consisting of a halogen atom, hydroxy, (Cl-4)alkyl optionally substituted with one or more halogen atoms, and (Cl- 4)alkoxy optionally substituted with one or more halogen atoms;

p is 0 or an integer from 1 to 4; and

T is absent or attached to R3 and selected from the group consisting of -0-, - 0-(Cl-4)alkyl-, -S-, -SO-, -SO2-, -NH-, -CO-, -CH=CH-, -C≡C- and

cyclopropylene;

R3 is selected from the group consisting of(C3-6)cycloalkyl, (C4-6)cycloalkenyl, phenyl, biphenyl, naphthyl, a monocyclic heterocycle and a 8-10 membered fused bicyclic group, each optionally substituted with one or more substituents

independently selected from the group consisting of:

o halogen, o cyano,

o (Cl-6)alkyl optionally substituted with one or more fluoro atoms, o (Cl-4)alkoxy optionally substituted with one or more fluoro atoms or with (C3-6)cycloalkyl,

o (C3-6)cycloalkoxy optionally substituted with one or more fluoro atoms; o -S-(Cl-4)-alkyl,

o -SF ₅ ,

o phenoxy, benzyl or benzyloxy, and

o (C3-8)cycloalkyl optionally substituted with phenyl, (Cl-4)alkyl, (Cl-

4)alkoxy or a halogen atom;

R4 is absent or selected from the group consisting of a halogen atom, (Cl-4)alkyl optionally substituted with one or more halogen atoms, and (Cl-4)alkoxy optionally substituted with one or more halogen atoms.

In a further aspect the invention provides a pharmaceutical composition comprising a compound according to the invention or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable auxiliary.

In a still further aspect the invention provides a method of treatment or alleviation of a disease or disorder in which an SIP receptor is involved or in which modulation of the endogenous SIP signaling system via an SIP receptor is involved, preferably S1P5, comprising administering to a patient in need thereof a compound according to the invention or a pharmaceutically acceptable salt thereof.

In a still further aspect the invention provides a use of a compound according to the invention or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for the treatment or alleviation of a disease or disorder in which an SIP receptor is involved or in which modulation of the endogenous SIP signaling system via an SIP receptor is involved, preferably S1P5 receptor.

In a still further aspect the invention provides a compound according to the invention or a pharmaceutically acceptable salt thereof for use in therapy.

In a still further aspect the invention provides a compound according to the invention or a pharmaceutically acceptable salt thereof for use in the treatment or alleviation of a disease or disorder in which an SIP receptor is involved or in which modulation of the endogenous SIP signaling system via an SIP receptor is involved, preferably S1P5.

Detailed description of the invention

The compounds of the invention are modulators of the SIP receptor, in particular of the S1P5 receptor. More specifically, the compounds of the invention are S1P5 receptor agonists. The compounds of the invention and their

pharmaceutically acceptable salts are in particular suitable for agonizing S1P5 in a subject suffering from a disorder in which modulation of S1P5 activity and the subsequent ceramide/SlP axis is beneficial. Administration of such compound to a subject is preferably such that S1P5 activity in the subject is altered and treatment is achieved. The compounds of the present invention are particularly suitable to treat or alleviate diseases and disorder s in which an SIP receptor is involved or in which modulation of the endogenous SIP signaling system via an SIP receptor is involved. In particular the compounds of the present invention are suitable to treat or alleviate a disorder or disorder selected from the group consisting of Alzheimer's Disease (AD) and associated dementia's, amyloid 6-associated disorders, Mild Cognitive Impairment (MCI), Parkinson's Disease (PD), Lewy Body Dementia (LBD), Progressive Supranuclear Palsy (PSP), Cerebral Palsy (CP), Amyotrophic Lateral Sclerosis (ALS), Frontal Temporal Lobe Dementia (FTLD), multiple sclerosis, Huntington's Disease, neurological symptoms of sphingolipidosis disorders, a lysosomal storage disorder including Tay Sachs Disease, Sandhoff Disease, Fabry's Disease, Krabbe Disease, Gaucher's Disease, Niemann Pick A, B or C, and Batten's Disease, stroke, HIV-associated Dementia (HAD), HIV-associate Neurocognitive Disorder (HAND), HIV-associated neuropathy, schizophrenia, cognitive deficits in Schizophrenia, an attention deficit disorder including Anxiety Attention Deficit Disorder and Attention Deficit Hyperactivity Disorder (ADHD), a bipolar disorder, Obsessive- Compulsive Behavior, pain including neuropathic, back pain and pain-associated with multiple sclerosis, spinal cord injury, Parkinson's Disease, epilepsy, diabetes and cancer, cancer-induced peripheral neuropathy

(CIPN), depression, treatment-resistant depression, Creutzfeld- Jakob Disease and other Prion-related Disorders, Down's Syndrome, autism, age-related cognitive decline or memory impairment, cognitive deficits associated with diabetes, dementia, dementia associated with Down's Syndrome, cognitive deficits in psychiatric disorders, dementia associated with Lewy Body pathology, diminished CNS function associated with traumatic brain injury, Pick's Disease, spinal cord injury, a demyelinating disorder, a disorder of basal ganglia and AIDS-associated dementia. Given the neuro-inflammatory actions of SIP receptors, and S1P5 in specific, as well as the peripheral localization of S1P5 in skin tissue and a role in endothelial function and NK cells, the compounds of the invention are further suitable to treat or alleviate a disease with a neuro-inflammatory component, in particular a disease or disorder selected from the group consisting of Psoriasis type 1 and type 2, atopic dermatitis, dermatitis scleroderma, insulin- dependent diabetes mellitus, ulcerative colitis, atherosclerosis, sepsis syndrome, septic shock, Dengue hemorrhagic fever, Dengue, atopic allergy, HIV/AIDS, barrier-integrity associated lung diseases, leukemia, contact dermatitis, encephalomyelitis, Epstein Barr virus infection and other virus infections requiring cell-cell fusion.

In the compounds of the invention, or pharmaceutically acceptable salts thereof, m is 0 or 1 and n is 0 or 1. The nitrogen containing ring preferably is a 4- membered or 6-membered ring. Hence, preferably m and n are both 0 or both 1. In one embodiment, m and n are both 1 and the compound has the formula (lb):

formula (lb).

Most preferably m and n are both 0 and the compound has the formula (la):

formula (la).

In one embodiment X is O. In a preferred embodiment, X is CH2. In the compounds of the invention, or pharmaceutically acceptable salts thereof, L is attached to one of the atoms numbered 1, 2, 3 or 4. Preferably, the group L-R3 is attached to one of the carbon atoms numbered 2 or 3. Hence, formula (I is preferably selected from formula (Ic) and formula (Id) :

formula (Ic) formula (Id)

In a further preferred embodiment, formula (I) is selected from formula (Ie) and

formula (Ie) formula (If)

In a particularly preferred embodiment, a compound of the invention is a compound of formula (Ie).

L is a group -W-(CH2)p-T- wherein:

W is attached to the phenylene moiety and selected from the group consisting of -0- , -CO-, -S-, -SO-, -SO2-, -NH-, -CH2-CH2-, -CF2-CH2-, -CH2-CF2-, -CH=CH-, - C(CF ₃ )=CH-, -CH=C(CF ₃ )-, -C≡C-, phenyl, -(C3-7)cycloalkyl-, -pyridyl-, -thienyl- and -thiazolyl-, wherein the phenyl, (C3-7)cycloalkyl, pyridyl, thienyl or thiazolyl is optionally substituted with one or more substituents independently selected from the group consisting of a halogen atom, hydroxy, (Cl-4)alkyl optionally substituted with one or more halogen atoms, and (Cl-4)alkoxy optionally substituted with one or more halogen atoms;

p is 0 or an integer from 1 to 4; and

T is absent or attached to R3 and selected from the group consisting of -0-, -0-(Cl- 4)alkyl-, -S-, -SO-, -SO2-, -NH-, -CO-, -CH=CH-, -C≡C- and cyclopropylene;

Preferably, W is selected from the group consisting of -0-, -CO-, -S-, - SO-, -SO2-, -CH2-CH2-, -CF2-CH2-, -CH2-CF2-, -CH=CH-, -C(CF ₃ )=CH-, -CH=C(CF ₃ )- , -C≡C-, and -phenyl-, p is 0, or an integer from 1 to 4 and T is absent or selected from the group consisting of -O- and -0-(Cl-4)alkyl-.

In a particular embodiment, T is -O- or -0-(Cl-4)alkyl-, preferably -O- or -O-CH2-, if W is selected from the group consisting of -O- and optionally substituted -phenyl, -(C3-7)cycloalkyl-, -pyridyl-, -thienyl- or -thiazolyl-. Otherwise, i.e. if W is - CO-, -S-, -SO-, -SO2-, -NH-, -CH2-CH2-, -CF2-CH2-, -CH2-CF2-, -CH=CH-, - C(CF ₃ )=CH-, -CH=C(CF ₃ )- or -C≡C-, T is preferably absent.

In a further preferred embodiment, L is selected from the group consisting of -(C2-4)alkyl-, -0-, -0-(Cl-3)alkyl-, -0-(Cl-4)alkyl-0-, -phenyl-(Cl- 4)alkyl-, -phenyl-0-(Cl-4)alkyl-, -CH=CH- and -C≡C-, more preferably from the group consisting of -(C2-4)alkyl-, -0-, -0-(Cl-3)alkyl-, -0-(CH ₂ ) ₂ -0-, -phenyl-0-CH ₂ - and -C≡C-.

Rl is selected from the group consisting of -(Cl-4)alkylene-R2, -(C3- 6)cycloalkylene-R2, -(Cl-3)alkylene-(C3-6)cycloalkylene-R2 and -(C3-

6)cycloalkylene-(Cl-3)alkylene-R2, wherein the (Cl-4)alkylene is optionally substituted with up to 3 carbon atoms, with (CH2)2 to form a cyclopropyl moiety or with (CH2)3 to form a cyclobutyl moiety. Preferably Rl is -(Cl-3)alkylene-R2 or -

(C3-6)cycloalkylene-R2, wherein the (Cl-3)alkylene is optionally substituted with up to two CH3 groups, with (CH2)2 to form a cyclopropyl moiety or with (CH2)3 to form a cyclobutyl moiety.

In a preferred embodiment, Rl is selected from the group consisting of -

R2

-R2, -(CH ₂ ) ₂ -R2, -CH(CH ₃ )-CH ₂ -R2, -CH2-C(CH ₃ )-CH ₂ -R2, and -l,3-cyclobutylene-R2.

In a further preferred embodiment, Rl is selected from the group consisting of -l,3-cyclobutylene-R2 and -(Cl-3)alkylene-R2, wherein the (Cl)alkyl is unsubstituted and the (C2)alkyl and the (C3)alkyl are substituted with up to two CH3 groups, with (CH2)2 to form a cyclopropyl moiety or with (CH2)3 to form a cyclobutyl moiety.

In a further preferred embodiment, Rl is selected from the group consisting of -CH2-R2, -C2-alkylene-R2 wherein the C2-alkylene is substituted with up to two CH3 groups, with (CH2)2 to form a cyclopropyl moiety or with (CH2)3 to form a cyclobutyl moiety, -C3-alkylene-R2 wherein the alkylene is substituted with one CH3 group, and -(C3-6)cycloalkylene-R2. In a particularly preferred

emb elected from the group consisting of -CH2-R2, -CH2-C(CH3)-

CH2 and -l,3-cyclobutylene-R2, wherein R2 is preferably COOH. In

R2>

a further particularly preferred embodiment, Rl is -CH2-R2, ^—^ or -1,3- cyclobutylene-R2, wherein R2 is COOH.

R2 is selected from the group consisting of -COOH, -OH, -OPO3H2, - PO3H2, -COO(Cl-4)alkyl and tetrazol-5-yl. R2 is preferably selected from the group consisting of -OH, -COOH and -COO(Cl-4)alkyl. In a particularly preferred embodiment, R2 is -COOH.

R3 is selected from the group consisting of (C3-6)cycloalkyl, (C4- 6)cycloalkenyl, phenyl, biphenyl, naphthyl, a monocyclic heterocycle and a 8-10 membered fused bicyclic group, each optionally substituted with one or more substituents independently selected from the group consisting of:

o halogen,

o cyano,

o (Cl-6)alkyl optionally substituted with one or more fluoro atoms, o (Cl-4)alkoxy optionally substituted with one or more fluoro atoms or with (C3-6)cycloalkyl,

o (C3-6)cycloalkoxy optionally substituted with one or more fluoro atoms; o -S-(Cl-4)-alkyl,

o -SF ₅ ,

o phenoxy, benzyl or benzyloxy, and

o (C3-8)cycloalkyl optionally substituted with phenyl, (Cl-4)alkyl, (Cl- 4)alkoxy or a halogen atom.

Preferably, R3 is selected from the group consisting of (C3-6)cycloalkyl, (C4-6)cycloalkenyl, phenyl, a monocyclic heterocycle and a 8-10 membered fused bicyclic group, each optionally substituted with one or more substituents, preferably 1 to 3 substituents, independently selected from the group consisting of:

o halogen,

o cyano,

o (Cl-4)alkyl optionally substituted with one or more fluoro atoms, o (Cl-4)alkoxy optionally substituted with one or more fluoro atoms or with (C3-6)cycloalkyl,

o (C3-6)cycloalkoxy optionally substituted with one or more fluoro atoms; and

o (C3-8)cycloalkyl optionally substituted with (Cl-4)alkyl, (Cl-4)alkoxy or a halogen atom.

More preferably, R3 is selected from the group consisting of: o (C3-6)cycloalkyl, preferably cyclohexyl, optionally substituted with (Cl- 4)alkyl;

o monocyclic heterocycle, preferably oxanyl or pyridyl, most preferably pyridyl, optionally substituted with 1 or 2 substituents independently selected from the group consisting of:

• halogen,

• cyano,

• (Cl-4)alkyl optionally substituted with one or more fluoro atoms,

• (Cl-4)alkoxy optionally substituted with one or more fluoro atoms or with (C3-6)cycloalkyl,

• (C3-5)cycloalkoxy optionally substituted with one or more fluoro atoms; and

• (C3-6)cycloalkyl optionally substituted with (Cl-4)alkyl, (Cl-4)alkoxy or a halogen atom;

o indanyl, optionally substituted with one or two halogen atoms;

o 8-10 membered fused bicyclic group, preferably 2,3-dihydrobenzofuranyl, or indanyl, optionally substituted with one or two halogen atoms; o phenyl optionally substituted with 1 to 3 substituents independently selected from the group consisting of:

• halogen,

• cyano, • (Cl-4)alkyl optionally substituted with one or more fluoro atoms,

• (Cl-4)alkoxy optionally substituted with one or more fluoro atoms or with (C3-6)cycloalkyl,

• (C3-5)cycloalkoxy optionally substituted with one or more fluoro atoms; and

• (C3-6)cycloalkyl optionally substituted with (Cl-4)alkyl, (Cl-4)alkoxy or a halogen atom.

In a further preferred embodiment, R3 is selected from the group consisting of:

· phenyl, indanyl, indolyl, oxanyl or pyridyl , optionally substituted with one or more substituents independently selected from the group consisting of: o a halogen atom,

o (Cl-4)alkyl optionally substituted with one or more fluoro atoms, o (Cl-4)alkoxy optionally substituted with one or more fluoro atoms or with (C3-6)cycloalkyl, (C3-6)cycloalkoxy optionally substituted with one or more fluoro atoms, and

• 2,3-dihydrobenzofuranyl or 1,3-dioxaindanyl.

A particularly preferred R3 is pyridyl, optionally substituted with 1 or 2 substituents independelty selected from the group consisting of halogen, cyano, (Cl 4)alkyl optionally substituted with one or more fluoro atoms, (Cl 4)alkoxy optionally substituted with one or more fluoro atoms or with (C3-6)cycloalkyl, (C3-

5) cycloalkoxy optionally substituted with one or more fluoro atoms, and (C3

6) cycloalkyl optionally substituted with (Cl-4)alkyl, (Cl-4)alkoxy or a halogen atom. Such optionally substituted pyridyl is further preferably attached to the cyclic core via linker -O-CH2-, whereby the -CH2- is attached to R3.

R4 is absent or is attached to atom 1, 2, 3 or 4 and selected from the group consisting of a halogen atom, (Cl-4)alkyl optionally substituted with one or more halogen atoms, and (Cl-4)alkoxy optionally substituted with one or more halogen atoms. Preferably, R4 is absent or a halogen atom. In a particularly preferred embodiment, R4 is absent. Further particularly preferred compounds of the invention are compounds of formula (I), preferably formula (Ic) or (Id) , or pharmaceutically acceptable saltsthereof, wherein

X is CH ₂ or O;

m and n are both 0 or both 1, preferably both 0;

Rl is selected from the group consisting of -CH2-R2, -C2-alkyli wherein the C2-alkylene is substituted with up to two carbon atoms, with (CH2)2 to form a cyclopropyl moiety or with (CH2)3 to form a cyclobutyl moiety, and -(C3- 6)cycloalkylene-R2, wherein R2 is selected from the group consisting of -COOH, - OH, -OPO3H2, -PO3H2, -COO(Cl-4)alkyl and tetrazol-5-yl, preferably from the group consisting of -OH, -COOH and -COO(Cl-4)alkyl;

L is attached to atom 1, 2, 3 or 4, preferably to atom 2 or 3, and is a group -W-(CH2)p-T- wherein:

W is attached to the phenylene moiety and selected from the group consisting of -0-, -CO-, -S-, -SO-, -SO2-, -CH2-CH2-, -CF2-CH2-, -CH2-CF2-, -CH=CH- , -C(CF ₃ )=CH-, -CH=C(CF ₃ )-, -C≡C-, and -phenyl-,

p is 0, or an integer from 1 to 4 and

T is absent or selected from the group consisting of -O- and -0-(Cl-

4)alkyl-;

R3 is selected from the group consisting of (C3-6)cycloalkyl, (C4-

6)cycloalkenyl, phenyl, a monocyclic heterocycle and a 8-10 membered fused bicyclic group, each optionally substituted with one or more substituents, preferably 1 to 3 substituents, independently selected from the group consisting of:

o halogen,

o cyano,

o (Cl 4)alkyl optionally substituted with one or more fluoro

atoms,

o (Cl 4)alkoxy optionally substituted with one or more fluoro atoms or with (C3-6)cycloalkyl,

o (C3-6)cycloalkoxy optionally substituted with one or more

fluoro atoms; and

o (C3 8)cycloalkyl optionally substituted with (Cl-4)alkyl, (Cl- 4)alkoxy or a halogen atom; R4 is absent or selected from the group consisting of a halogen atom, (Cl-4)alkyl optionally substituted with one or more halogen atoms, and (Cl- 4)alkoxy optionally substituted with one or more halogen atoms.

Further particularly preferred compounds of the invention are compounds of formula (Ie), or pharmaceutically acceptable salts thereof,

wherein

X is CH ₂ or O;

Rl is selected from the group consisting of -CH2-R2, -C2-alkylene-R2 wherein the C2-alkylene is substituted with up to two carbon atoms, with (CH2)2 to form a cyclopropyl moiety or with (CH2)3 to form a cyclobutyl moiety, -C3-alkylene- R2 wherein the 3alkylene is substituted with one carbon atom, and -(C3- 6)cycloalkylene-R2, wherein R2 is selected from the group consisting of -COOH, - OH, -OPO3H2, -PO3H2, -COO(Cl-4)alkyl and tetrazol-5-yl, preferably from the group consisting of -OH, -COOH and -COO(Cl-4)alkyl;

L is a group -W-(CH2)p-T- wherein:

W is attached to the phenylene moiety and selected from the group consisting of -O-, -CO-, -S-, -SO-, -SO2-, -CH2-CH2-, -CF2-CH2-, -CH2-CF2-, -CH=CH- , -C(CF ₃ )=CH-, -CH=C(CF ₃ )-, -C≡C-, and -phenyl-,

p is 0, or an integer from 1 to 4 and

T is absent or selected from the group consisting of -O- and -0-(Cl-

4)alkyl-;

R3 is selected from the group consisting of:

o (C3-6)cycloalkyl, preferably cyclohexyl, optionally substituted with (Cl- 4)alkyl;

o monocyclic heterocycle, preferably oxanyl or pyridyl, optionally substituted with 1 or 2 substituents independently selected from the group consisting of:

• halogen,

cyano, • (Cl-4)alkyl optionally substituted with one or more fluoro atoms,

• (Cl-4)alkoxy optionally substituted with one or more fluoro atoms or with (C3-6)cycloalkyl,

• (C3-5)cycloalkoxy optionally substituted with one or more fluoro atoms; and

• (C3-6)cycloalkyl optionally substituted with (Cl-4)alkyl, (Cl-4)alkoxy or a halogen atom,

o indanyl, optionally substituted with one or two halogen atoms

o 8-10 membered fused bicyclic group, preferably 2,3-dihydrobenzofuranyl, indanyl, indoly or 1,3-dioxaindanyl, optionally substituted with one or two halogen atoms;

o phenyl optionally substituted with 1 to 3 substituents independently

selected from the group consisting of:

• halogen,

· cyano,

• (Cl-4)alkyl optionally substituted with one or more fluoro atoms,

• (Cl-4)alkoxy optionally substituted with one or more fluoro atoms or with (C3-6)cycloalkyl,

• (C3-5)cycloalkoxy optionally substituted with one or more fluoro atoms; and

• (C3-6)cycloalkyl optionally substituted with (Cl-4)alkyl, (Cl-4)alkoxy or a halogen atom; and

R4 is absent.

Further particularly preferred compounds of the invention are ds of formula (Ie), or pharmaceutically acceptable salts thereof,

wherein

X is CH ₂ or O; Rl is selected from the group consisting of -CH2-R2, -CH2-C(CH3)-CH2- R2, and -l,3-cyclobutylene-R2, wherein R2 is selected from the group consisting of - OH, -COOH and -COO(Cl-4)alkyl, and preferably is -OH or -COOH, more preferably -COOH;

L is selected from the group consisting of -(C2-4)alkyl-, -0-, -0-(Cl-

3)alkyl-, -0-(Cl-4)alkyl-0-, -phenyl-(Cl-4)alkyl-, -phenyl-0-(Cl-4)alkyl-, -CH=CH- and -C≡C-, more preferably from the group consisting of -(C2-4)alkyl-, -0-, -0-(Cl- 3)alkyl-, -0-(CH ₂ ) ₂ -0-, -phenyl-0-CH ₂ - and -C≡C-;

R3 is selected from the group consisting of:

o (C3-6)cycloalkyl, preferably cyclohexyl, optionally substituted with (Cl-

4)alkyl;

o monocyclic heterocycle, preferably oxanyl or pyridyl, optionally substituted with one or two substituents independently selected from the group consisting of:

· halogen,

• cyano,

• (Cl-4)alkyl optionally substituted with one or more fluoro atoms,

• (Cl-4)alkoxy optionally substituted with one or more fluoro atoms or with (C3-6)cycloalkyl,

· (C3-5)cycloalkoxy optionally substituted with one or more fluoro atoms; and

• (C3-6)cycloalkyl optionally substituted with (Cl-4)alkyl, (Cl-4)alkoxy or a halogen atom,

o indanyl, optionally substituted with one or two halogen atoms

o 8-10 membered fused bicyclic group, preferably 2, 3-dihydrobenzofuranyl, indanyl, indoly or 1,3-dioxaindanyl, optionally substituted with one or two halogen atoms;

o phenyl optionally substituted with 1 to 3 substituents independently

selected from the group consisting of:

· halogen,

• cyano,

• (Cl-4)alkyl optionally substituted with one or more fluoro atoms, (Cl-4)alkoxy optionally substituted with one or more fluoro atoms or with (C3-6)cycloalkyl,

(C3-5)cycloalkoxy optionally substituted with one or more fluoro atoms; and

(C3-6)cycloalkyl optionally substituted with (Cl-4)alkyl, (Cl-4)alkoxy or a halogen atom; and

is absent.

Further particularly preferred compounds of the invention are compounds of formula (Ie), or pharmaceutically acceptable salts thereof,

wherein

X is CH ₂ or O;

Rl is selected from the group consisting of -CH2-R2, -CH2-C(CH3)-CH2-

R2, and -l,3-cyclobutylene-R2, wherein R2 is selected from the group consisting of -OH, -COOH and -COO(Cl-4)alkyl, and preferably is -OH or -COOH, more preferably -COOH;

L is -0-(Cl-3)alkyl-, preferably -O-CH2-;

R3 is a monocyclic heterocycle, preferably oxanyl or pyridyl, optionally substituted with one or two substituents independently selected from the group consisting of

• halogen,

• (Cl-4)alkyl optionally substituted with one or more fluoro atoms,

• (Cl-4)alkoxy optionally substituted with one or more fluoro atoms or with (C3-6)cycloalkyl,

• (C3-5)cycloalkoxy optionally substituted with one or more fluoro atoms; and

• (C3-6)cycloalkyl optionally substituted with (Cl-4)alkyl, (Cl-4)alkoxy or a halogen atom; and

R4 is absent. Further particularly preferred compounds of the invention are compounds of formula (I), or pharmaceutically acceptable salts thereof, wherein

X is CH ₂ ;

m and n are both 0 or both 1, preferably both 0;

Rl is selected from the group consisting of -l,3-cyclobutylene-R2 and - (Ci-3)alkylene-R2 wherein the (Cl)alkylene is unsubstituted, and the (C2)-alkylene and the (C3)-alkylene ares substituted with up to two carbon atoms, with (CH2)2 to form a cyclopropyl moiety or with (CH2)3 to form a cyclobutyl moiety, wherein R2 is selected from the group consisting of -COOH, -OH, -OPO3H2, -PO3H2, -COO(Cl-

4)alkyl and tetrazol-5-yl, preferably from the group consisting of -OH, -COOH and - COO(Cl-4)alkyl;

L is attached to atom 2 or 3, and is a group -W-(CH2)p-T- wherein:

W is attached to the phenylene moiety and selected from the group consisting of -0-, -CO-, -S-, -SO-, -SO2-, -CH2-CH2-, -CF2-CH2-, -CH2-CF2-, -CH=CH- , -C(CF ₃ )=CH-, -CH=C(CF ₃ )-, -C≡C-, and -phenyl-,

p is 0, or an integer from 1 to 4 and

T is absent or selected from the group consisting of -O- and -0-(Cl-

4)alkyl-;

R3 is selected from the group consisting of:

o (C3-6)cycloalkyl, preferably cyclohexyl, optionally substituted with (Cl- 4)alkyl;

o monocyclic heterocycle, preferably oxanyl or pyridyl, optionally

substituted with 1 or 2 substituents independently selected from the group consisting of:

• halogen,

• cyano,

• (Cl-4)alkyl optionally substituted with one or more fluoro atoms,

• (Cl-4)alkoxy optionally substituted with one or more fluoro atoms or with (C3-6)cycloalkyl,

• (C3-5)cycloalkoxy optionally substituted with one or more fluoro atoms; and • (C3-6)cycloalkyl optionally substituted with (Cl-4)alkyl, (Cl-4)alkoxy or a halogen atom,

o indanyl, optionally substituted with one or two halogen atoms

o 8-10 membered fused bicyclic group, preferably preferably 2,3- dihydrobenzofuranyl, indanyl, indoly or 1,3-dioxaindanyl, optionally substituted with one or two halogen atoms;

o phenyl optionally substituted with 1 to 3 substituents independently selected from the group consisting of:

• halogen,

· cyano,

• (Cl-4)alkyl optionally substituted with one or more fluoro atoms,

• (Cl-4)alkoxy optionally substituted with one or more fluoro atoms or with (C3-6)cycloalkyl,

• (C3-5)cycloalkoxy optionally substituted with one or more fluoro atoms; and

• (C3-6)cycloalkyl optionally substituted with (Cl-4)alkyl, (Cl-4)alkoxy or a halogen atom;

R4 is absent or selected from the group consisting of a halogen atom, (Cl-4)alkyl optionally substituted with one or more halogen atoms, and (Cl- 4)alkoxy optionally substituted with one or more halogen atoms.

Further preferred compounds of the invention are depicted in table 1, and include their pharmaceutically acceptable salts.

Particularly preferred compounds depicted in table 1 are compounds having a EC50 for the S1P5 receptor of 100 nM or less, as shown in table 1, i.e. compounds having an S1P5 EC50 range A or B in table 1. Such compounds having an EC50 for the S1P5 receptor of 100 nM or less further preferably have an EC50 for at least one of the SlPl receptor, the S1P3 receptor and the S1P4 receptor of more than 1 μΜ. Hence, in a preferred embodiment are provided compounds depicted in table 1 having an S1P5 EC50 of 100 nM or less (indicated with range A or B in table 1) and EC50 of more than 1 μΜ for at least one of the SlPl receptor, the S1P3 receptor and the S1P4 receptor. Further particularly preferred compounds depicted in table 1 are compounds having a EC50 for the S1P5 receptor of 10 nM or less, as shown in table 1, i.e. compounds having an S1P5 EC50 range A in table 1. Hence, a preferred compound according to the invention is selected from the group consisting of:

3-(5'-((2-chloro-6-ethylbenzyl)oxy)-l',3'-dihydrospiro[az etidine-3,2'-inden]-l- yl)propanoic acid;

2-(5'-((2-chloro-6-cyclopropylbenzyl)oxy)-l',3'-dihydrospiro [azetidine-3,2'-inden]-l- yl)acetic acid;

2-(5'-((3-chlorobenzyl)oxy)-l',3'-dihydrospiro[azetidine-3,2 '-inden]-l-yl)acetic acid compound with acetic acid;

2-(5'-((2-fluoro-6-methylbenzyl)oxy)-l',3'-dihydrospiro[azet idine-3,2'-inden]-l- yl)acetic acid;

2-(5'-((2-chloro-6-fluorobenzyl)oxy)-l',3'-dihydrospiro[azet idine-3,2'-inden]-l- yl)acetic acid;

2-(5'-((2-fluoro-6-(trifluoromethyl)benzyl)oxy)-l',3'-dih ydrospiro[azetidine-3,2'- inden]-l-yl)acetic acid;

2-(5'-((2-chloro-6-(trifluoromethyl)benzyl)oxy)-l',3'-dihydr ospiro[azetidine-3,2'- inden]-l-yl)acetic acid;

2-(5'-((2-ethyl-6-fluorobenzyl)oxy)-l',3'-dihydrospiro[azeti dine-3,2'-inden]-l-yl)acetic acid;

2-(5'-((2,5-dichlorobenzyl)oxy)-l',3'-dihydrospiro[azetidine -3,2'-inden]-l-yl)acetic acid;

2-(5'-((2-chloro-6-ethylbenzyl)oxy)-l',3'-dihydrospiro[azeti dine-3,2'-inden]-l-yl)acetic acid;

2-(5'-((5-fluoro-2-(trifluoromethyl)benzyl)oxy)-l',3'-dih ydrospiro[azetidine-3,2'- inden]-l-yl)acetic acid;

l-((5'-((2-chloro-6-ethylbenzyl)oxy)-l',3'-dihydrospiro[a zetidine-3,2'-inden]-l- yl)methyl)cyclopropanecarboxylic acid;

l-((5'-((2,6-dimethylbenzyl)oxy)-l',3'-dihydrospiro[azeti dine-3,2'-inden]-l- yl)methyl)cyclopropanecarboxylic acid;

l-((5'-((2-chloro-6-cyclopropylbenzyl)oxy)-l',3'-dihydros piro[azetidine-3,2'-inden]-l- yl)methyl)cyclopropanecarboxylic acid; l-((5'-((2,6-dichlorobenzyl)oxy)-l',3'-dihydrospiro [azetidine-3,2'-inden]-l- yl)methyl)cyclopropanecarboxylic acid;

l-((5'-((2-chloro-6-(trifluoromethyl)benzyl)oxy)-l 3'-dihydrospiro[azetidine-3,2'- inden]-l-yl)methyl)cyclopropanecarboxylic acid;

l-((5'-((2-ethyl-6-fluorobenzyl)oxy)-l',3'-dihydrospiro[a zetidine-3,2'-inden]-l- yl)methyl)cyclopropanecarboxylic acid;

l-((5'-((2-fluoro-6-(trifluoromethyl)benzyl)oxy)-l',3'-di hydrospiro[azetidine-3,2'- inden]-l-yl)methyl)cyclopropanecarboxylic acid;

l-((5'-(4-((3-fluorobenzyl)oxy)phenyl)-l',3'-dihydrospiro [azetidine-3,2'-inden]-l- yl)methyl)cyclopropanecarboxylic acid;

1- ((5'-(2,6-dichlorophenethoxy)-l',3'-dihydrospiro[azetidine-3 ,2'-inden]-l- yl)methyl)cyclopropanecarboxylic acid;

2- (5'-(2-chlorophenethoxy)-l 3'-dihydrospiro[azetidine-3,2'-inden]-l-yl)acetic acid; 2-(5'-(2,6-dichlorophenethoxy)-l 3'-dihydrospiro[azetidine-3,2'-inden]-l-yl)acetic acid;

4-(5'-((2-chloro-6-ethylbenzyl)oxy)-l',3'-dihydrospiro[azeti dine-3,2'-inden]-l-yl)-3- methylbutanoic acid;

2-(5'-((2,3-dihydro-lH nden-l-yl)oxy)-l',3'-dihydrospiro[azetidine-3,2'-inden]-l- yl)acetic acid;

2-(5'-((7-chloro-2,3-dihydro H-inden-l-yl)oxy)-l',3'-dihydrospiro[azetidine-3,2'- inden]-l-yl)acetic acid;

2-(5'-((5-bromo-7-fluoro-2,3-dihydro-lH-inden-l-yl)oxy)-l 3'-dihydrospiro[azetidine- 3,2'-inden]-l-yl)acetic acid;

2-(5'-((5,7-dichloro-2,3-dihydro-lH-inden-l-yl)oxy)-l 3'-dihydrospiro[azetidine-3,2'- inden]-l-yl)acetic acid;

2-(5'-((2,3-dihydro-lH nden-4-yl)methoxy)-l 3'-dihydrospiro[azetidine-3,2'-inden]-

1- yl) acetic acid;

2- (5'-((6 sopropoxypyridin-3-yl)ethynyl)-l 3'-dihydrospiro[azetidine-3,2'-inden]-l- yl)acetic acid;

2-(5'-((4-methylcyclohexyl)ethynyl)-l 3'-dihydrospiro[azetidine-3,2'-inden]-l- yl)acetic acid;

2-(5'-((4-ethoxyphenyl)ethynyl)-l 3'-dihydrospiro[azetidine-3,2'-inden]-l-yl)acetic acid; 2-(5'-((6-(cyclopentyloxy)pyridin-3-yl)ethynyl)-l',3'-dihydr ospiro[azetidine-3,2'- inden]-l-yl)acetic acid;

2- (5'-((6-((l,l,l-trifluoropropan-2-yl)oxy)pyridin-3-yl)ethyny l)-l',3'- dihy drospiro [azetidine- 3 , 2' -inden] - 1 -yl)acetic acid;

2-(5'-((2-chlorophenyl)ethynyl)-l 3'-dihydrospiro[azetidine-3,2' nden]-l-yl)acetic acid;

3- (5'-((2-cyclopropyl-6-fluorobenzyl)oxy)-l',3'-dihydrospiro[a zetidine-3,2'-inden]-l- yl)cyclobutanecarboxylic acid;

3-(5'-((2-chloro-6-cyclopropylbenzyl)oxy)-l',3'-dihydrospiro [azetidine-3,2'-inden]-l- yl)cyclobutanecarboxylic acid;

3-(5'-((2,6-dichlorobenzyl)oxy)-l',3'-dihydrospiro[azetidine -3,2'-inden]-l- yl)cyclobutanecarboxylic acid;

3-(5'-((2-chloro-6-ethylbenzyl)oxy)-l',3'-dihydrospiro[azeti dine-3,2'-inden]-l- yl)cyclobutanecarboxylic acid;

3-(5'-((6-(cyclopentyloxy)pyridin-3-yl)ethynyl)-l',3'-dih ydrospiro[azetidine-3,2'- inden]-l-yl)cyclobutanecarboxylic acid;

3-(5'-((4 sopropoxyphenyl)ethynyl)-l',3'-dihydrospiro[azetidine-3,2'-i nden]-l- yl)cyclobutanecarboxylic acid;

3-(5'-((4-ethoxy-3-fluorophenyl)ethynyl)-l 3'-dihydrospiro[azetidine-3,2'-inden]-l- yl)cyclobutanecarboxylic acid;

3-(5'-((4-methylcyclohexyl)ethynyl)-l 3'-dihydrospiro[azetidine-3,2'-inden]-l- yl)cyclobutanecarboxylic acid;

3-(5'-((6-((l,l,l-trifluoropropan-2-yl)oxy)pyridin-3-yl)ethy nyl)-l',3'- dihy drospiro [azetidine- 3, 2' -inden] -l-yl)cyclobutanecarboxylic acid;

3-(5'-((2,3-dihydro-lH-inden-l-yl)oxy)-l',3'-dihydrospiro [azetidine-3,2'-inden]-l- yl)cyclobutanecarboxylic acid;

3-(5'-((7-chloro-2,3-dihydro-lH-inden-l-yl)oxy)-l',3'-dihydr ospiro[azetidine-3,2'- inden]-l-yl)cyclobutanecarboxylic acid;

2-(5'-((2,6-dichlorobenzyl)oxy)-l',3'-dihydrospiro[azetidine -3,2'-inden]-l-yl)acetic acid;

2-(5'-((2-cyclopropyl-6-fluorobenzyl)oxy)-l',3'-dihydrospiro [azetidine-3,2'-inden]-l- yl)acetic acid; 2-(5'-((2-cyclopropylbenzyl)oxy)-l 3'-dihydrospiro[azetidine-3,2'-inden]-l-yl)acetic acid;

l-((5'-((4 sopropoxyphenyl)ethynyl)-l 3'-dihydrospiro[azetidine-3,2'-inden]-l- yl)methyl)cyclopropanecarboxylic acid;

l-((5'-((4-methylcyclohexyl)ethynyl)-l 3'-dihydrospiro[azetidine-3,2'-inden]-l- yl)methyl)cyclopropanecarboxylic acid;

l-((5'-((6-((l,l,l-trifluoropropan-2-yl)oxy)pyridin-3-yl) ethynyl)-l',3'- dihydrospiro[azetidine-3,2'-inden]-l-yl)methyl)cyclopropanec arboxylic acid;

l-((5'-((7-chloro-2,3-dihydro-lH-inden-l-yl)oxy)-l',3'-di hydrospiro[azetidine-3,2'- inden]-l-yl)methyl)cyclopropanecarboxylic acid;

1- ((5'-((2-cyclopropyl-6-fluorobenzyl)oxy)-l',3'-dihydrospiro[ azetidine-3,2'-inden]-l- yl)methyl)cyclopropanecarboxylic acid;

2- (6'-(cyclohexylethynyl)-3'H-spiro[azetidine-3,2'-benzofuran] -l-yl)acetic acid;

2-(6'-(phenylethynyl)-3'H-spiro[azetidine-3,2'-benzofuran ]-l-yl)acetic acid;

2-(6'-((3-chlorophenyl)ethynyl)-3'H-spiro[azetidine-3,2'- benzofuran]-l-yl)acetic acid; 2-(6'-((2-chlorophenyl)ethynyl)-3'H-spiro[azetidine-3,2'-ben zofuran]-l-yl)acetic acid;

1- ((6'-((2-chloro-6-ethylbenzyl)oxy)-3'H-spiro[azetidine-3,2'- benzofuran]-l- yl)methyl)cyclopropanecarboxylic acid;

4-(6'-((2-chloro-6-ethylbenzyl)oxy)-3'H-spiro[azetidine-3,2' -benzofuran]-l-yl)-3- methylbutanoic acid;

2- (6'-((2-chloro-6-ethylbenzyl)oxy)-3'H-spiro[azetidine-3,2'-b enzofuran]-l-yl)acetic acid;

2-(5-((2-ethyl-6-fluorobenzyl)oxy)-l,3-dihydrospiro[indene-2 ,4'^iperidin]-l'-yl)acetic acid;

2-(5-((2,6-dichlorobenzyl)oxy)-l,3-dihydrospiro[indene-2, 4'^iperidin]-l'-yl)acetic acid and

2-(5-((2-chloro-6-ethylbenzyl)oxy)-l,3-dihydrospiro[indene-2 ,4'-piperidin]-l'- yl) acetic acid,

or a pharmaceutically acceptable salt of any of these compounds.

Such compounds having an EC50 for the S1P5 receptor of lOnM or less further preferably have an EC50 for at least one of the SlPl receptor, the S1P3 receptor and the S1P4 receptor of more than 1 μΜ. Thus, in a preferred

embodiment are provided compounds depicted in table 1 having an S1P5 EC50 of 10 nM or less (indicated with range A in table 1) and a EC50 of more than 1 μΜ for at least one of the SlPl receptor, the S1P3 receptor and the S1P4 receptor. Hence, a preferred compound according to the invention is selected from the group consisting of:

3-(5'-((2-chloro-6-ethylbenzyl)oxy)-l',3'-dihydrospiro[az etidine-3,2'-inden]-l- yl)propanoic acid;

2-(5'-((2-chloro-6-cyclopropylbenzyl)oxy)-l',3'-dihydrospiro [azetidine-3,2'-inden]-l- yl)acetic acid;

2-(5'-((3-chlorobenzyl)oxy)-l',3'-dihydrospiro[azetidine-3,2 '-inden]-l-yl)acetic acid compound with acetic acid;

2-(5'-((2-fluoro-6-methylbenzyl)oxy)-l',3'-dihydrospiro[azet idine-3,2'-inden]-l- yl)acetic acid;

2-(5'-((2-chloro-6-fluorobenzyl)oxy)-l',3'-dihydrospiro[azet idine-3,2'-inden]-l- yl)acetic acid;

2-(5'-((2-fluoro-6-(trifluoromethyl)benzyl)oxy)-l',3'-dih ydrospiro[azetidine-3,2'- inden]-l-yl)acetic acid;

2-(5'-((2-chloro-6-(trifluoromethyl)benzyl)oxy)-l',3'-dihydr ospiro[azetidine-3,2'- inden]-l-yl)acetic acid;

2-(5'-((2-ethyl-6-fluorobenzyl)oxy)-l',3'-dihydrospiro[azeti dine-3,2'-inden]-l-yl)acetic acid;

2-(5'-((2,5-dichlorobenzyl)oxy)-l',3'-dihydrospiro[azetidine -3,2'-inden]-l-yl)acetic acid;

2-(5'-((2-chloro-6-ethylbenzyl)oxy)-l',3'-dihydrospiro[azeti dine-3,2'-inden]-l-yl)acetic acid;

2-(5'-((5-fluoro-2-(trifluoromethyl)benzyl)oxy)-l',3'-dih ydrospiro[azetidine-3,2'- inden]-l-yl)acetic acid;

l-((5'-((2-chloro-6-ethylbenzyl)oxy)-l',3'-dihydrospiro[a zetidine-3,2'-inden]-l- yl)methyl)cyclopropanecarboxylic acid;

l-((5'-((2,6-dimethylbenzyl)oxy)-l',3'-dihydrospiro[azeti dine-3,2'-inden]-l- yl)methyl)cyclopropanecarboxylic acid;

l-((5'-((2-chloro-6-cyclopropylbenzyl)oxy)-l',3'-dihydros piro[azetidine-3,2'-inden]-l- yl)methyl)cyclopropanecarboxylic acid; l-((5'-((2,6-dichlorobenzyl)oxy)-l',3'-dihydrospiro [azetidine-3,2'-inden]-l- yl)methyl)cyclopropanecarboxylic acid;

l-((5'-((2-chloro-6-(trifluoromethyl)benzyl)oxy)-l 3'-dihydrospiro[azetidine-3,2'- inden]-l-yl)methyl)cyclopropanecarboxylic acid;

l-((5'-((2-ethyl-6-fluorobenzyl)oxy)-l',3'-dihydrospiro[a zetidine-3,2'-inden]-l- yl)methyl)cyclopropanecarboxylic acid;

l-((5'-((2-fluoro-6-(trifluoromethyl)benzyl)oxy)-l',3'-di hydrospiro[azetidine-3,2'- inden]-l-yl)methyl)cyclopropanecarboxylic acid;

l-((5'-(4-((3-fluorobenzyl)oxy)phenyl)-l',3'-dihydrospiro [azetidine-3,2'-inden]-l- yl)methyl)cyclopropanecarboxylic acid;

1- ((5'-(2,6-dichlorophenethoxy)-l',3'-dihydrospiro[azetidine-3 ,2'-inden]-l- yl)methyl)cyclopropanecarboxylic acid;

2- (5'-(2-chlorophenethoxy)-l 3'-dihydrospiro[azetidine-3,2'-inden]-l-yl)acetic acid; 2-(5'-(2,6-dichlorophenethoxy)-l 3'-dihydrospiro[azetidine-3,2'-inden]-l-yl)acetic acid;

4-(5'-((2-chloro-6-ethylbenzyl)oxy)-l',3'-dihydrospiro[azeti dine-3,2'-inden]-l-yl)-3- methylbutanoic acid;

2-(5'-((2,3-dihydro-lH nden-l-yl)oxy)-l',3'-dihydrospiro[azetidine-3,2'-inden]-l- yl)acetic acid;

2-(5'-((7-chloro-2,3-dihydro H-inden-l-yl)oxy)-l',3'-dihydrospiro[azetidine-3,2'- inden]-l-yl)acetic acid;

2-(5'-((5-bromo-7-fluoro-2,3-dihydro-lH-inden-l-yl)oxy)-l 3'-dihydrospiro[azetidine- 3,2'-inden]-l-yl)acetic acid;

2-(5'-((5,7-dichloro-2,3-dihydro-lH-inden-l-yl)oxy)-l 3'-dihydrospiro[azetidine-3,2'- inden]-l-yl)acetic acid;

2-(5'-((2,3-dihydro-lH nden-4-yl)methoxy)-l 3'-dihydrospiro[azetidine-3,2'-inden]-

1- yl) acetic acid;

2- (5'-((6 sopropoxypyridin-3-yl)ethynyl)-l 3'-dihydrospiro[azetidine-3,2'-inden]-l- yl)acetic acid;

2-(5'-((4-methylcyclohexyl)ethynyl)-l 3'-dihydrospiro[azetidine-3,2'-inden]-l- yl)acetic acid;

2-(5'-((2-chlorophenyl)ethynyl)-l 3'-dihydrospiro[azetidine-3,2' nden]-l-yl)acetic acid; 3-(5'-((2-cyclopropyl-6-fluorobenzyl)oxy)-l 3'-dihydrospiro[azetidine-3,2'-inden]-l- yl)cyclobutanecarboxylic acid;

3-(5'-((2,6-dichlorobenzyl)oxy)-l',3'-dihydrospiro[azetidine -3,2'-inden]-l- yl)cyclobutanecarboxylic acid;

3-(5'-((4 sopropoxyphenyl)ethynyl)-l',3'-dihydrospiro[azetidine-3,2'-i nden]-l- yl)cyclobutanecarboxylic acid;

3-(5'-((4-ethoxy-3-fluorophenyl)ethynyl)-l 3'-dihydrospiro[azetidine-3,2'-inden]-l- yl)cyclobutanecarboxylic acid;

3-(5'-((4-methylcyclohexyl)ethynyl)-l 3'-dihydrospiro[azetidine-3,2'-inden]-l- yl)cyclobutanecarboxylic acid;

3-(5'-((2,3-dihydro-lH nden-l-yl)oxy)-l',3'-dihydrospiro[azetidine-3,2'-inden]-l- yl)cyclobutanecarboxylic acid;

2-(5'-((2,6-dichlorobenzyl)oxy)-l 3'-dihydrospiro[azetidine-3,2'-inden]-l-yl)acetic acid;

2-(5'-((2-cyclopropyl-6-fluorobenzyl)oxy)-l',3'-dihydrosp iro[azetidine-3,2'-inden]-l- yl)acetic acid;

2-(5'-((2-cyclopropylbenzyl)oxy)-l',3'-dihydrospiro[azetidin e-3,2'-inden]-l-yl)acetic acid;

l-((5'-((4 sopropoxyphenyl)ethynyl)-l',3'-dihydrospiro[azetidine-3,2'-i nden]-l- yl)methyl)cyclopropanecarboxylic acid;

l-((5'-((4-methylcyclohexyl)ethynyl)-l 3'-dihydrospiro[azetidine-3,2'-inden]-l- yl)methyl)cyclopropanecarboxylic acid;

l-((5'-((6-((l,l,l-trifluoropropan-2-yl)oxy)pyridin-3-yl) ethynyl)-l',3'- dihydrospiro[azetidine-3,2'-inden]-l-yl)methyl)cyclopropanec arboxylic acid;

l-((5'-((7-chloro-2,3-dihydro-lH-inden-l-yl)oxy)-l',3'-di hydrospiro[azetidine-3,2'- inden]-l-yl)methyl)cyclopropanecarboxylic acid;

1- ((5'-((2-cyclopropyl-6-fluorobenzyl)oxy)-l',3'-dihydrospiro[ azetidine-3,2'-inden]-l- yl)methyl)cyclopropanecarboxylic acid;

2- (6'-(cyclohexylethynyl)-3'H-spiro[azetidine-3,2'-benzofuran] -l-yl)acetic acid;

2-(6'-(phenylethynyl)-3'H-spiro[azetidine-3,2'-benzofuran ]-l-yl)acetic acid;

2-(6'-((3-chlorophenyl)ethynyl)-3'H-spiro[azetidine-3,2'-ben zofuran]-l-yl)acetic acid; 2-(6'-((2-chlorophenyl)ethynyl)-3'H-spiro[azetidine-3,2'-ben zofuran]-l-yl)acetic acid; 1- ((6'-((2-chloro-6-ethylbenzyl)oxy)-3'H-spiro[azetidine-3,2'- benzofuran]-l- yl)methyl)cyclopropanecarboxylic acid;

4-(6'-((2-chloro-6-ethylbenzyl)oxy)-3'H-spiro[azetidine-3,2' -benzofuran]-l-yl)-3- methylbutanoic acid;

2-(5-((2-ethyl-6-fluorobenzyl)oxy)-l,3-dihydrospiro[inden e-2,4'^iperidin]-l'-yl)acetic acid;

2- (5-((2,6-dichlorobenzyl)oxy)-l,3-dihydrospiro[indene-2,4'^ip eridin]-l'-yl)acetic acid and

2- (5-((2-chloro-6-ethylbenzyl)oxy)-l,3-dihydrospiro[indene-2,4 '-piperidin]-l'- yl)acetic acid,

or a pharmaceutically acceptable salt of any of these compounds.

In a preferred embodiment, a compound of the invention has a EC50 for the S1P5 receptor of 10 nM or less, i.e. compounds having an S1P5 EC50 range A in table 1, and an EC50 of more than 1 μΜ for the S1P1 receptor. Hence, a preferred compound according to the invention is selected from the group consisting of:

3- (5'-((2-chloro-6-ethylbenzyl)oxy)-l',3'-dihydrospiro[azetidi ne-3,2'-inden]-l- yl)propanoic acid;

2-(5'-((2-chloro-6-cyclopropylbenzyl)oxy)-l',3'-dihydrospiro [azetidine-3,2'-inden]-l- yl)acetic acid;

2-(5'-((3-chlorobenzyl)oxy)-l',3'-dihydrospiro[azetidine-3,2 '-inden]-l-yl)acetic acid compound with acetic acid;

2-(5'-((2-fluoro-6-methylbenzyl)oxy)-l',3'-dihydrospiro[azet idine-3,2'-inden]-l- yl)acetic acid;

2-(5'-((2-chloro-6-fluorobenzyl)oxy)-l',3'-dihydrospiro[a zetidine-3,2'-inden]-l- yl)acetic acid;

2-(5'-((2-fluoro-6-(trifluoromethyl)benzyl)oxy)-l',3'-dihydr ospiro[azetidine-3,2'- inden]-l-yl)acetic acid;

2-(5'-((2-chloro-6-(trifluoromethyl)benzyl)oxy)-l',3'-dihydr ospiro[azetidine-3,2'- inden]-l-yl)acetic acid;

2-(5'-((2-ethyl-6-fluorobenzyl)oxy)-l',3'-dihydrospiro[azeti dine-3,2'-inden]-l-yl)acetic acid; 2-(5'-((2,5-dichlorobenzyl)oxy)-l 3'-dihydrospiro[azetidine-3,2'-inden]-l-yl)acetic acid;

2-(5'-((2-chloro-6-ethylbenzyl)oxy)-l 3'-dihydrospiro[azetidine-3,2'-inden]-l-yl)acetic acid;

2-(5'-((5-fluoro-2-(trifluoromethyl)benzyl)oxy)-l',3'-dih ydrospiro[azetidine-3,2'- inden]-l-yl)acetic acid;

l-((5'-((2-chloro-6-ethylbenzyl)oxy)-l',3'-dihydrospiro[a zetidine-3,2'-inden]-l- yl)methyl)cyclopropanecarboxylic acid;

l-((5'-((2,6-dimethylbenzyl)oxy)-l',3'-dihydrospiro[azeti dine-3,2'-inden]-l- yl)methyl)cyclopropanecarboxylic acid;

l-((5'-((2-chloro-6-cyclopropylbenzyl)oxy)-l',3'-dihydros piro[azetidine-3,2'-inden]-l- yl)methyl)cyclopropanecarboxylic acid;

l-((5'-((2,6-dichlorobenzyl)oxy)-l',3'-dihydrospiro [azetidine-3,2'-inden]-l- yl)methyl)cyclopropanecarboxylic acid;

l-((5'-((2-chloro-6-(trifluoromethyl)benzyl)oxy)-l',3'-di hydrospiro[azetidine-3,2'- inden]-l-yl)methyl)cyclopropanecarboxylic acid;

l-((5'-((2-ethyl-6-fluorobenzyl)oxy)-l',3'-dihydrospiro[a zetidine-3,2'-inden]-l- yl)methyl)cyclopropanecarboxylic acid;

l-((5'-((2-fluoro-6-(trifluoromethyl)benzyl)oxy)-l',3'-di hydrospiro[azetidine-3,2'- inden]-l-yl)methyl)cyclopropanecarboxylic acid;

l-((5'-(4-((3-fluorobenzyl)oxy)phenyl)-l',3'-dihydrospiro [azetidine-3,2'-inden]-l- yl)methyl)cyclopropanecarboxylic acid;

1- ((5'-(2,6-dichlorophenethoxy)-l',3'-dihydrospiro[azetidine-3 ,2'-inden]-l- yl)methyl)cyclopropanecarboxylic acid;

2-(5'-(2-chlorophenethoxy)-l 3'-dihydrospiro[azetidine-3,2'-inden]-l-yl)acetic acid;

2- (5'-(2,6-dichlorophenethoxy)-l 3'-dihydrospiro[azetidine-3,2'-inden]-l-yl)acetic acid;

2-(5'-((2,3-dihydro-lH nden-l-yl)oxy)-l',3'-dihydrospiro[azetidine-3,2'-inden]-l- yl)acetic acid;

2-(5'-((7-chloro-2,3-dihydro H-inden-l-yl)oxy)-l',3'-dihydrospiro[azetidine-3,2'- inden]-l-yl)acetic acid;

2-(5'-((5-bromo-7-fluoro-2,3-dihydro-lH-inden-l-yl)oxy)-l 3'-dihydrospiro[azetidine- 3,2'-inden]-l-yl)acetic acid; 2-(5'-((5,7-dichloro-2,3-dihydro-lH-m

inden]-l-yl)acetic acid;

2-(5'-((2,3-dihydro-lH nden-4-yl)methoxy)-l 3'-dihydrospiro[azetidine-3,2'-inden]-

1- yl) acetic acid;

2-(5'-((4-methylcyclohexyl)ethynyl)-l',3'-dihydrospiro[az etidine-3,2'-inden]-l- yl)acetic acid;

2- (5'-((2-chlorophenyl)ethynyl)-l 3'-dihydrospiro[azetidine-3,2'-inden]-l-yl)acetic acid;

3- (5'-((2-cyclopropyl-6-fluorobenzyl)oxy)-l',3'-dihydrospiro[a zetidine-3,2'-inden]-l- yl)cyclobutanecarboxylic acid;

3-(5'-((2,6-dichlorobenzyl)oxy)-l',3'-dihydrospiro[azetidine -3,2'-inden]-l- yl)cyclobutanecarboxylic acid;

3-(5'-((4-methylcyclohexyl)ethynyl)-l 3'-dihydrospiro[azetidine-3,2'-inden]-l- yl)cyclobutanecarboxylic acid;

3-(5'-((2,3-dihydro-lH nden-l-yl)oxy)-l',3'-dihydrospiro[azetidine-3,2'-inden]-l- yl)cyclobutanecarboxylic acid;

2-(5'-((2,6-dichlorobenzyl)oxy)-l 3'-dihydrospiro[azetidine-3,2'-inden]-l-yl)acetic acid;

2-(5'-((2-cyclopropyl-6-fluorobenzyl)oxy)-l',3'-dihydrospiro [azetidine-3,2'-inden]-l- yl)acetic acid;

2-(5'-((2-cyclopropylbenzyl)oxy)-l',3'-dihydrospiro[azetidin e-3,2'-inden]-l-yl)acetic acid;

l-((5'-((4-methylcyclohexyl)ethynyl)-l 3'-dihydrospiro[azetidine-3,2'-inden]-l- yl)methyl)cyclopropanecarboxylic acid;

l-((5'-((7-chloro-2,3-dihydro-lH-inden-l-yl)oxy)-l',3'-di hydrospiro[azetidine-3,2'- inden]-l-yl)methyl)cyclopropanecarboxylic acid;

1- ((5'-((2-cyclopropyl-6-fluorobenzyl)oxy)-l',3'-dihydrospiro[ azetidine-3,2'-inden]-l- yl)methyl)cyclopropanecarboxylic acid;

2- (6'-(cyclohexylethynyl)-3'H-spiro[azetidine-3,2'-benzofuran] -l-yl)acetic acid;

2-(6'-(phenylethynyl)-3'H-spiro[azetidine-3,2'-benzofuran ]-l-yl)acetic acid;

2-(6'-((3-chlorophenyl)ethynyl)-3'H-spiro[azetidine-3,2'-ben zofuran]-l-yl)acetic acid; 2-(6'-((2-chlorophenyl)ethynyl)-3'H-spiro[azetidine-3,2'-ben zofuran]-l-yl)acetic acid; 1- ((6'-((2-chloro-6-ethylbenzyl)oxy)-3'H-spiro[azetidine-3,2'- benzofuran]-l- yl)methyl)cyclopropanecarboxylic acid;

4-(6'-((2-chloro-6-ethylbenzyl)oxy)-3'H-spiro[azetidine-3,2' -benzofuran]-l-yl)-3- methylbutanoic acid;

2-(5-((2-ethyl-6-fluorobenzyl)oxy)-l,3-dihydrospiro[inden e-2,4'^iperidin]-l'-yl)acetic acid;

2- (5-((2,6-dichlorobenzyl)oxy)-l,3-dihydrospiro[indene-2,4'^ip eridin]-l'-yl)acetic acid and

2- (5-((2-chloro-6-ethylbenzyl)oxy)-l,3-dihydrospiro[indene-2,4 '-piperidin]-l'- yl)acetic acid,

or a pharmaceutically acceptable salt of any of these compounds.

In another preferred embodiment, a compound of the invention has a EC50 for the S1P5 receptor of 10 nM or less, i.e. compounds having an S1P5 EC50 range A in table 1, and a EC50 of more than 1 μΜ for the S1P3 receptor. Hence, a preferred compound according to the invention is selected from the group consisting of:

3- (5'-((2-chloro-6-ethylbenzyl)oxy)-l',3'-dihydrospiro[azetidi ne-3,2'-inden]-l- yl)propanoic acid;

2-(5'-((2-chloro-6-cyclopropylbenzyl)oxy)-l',3'-dihydrospiro [azetidine-3,2'-inden]-l- yl)acetic acid;

2-(5'-((3-chlorobenzyl)oxy)-l',3'-dihydrospiro[azetidine-3,2 '-inden]-l-yl)acetic acid compound with acetic acid;

2-(5'-((2,5-dichlorobenzyl)oxy)-l',3'-dihydrospiro[azetidine -3,2'-inden]-l-yl)acetic acid;

2-(5'-((2-chloro-6-ethylbenzyl)oxy)-l',3'-dihydrospiro[az etidine-3,2'-inden]-l-yl)acetic acid;

l-((5'-((2-chloro-6-ethylbenzyl)oxy)-l',3'-dihydrospiro[a zetidine-3,2'-inden]-l- yl)methyl)cyclopropanecarboxylic acid;

l-((5'-((2,6-dimethylbenzyl)oxy)-l',3'-dihydrospiro[azeti dine-3,2'-inden]-l- yl)methyl)cyclopropanecarboxylic acid;

l-((5'-((2-chloro-6-cyclopropylbenzyl)oxy)-l',3'-dihydros piro[azetidine-3,2'-inden]-l- yl)methyl)cyclopropanecarboxylic acid; l-((5'-((2,6-dichlorobenzyl)oxy)-l',3'-dihydrospiro [azetidine-3,2'-inden]-l- yl)methyl)cyclopropanecarboxylic acid;

1- ((5'-(4-((3-fluorobenzyl)oxy)phenyl)-l 3'-dihydrospiro[azetidine-3,2'-inden]-l- yl)methyl)cyclopropanecarboxylic acid;

l-((5'-(2,6-dichlorophenethoxy)-l 3'-dihydrospiro[azetidine-3,2'-inden]-l- yl)methyl)cyclopropanecarboxylic acid;

2- (5'-(2-chlorophenethoxy)-l 3'-dihydrospiro[azetidine-3,2'-inden]-l-yl)acetic acid; 2-(5'-(2,6-dichlorophenethoxy)-l 3'-dihydrospiro[azetidine-3,2'-inden]-l-yl)acetic acid;

4-(5'-((2-chloro-6-ethylbenzyl)oxy)-l 3'-dihydrospiro[azetidine-3,2'-inden]-l-yl)-3- methylbutanoic acid;

2-(5'-((2,6-dichlorobenzyl)oxy)-l 3'-dihydrospiro[azetidine-3,2'-inden]-l-yl)acetic acid;

2-(5'-((2-cyclopropyl-6-fluorobenzyl)oxy)-l',3'-dihydrospiro [azetidine-3,2'-inden]-l- yl)acetic acid;

2-(5'-((2-cyclopropylbenzyl)oxy)-l',3'-dihydrospiro[azetidin e-3,2'-inden]-l-yl)acetic acid;

2-(5-((2-ethyl-6-fluorobenzyl)oxy)-l,3-dihydrospiro[indene-2 ,4'^iperidin]-l'-yl)acetic acid;

2-(5-((2,6-dichlorobenzyl)oxy)-l,3-dihydrospiro[indene-2, 4'^iperidin]-l'-yl)acetic acid and

2- (5-((2-chloro-6-ethylbenzyl)oxy)-l,3-dihydrospiro[indene-2,4 '-piperidin]-l'- yl) acetic acid,

or a pharmaceutically acceptable salt of any of these compounds.

In another preferred embodiment, a compound of the invention has a

EC50 for the S1P5 receptor of 10 nM or less, i.e. compounds having an S1P5 EC50 range A in table 1, and a EC50 of more than 1 μΜ for the S1P4 receptor. Hence, a preferred compound according to the invention is selected from the group consisting of:

2-(5'-((6-isopropoxypyridin-3-yl)ethynyl)-l',3'-dihydrosp iro[azetidine-3,2'-inden]-l- yl)acetic acid;

3- (5'-((4-isopropoxyphenyl)ethynyl)-l',3'-dihydrospiro[azetidi ne-3,2'-inden]-l- yl)cyclobutanecarboxylic acid; 3-(5'-((4-ethoxy-3-fluorophenyl)ethynyl)-l 3'-dihyd

yl)cyclobutanecarboxylic acid;

1- ((5'-((4 sopropoxyphenyl)ethynyl)-l 3'-dihydrospiro[azetidine-3,2'-inden]-l- yl)methyl)cyclopropanecarboxylic acid and

l-((5'-((6-((l,l,l-trifluoropropan-2-yl)oxy)pyridin-3-yl) ethynyl)-l',3'- dihydrospiro[azetidine-3,2'-inden]-l-yl)methyl)cyclopropanec arboxylic acid, or a pharmaceutically acceptable salt of any of these compounds.

In another preferred embodiment are provided compounds depicted in table 1 having an S1P5 EC50 of 10 nM or less (indicated with range A in table 1) and a EC50 of more than 1 μΜ for at least two of the SlPl receptor, the S1P3 receptor and the S1P4 receptor. Hence, a preferred compound according to the invention is selected from the group consisting of:

3-(5'-((2-chloro-6-ethylbenzyl)oxy)-l',3'-dihydrospiro[azeti dine-3,2'-inden]-l- yl)propanoic acid;

2-(5'-((2-chloro-6-cyclopropylbenzyl)oxy)-l',3'-dihydrosp iro[azetidine-3,2'-inden]-l- yl)acetic acid;

2- (5'-((3-chlorobenzyl)oxy)-l',3'-dihydrospiro[azetidine-3,2'- inden]-l-yl)acetic acid compound with acetic acid;

2-(5'-((2,5-dichlorobenzyl)oxy)-l',3'-dihydrospiro[azetidine -3,2'-inden]-l-yl)acetic acid;

2-(5'-((2-chloro-6-ethylbenzyl)oxy)-l',3'-dihydrospiro[azeti dine-3,2'-inden]-l-yl)acetic acid;

l-((5'-((2-chloro-6-ethylbenzyl)oxy)-l',3'-dihydrospiro[a zetidine-3,2'-inden]-l- yl)methyl)cyclopropanecarboxylic acid;

l-((5'-((2,6-dimethylbenzyl)oxy)-l',3'-dihydrospiro[azeti dine-3,2'-inden]-l- yl)methyl)cyclopropanecarboxylic acid;

l-((5'-((2-chloro-6-cyclopropylbenzyl)oxy)-l',3'-dihydros piro[azetidine-3,2'-inden]-l- yl)methyl)cyclopropanecarboxylic acid;

l-((5'-((2,6-dichlorobenzyl)oxy)-l',3'-dihydrospiro [azetidine-3,2'-inden]-l- yl)methyl)cyclopropanecarboxylic acid;

l-((5'-(4-((3-fluorobenzyl)oxy)phenyl)-l',3'-dihydrospiro [azetidine-3,2'-inden]-l- yl)methyl)cyclopropanecarboxylic acid; 1- ((5'-(2,6-dichlorophenethoxy)-l 3'-dihydrospiro[azetidine-3,2'-inden]-l- yl)methyl)cyclopropanecarboxylic acid;

2- (5'-(2-chlorophenethoxy)-l 3'-dihydrospiro[azetidine-3,2'-inden]-l-yl)acetic acid; 2-(5'-(2,6-dichlorophenethoxy)-l 3'-dihydrospiro[azetidine-3,2'-inden]-l-yl)acetic acid;

2-(5'-((2,6-dichlorobenzyl)oxy)-l 3'-dihydrospiro[azetidine-3,2'-inden]-l-yl)acetic acid;

2-(5'-((2-cyclopropyl-6-fluorobenzyl)oxy)-l',3'-dihydrospiro [azetidine-3,2'-inden]-l- yl)acetic acid;

2-(5'-((2-cyclopropylbenzyl)oxy)-l',3'-dihydrospiro[azeti dine-3,2'-inden]-l-yl)acetic acid;

2-(5-((2-ethyl-6-fluorobenzyl)oxy)-l,3-dihydrospiro[indene-2 ,4'-piperidin]-l'-yl)acetic acid;

2-(5-((2,6-dichlorobenzyl)oxy)-l,3-dihydrospiro[indene-2,4'- piperidin]-l'-yl)acetic acid and

2-(5-((2-chloro-6-ethylbenzyl)oxy)-l,3-dihydrospiro[indene-2 ,4'-piperidin]-l'- yl) acetic acid

or a pharmaceutically acceptable salt of any of these compounds. As used herein, the term "halogen" or "a halogen atom" refers to fluoro, chloro, bromo, or iodo. Preferred halogen atoms are fluoro and chloro.

As used herein, the term "(Cx-y)alkyl" refers to a branched or unbranched alkyl group having x-y carbon atoms. For instance, (Cl-4)alkyl means a branched or unbranched alkyl group having 1-4 carbon atoms, for example methyl, ethyl, propyl, isopropyl or butyl. Similarly, the term "(Cl-2) alkyl" refers to an alkyl group having 1 or 2 carbon atoms. Preferred alkyl groups are methyl and ethyl.

As used herein, the term (Cx-y)alkoxy refers to an alkoxy group having x-y carbon atoms, wherein the alkyl moiety is as defined above. For instance, the term (Cl-4)alkoxy means an alkoxy group having a (Cl-4)-alkyl moiety. Examples of alkoxy groups are methoxy, ethoxy, and -0-CH(CH3)-CF3.

As used herein, the term "(Cx-y)alkylene" refers to a branched or unbranched saturated alkylene group having x-y carbon atoms. For instance, the term "(Cl-4)alkylene" means a saturated alkylene group having 1-4 carbon atoms, for example methylene, (CH ₂ ) ₃ -CHCH ₃ -, -C(CH ₃ ) ₂ -, -CHCH3CH2-. In the definition of Rl as -(Cl-4)alkylene-R2, one or more carbon atoms in the alkylene group may independently be substituted with (CH2)2 to form a cyclopropyl moiety, for instance to form an Rl group — or with (CH2)3 to form a cyclobutyl moiety.

As used herein a dashed line in a partial structure, such as ^—^ means that the partial structure is attached to the remainder of the structure at the site of the dashed line. For instance if Rl is — ¹ , the compound of

formula (I) is

As used herein the term "(Cx-y)alkenyl" means a branched or unbranched alkenyl group having x-y carbon atoms, wherein the double bond may be present at various positions in the group. Examples are ethenyl, propenyl, 1- butenyl, 2-butenyl. For instance, the term "(C2-4)alkenyl" means a branched or unbranched alkenyl group having 2-4 carbon atoms.

As used herein, the term "(Cx-y)alkynyl" refers to a branched or unbranched alkynyl group having x-y carbon atoms, wherein the triple bond may be present at different positions in the group, for example ethynyl, propanyl, 1- butynyl, 2-butynyl. For instance, the term "(C2-4)alkynyl" refers to a branched or unbranched alkynyl group having 2-4 carbon atoms.

As used herein the term "(Cx-y)cycloalkyl" refers to a cyclic alkyl group having x-y carbon atoms. For instance, the term "(C3-6)cycloalkyl" refers to a cyclic alkyl group having 3-6 carbon atoms, i.e. cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl. A preferred (C3-8)cycloalkyl in the definition of R3 is cyclopentyl, cyclohexyl or cycloheptyl, more preferably cyclohexyl.

As used herein the term "(Cx-y)cycloalkoxy" means an alkoxy as defined above wherein the alkyl moiety is a Cx-y-cycloalkyl, e.g. As used herein the term "(Cx-y)cycloalkenyl" means a cyclic alkenyl group having x-y carbon atoms. For instance, the term "(C4-6)cycloalkenyl" means a cyclic alkenyl group having 4-6 carbon atoms and comprising one or two double bonds, for example cyclohexenyl. Preferably a cycloalkenyl as used herein has one carbon-carbon double bond, e.g. cyclobutene, cyclopentene, cyclohexene and cycloheptene.

As used herein the term "(Cx-y)cycloalkylene" means a saturated cyclic group having x-y carbon atoms. For instance, the term "(C3-7)cycloalkylene" means a saturated cyclic group having 3-7 carbon atoms, e.g. cyclobutylene,

cyclopentylene, cyclohexylene and cycloheptane.

As used herein the term "8-10 membered fused bicyclic group" for R3 means a fused ring system of two ring structures together having 8-10 atoms. The rings can be either aromatic or non-aromatic ring structures, preferably the fused bicyclic group contains at least one aromatic ring. Preferred 8-10 membered fused bicyclic groups in the definition of R3 contain up to two heteroatoms, preferably O, S and/or N. Preferred 8-10 membered bused bicyclic groups are indane, tetralin, benzofuran, isobenzofuran, dihydrobenzofuran, dihydroisobenzofuran,

tetrahydrobenzofuran, tetrahydroisobenzofuran, indoline, isoindoline, indole, isoindole, dihydroindole, dihydroisoindole, tetrahydroindole, tetrahydroisoindole, quinolone, isoquinoline, tetrahydroquinoline, tetrahydroisoquinoline, quinoxaline,, dihydroquinoxaline, tetrahydroquinoxaline, quinazoline, dihydroquinazoline, tetrahydroquinazoline, dihydrobenzopyran, benzothiophene, benzo[c]thiophene, dihydrobenzothiophene, dihydrobenzo[c]thiophene, tetrahydrobenzothiophene, tetrahydroquinoxaline, indazole, dihydroindazole, tetrahydroindazole,

benzimidazole, dihydrobenzimidazole and tetrahydrobenzimidazole, benzoxazole, dihydrobenzoxazole, tetrahydrobenzoxazole, benzisoxazole, dihydrobenzisoxazole and tetrahydrobenzisoxazole. More preferred 8-10 membered fused bicyclic groups in the definition of R3 are indanyl, benzofuranyl, isobenzofuranyl, indolyl, isoindolyl, indazolyl, benzimidazolyl, benzothiophenyl, benzo[c]thiophenyl benzoxazolyl, 2,3-dihydrobenzofuranyl and 1,3-dioxaindanyl, more preferably indanyl, indolyl, 2,3-dihydrobenzofuranyl and 1,3-dioxaindanyl.

As used herein the term "monocyclic heterocycle" means a heteroatom- containing cyclic group. The term "monocyclic heterocycle" encompasses monocyclic heteroaryl groups and non-aromatic heteromonocyclic groups. Preferred monocyclic heterocycles are furanyl, thienyl, pyrrolyl, oxanyl, oxazolyl, thiazolyl, imidazolyl, pyrazolyl, isoxazolyl, isothiazolyl, triazolyl, oxadiazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl, tetrahydrofuranyl, tetrahydropyranyl, dioxanyl, morpholinyl. Particularly preferred monocyclic heterocycles in the definition of R3 are pyridyl, piperidyl, oxanyl, pyranyl, thianyl and thiopyranyl, more preferably pyridyl and oxanyl.

With respect to substituents, the term "optionally substituted" indicates a group may be unsubstituted or substituted with the indicated number and type of the substituent(s). The term " one or more substituents independently selected from ..." means that if a group that is substituted with more than one substituent, these substituents may be the same or different from each other. Similarly, if multiple variables are independently chosen from more than one definition, such as m and n in present formula (I) which can be 0 or 1, the term "independently" means that each variables may have the same or different definition as the other variable(s).

The compounds of the present invention may contain one or more asymmetric centers and can thus occur as racemates and racemic mixtures, single enantiomers, diastereomeric mixtures and individual diastereomers. Additional asymmetric centers may be present depending upon the nature of the various substituents on the compound. Each such asymmetric center will independently produce two optical isomers and it is intended that all of the possible optical isomers and diastereomers in mixtures and as pure or partially purified compounds are included within the ambit of this invention. The present invention encompasses all such isomeric forms of these compounds. The independent syntheses of these diastereomers or their chromatographic separations may be achieved with any method known in the art, for instance as described in the Examples. The absolute stereochemistry of a compound may be determined by the x-ray crystallography of crystalline products or crystalline intermediates which are derivatized, if necessary, with a reagent containing an asymmetric center of known absolute configuration. If desired, racemic mixtures of the compounds may be separated so that the individual enantiomers are isolated. The separation can be carried out by methods well known in the art, such as chiral HPLC or SFC (Supercritical Fluid Chromatography) techniques. In the Examples, two suitable SFC methods are described.

Salts of compounds according to the invention are also provided. Such salts include, but are not limited to, acid addition salts and base addition salts. The term "pharmaceutically acceptable salt" as used herein refers to those salts retain the pharmacological activity of the compounds and that are, within the scope of sound medical judgment, suitable for use in humans or animals without undue toxicity, irritation, allergic response, and the like, and are commensurate with a reasonable benefit/risk ratio. Pharmaceutically acceptable salts are well-known in the art. They can be prepared in situ when isolating and purifying the compounds of the invention, or separately by reacting them with pharmaceutically acceptable non-toxic bases or acids, including inorganic or organic bases and inorganic or organic acids, for instance by reacting the free acid or free base forms of the product with one or more equivalents of the appropriate acid or base in a solvent or medium in which the salt is insoluble, or in a solvent such as water or an organic solvent which is then removed in vacuo or by freeze- drying, or by exchanging the cations of an existing salt for another cation on a suitable ion exchange resin. Examples of pharmaceutically acceptable acids and bases include organic and inorganic acids such as acetic acid, trifluoroacetic acid, hydrochloric acid, and bases.

Compounds may exist as polymorphs and as such are intended to be included in the present invention.

The compounds of the invention may be prepared by methods known in the art and to a skilled person. Suitable methods to prepare the compounds are described in the experimental section of this description.

Compounds according to the invention are useful in counteracting diseases or disorders mediated by an SIP receptor, preferably S1P5. They are preferably mixed with pharmaceutically suitable auxiliaries, e.g. as described in the standard reference "Remington, The Science and Practice of Pharmacy" (21st edition, Lippincott Williams & Wilkins, 2005, see especially Part 5: Pharmaceutical Manufacturing). The compounds together with pharmaceutically suitable auxiliaries may be compressed into solid dosage units, such as pills or tablets, or be processed into capsules or suppositories. By means of pharmaceutically suitable liquids the compounds can also be applied in the form of a solution, suspension or emulsion.

Provided is therefore a pharmaceutical composition comprising a compound according to the invention or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier, diluent and/or excipient. By "pharmaceutically acceptable" it is meant that the carrier, diluent or excipient must be compatible with the other ingredients of the formulation and not deleterious to the recipient thereof. In general, any pharmaceutically suitable additive which does not interfere with the function of the active compounds can be used. A pharmaceutical composition according to the invention is preferably suitable for human use.

Examples of suitable carriers comprise a solution, lactose, starch, cellulose derivatives and the like, or mixtures thereof. In a preferred embodiment said suitable carrier is a solution, for example saline. For making dosage units, e.g. tablets, the use of conventional additives such as fillers, colorants, polymeric binders and the like, is contemplated. Examples of excipients which can be incorporated in tablets, capsules and the like are the following: a binder such as gum tragacanth, acacia, corn starch or gelatin; an excipient such as

microcrystalline cellulose; a disintegrating agent such as corn starch,

pregelatinized starch, alginic acid and the like; a lubricant such as magnesium stearate; a sweetening agent such as sucrose, lactose or saccharin; a flavoring agent such as peppermint, oil of wintergreen or cherry. When the dosage unit form is a capsule, it may contain, in addition to materials of the above type, a liquid carrier such as fatty oil. Various other materials may be present as coatings or to otherwise modify the physical form of the dosage unit. For instance, tablets may be coated with shellac, sugar or both. A syrup or elixir may contain the active compound, sucrose as a sweetening agent, methyl and propyl parabens as preservatives, a dye and a flavoring such as cherry or orange flavor. Compositions for intravenous administration may for example be solutions of the compounds of the invention in sterile isotonic aqueous buffer. Where necessary, the intravenous compositions may include for instance solubilizing agents, stabilizing agents and/or a local anesthetic to ease the pain at the site of the injection. The compounds of the invention may be administered enterally or parenterally. The exact dose and regimen of these compounds and compositions thereof will be dependent on the biological activity of the compound per se, the age, weight and sex of the individual, the needs of the individual subject to whom the medicament is administered, the degree of affliction or need and the judgment of the medical practitioner. In general, parenteral administration requires lower dosages than other methods of administration which are more dependent upon adsorption. However, the dosages for humans are preferably 0.001 - 10 mg per kg body weight. In general, enteral and parenteral dosages will be in the range of 0.1 to 1.000 mg per day of total active ingredients.

In an embodiment of the invention, a pharmaceutical kit or kit of parts is provided comprising one or more containers filled with one or more

pharmaceutical compositions of the invention and optionally one or more pharmaceutically acceptable excipients as described herein. Associated with such container(s) can be various written materials such as instructions for use, or a notice in the form prescribed by a governmental agency regulating the

manufacture, use or sale of pharmaceuticals products, which notice reflects approval by the agency of manufacture, use, or sale for human or veterinary administration. Preferably, a pharmaceutical kit or kit of parts comprises instructions for use.

The compounds of the invention are modulators of the SIP receptor, in particular of the S1P5 receptor. More specifically, the compounds of the invention are S1P5 receptor agonists. The compounds are useful in the treatment or alleviation of diseases or disorders mediated by an SIP receptor, preferably S1P5. The compounds of the present invention are particularly suitable to treat or alleviate diseases and disorder s in which an SIP receptor is involved or in which modulation of the endogenous SIP signaling system via an SIP receptor is involved, preferably S1P5. Provided is therefore a method of treatment or alleviation of a disease or disorder in which an SIP receptor is involved or in which modulation of the endogenous SIP signaling system via an SIP receptor is involved, preferably S1P5, comprising administering to a patient in need thereof a compound according to the invention or a pharmaceutically acceptable salt thereof. Said patient is preferably a human patient.

Further provided is a use of a compound according to the invention or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for the treatment or alleviation of a disease or disorder in which an SIP receptor is involved or in which modulation of the endogenous SIP signaling system via an SIP receptor is involved, preferably S1P5 receptor.

Further provided is a compound according to the invention, or a pharmaceutically acceptable salt thereof for use in therapy, preferably for use as a medicament.

Further provided is a compound according to the invention or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising such compound or a pharmaceutically acceptable salt thereof, for use in the treatment or alleviation of a disease or disorder in which an SIP receptor is involved or in which modulation of the endogenous SIP signaling system via an SIP receptor is involved, preferably S1P5.

Said diseases or disorder is preferably selected from the group consisting of Alzheimer's Disease (AD), multiple sclerosis, Huntington's Disease and Parkinson's Disease. Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention pertains. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, suitable methods and materials are described in this document.

Features may be described herein as part of the same or separate aspects or embodiments of the present invention for the purpose of clarity and a concise description. It will be appreciated by the skilled person that the scope of the invention may include embodiments having combinations of all or some of the features described herein as part of the same or separate embodiments.

References described herein are incorporated by reference. Neither these, nor any other documents or citations to any references, are admitted to be prior art documents or citations.

The invention will be explained in more detail in the following, non- limiting examples.

Examples Abbreviations

AIBN azobisisobutyronitril

ACN acetonitrile

DBU diazabicyclo[5.4.0]undec-7-ene

Bn benzyl

DCM dichloromethane

DEAD diethyl azodicarboxylate

DIPEA N,N-Diisopropylethylamine

DMA N, N- dimethylacetamide

DMF N, N- dimethylformamide

DMSO dimethyl sulfoxide

EA ethyl acetate

Eq molar equivalent

EtOAc ethyl acetate

EtOH ethanol

HEPES 2-[4-(2-hydroxyethyl)piperazin-l-yl]ethanesulfonic acid

HPLC high-performance liquid chromatography

LAH lithium aluminium hydride

LC-MS Liquid Chromatography - Mass Spectrometry

LDA lithium diisopropyl amine

MeOH methanol

NaOH sodium hydroxide

NEt3 triethylamine

NBS N-bromosuccinimide

NMR nuclear magnetic resonance

Pd-C palladium-on-carbon

PG protection group

Ph3P triphenylphosphine

PS-Triphenylphosphine polystyrene-triphenylphosphine (resin-bound

triphenylphosphine) RT room temperature

SFC supercritical fluid chromatography

TEA triethylamine

Tf20 trifluoromethanesulfonic anhydride

TFA trifluoroacetic acid

THF tetradydrofuran

TLC thin layer chromatography

v/v volume/volume

1. General methods

Chemicals

Chemicals were purchased from Sigma-Aldrich, Alfa, Acros and SCRC. Liquid Chromatography - Mass Spectrometry (LC-MS)

Generally, LC-MS measurements were run on Agilent 1200 HPLC/6100 SQ System controlled by Agilent ChemStation Software using one of the follow conditions: Method A: Mobile Phase: A: Water (0.01%TFA), B: ACN (0.01 %TFA)

Gradient: 5%B for 0.2min, increase to 95%B within 1.7min, 95%B for 1.3min, back to 5%B within O.Olmin.

Flow Rate: 2.3ml/min.

Column: XBridge C18, 4.6*50mm, 3.5um

Column Temperature: 50 °C

Method B: Mobile Phase: A: Water (10 mM NH4HCO3), B: ACN

Gradient: 5%for 0.2 min, increase to 95%B within 1.7min, 95%B for 1.4min, back to 5% B within 0.01 min.

Flow Rate: 2.1 ml/min.

Column: XBridge C18, 4.6*50mm, 3.5um

Column Temperature: 50 °C

Nuclear magnetic resonance (NMR)

The compounds were either characterized via proton-NMR in d6- dimethylsulfoxide,d-chloroform, d-methanol or d-pyridine on a 400 MHz (Bruker AVm 400) or 500 MHz NMR instrument (Bruker Avance 500 MHz with 5 mm BBFo-z-Grd) or a 600 MHz (Bruker Avance 600 MHz with 5 mm Cryoprobe CPTCI (1H-13C/15N z-Grd), and/or by mass spectrometry.

The magnetic nuclear resonance spectral properties (NMR) refer to the chemical shifts (δ) expressed in parts per million (ppm). The relative area of the shifts in the 1H-NMR spectrum corresponds to the number of hydrogen atoms for a particular functional type in the molecule. The nature of the shift, as regards multiplicity, is indicated as singlet (s), broad singlet (s. br.), doublet (d), broad doublet (d br.), triplet (t), broad triplet (t br.), quartet (q), quintet (quint.) and multiplet (m).

Separation of the pure enantiomers of chiral compounds.

Two Supercritical Fluid Chromatography (SFC) methods were used to separate enantiomers from racemates of chiral compounds, referred to as "analytical SFC" and "preparative SFC". The former is in particular suitable for small scale and the latter for larger scale.

Analytical SFC

Samples were run on an Agilent 1260 Infinity Hybrid SFC System, controlled by Agilent OpenLab CDS ChemStation Edition. The system consists of an injector, a heated column compartment including a switch for 15 columns, a CC -booster pump and a binary pump module for CO2 and modifier flow. Detection was done with an UV-detector and Agilent 1100 series quadrupole mass spectrometer (ESI ionization). The backpressure regulator was set to 160 bar and heated to 60°C. If not stated otherwise, the columns were 100 mm in length, 4.6 mm in diameter and packed with 5 μπι material. They were kept at RT during analysis. As mobile phase, a mixture of liquefied CO2 and organic modifier with additive was used as indicated for each sample. The flow rate was kept at 3.5 mL/min.

Preparative SFC

Preparative separations were carried out on a Waters Prep lOOq SFC System, controlled by Waters MassLynx Software. The system consists of an open bed injector/collector, a heated column compartment including a switch for 6 columns, a COi-booster pump, a pump module for modifier flow. Detection was done by UV and a quadrupole mass spectrometer (Waters Aquity QDa, ESI-ionization). To enable quantitative collection, the gas liquid separator was driven with a make-up flow of 30 mL/min methanol. The backpressure regulator was set to 120 bar and heated to 60°C. If not stated otherwise, the columns were 250 mm in length, 20 mm in diameter and packed with 5 μιη material. They were kept at 30°C during the separation. As mobile phase, a mixture of liquefied CO2 and organic modifier with additive was used as indicated for each sample. The flow rate was kept at 100 g/min.

_L General synthesis methods and synthesis of intermediates

Synthetic Scheme 1

Procedures of Synthetic Scheme 1:

Below the procedure of synthetic scheme 1 is described in detail for compounds wherein R4 is H. Appropriately substituted starting compound 1 can be used to prepare the corresponding substituted 3'H-spiro[azetidine-3,2'-benzofuran]-6'-ol. In brief, R4-substituted 2,4-dihydroxybenzaldehyde derivatives can be converted to the corresponding parabenzyl ether derivatives with benzyl bromide under basic conditions. Reaction with diethyl 2-bromomalonate under basic conditions gives the corresponding diethyl R4-substituted 6-(benzyloxy)-3-hydroxybenzofuran-2,2(3H)- dicarboxylate. Hydrogenation under acidic conditions affords the R4- substituted diethyl 6-hydroxybenzofuran-2,2(3H)-dicarboxylate. Reaction of the phenol derivative under basic conditions with benzyl bromide yields the corresponding R4- substituted diethyl 6-(benzyloxy)benzofuran-2,2(3H)-dicarboxylate. Reduction with e.g. lithium aluminium hydride can afford the corresponding (6-(benzyloxy)-2,3- dihydrobenzofuran-2,2-diyl)dimethanol. Treatment with trifluoromethanesulfonic anhydride gives the corresponding bis-triflate which upon reaction with benzyl amine could afford the corresponding R4- substituted l-benzyl-6'-(benzyloxy)-3'H- spiro[azetidine-3,2'-benzofuran]. Hydrogenation using e.g. Pd C yields the corresponding R4- substituted 3'H-spiro[azetidine-3,2'-benzofuran]-6'-ol.

Detailed procedure of synthetic scheme 1 for compounds wherein R4 is H: 1. Synthesis of compound 2

A mixture of sodium bicarbonate (1.216 g, 14.48 mmol), benzyl bromide (2.477 g, 14.48 mmol) and 2,4-dihydroxybenzaldehyde (2 g, 14.48 mmol)) in acetonitrile (50 mL) was stirred at 85 °C for 20 hours. The solvent was removed to give a brown oil The residue was diluted with 80 mL of water, extracted with ethyl acetate (3 x 75 mL). The combined organic layers were dried over Na2S04, filtered through glass funnel and concentrated to give an orange oil. The crude material was purified by silica gel column chromatography and eluted with 5% ethyl acetate/heptane. The following fractions were collected and concentrated to give the title compound 4- (benzyloxy)-2-hydroxybenzaldehyde (2.2 g, 8.67 mmol, 59.9 % yield) as a white solid.

LCMS(ESI-MS): m/z: 312.1 [M + H] ⁺ ; Rt = 2.09 min. (Method A)

2. Synthesis of compound 3

To a solution of 4-(benzyloxy)-2-hydroxybenzaldehyde (1.0 g, 4.38 mmol) in acetone (15 mL) was added K2CO3 (1.817 g, 13.14 mmol) and followed by addition of diethyl

2-bromomalonate (1.047 g, 4.38 mmol). The mixture was stirred at RT for 10 hours.

The mixture was filtered. The filtrate was concentrated under reduced pressure.

The crude material was purified by silica gel column chromatography and eluted with 50% ethyl acetate/hexane to give the title compound 3 (1.4 g, 3.08 mmol, 70.3 % yield) as a yellow solid.

LCMS(ESI-MS): m/z: 309 [M + Na] ⁺ ; Rt = 2.04 min. (Method A)

3. Synthesis of compound 4

To a solution of compound 3 (1.0 g, 2.59 mmol) in acetic acid (50 mL) was added Pd- C (1.0 g, 0.940 mmol) and a drop of H2SO4. The mixture was attached to a hydrogenation apparatus. The system was evacuated and then refilled with hydrogen several times. The mixture was stirred and hydrogenated at 20 °C for 15 hours. The solid was filtered off. The filtrate was concentrated. The residue was purified by silica gel column chromatography and eluted with ethyl acetate/hexane (1:1) to give the title compound diethyl 6-hydroxybenzofuran-2,2(3H)-dicarboxylate (0.5 g, 1.695 mmol, 65.5 % yield) as a white solid.

LCMS(ESI-MS): m/z: 281 [M + H] ⁺ ; Ri = 1.56 min. (Method B) 4. Synthesis of compound 5

To a solution of diethyl 6-hydroxybenzofuran-2,2(3H)-dicarboxylate (500 mg, 1.784 mmol) in acetone (5 mL) was added K2CO3 (616 mg, 4.46 mmol) and benzyl bromide (0.275 mL, 2.319 mmol). The mixture was stirred at 25 °C for 2 hours. LCMS showed the reaction was complete. The mixture was concentrated in vacuum. The residue was purified by silica gel column chromatography and eluted with ethyl acetate/petroleum ether=5: l) to give title compound diethyl 6- (benzyloxy)benzofuran-2,2(3H)-dicarboxylate (600 mg, 1.458 mmol, 82 % yield). LCMS(ESI-MS): m/z: 371 [M + H] ⁺ ; Rt = 2.19 min. (Method A)

5. Synthesis of compound 6

To a solution of diethyl 6-(benzyloxy)benzofuran-2,2(3H)-dicarboxylate (1.2g, 3.24 mmol) in THF( 5 mL) was added L1AIH4 (0.492 g, 12.96 mmol) at -5 °C. The mixture was stirred at -5 °C for 2 hours. LCMS showed the reaction was complete. The reaction was quenched by addition of water (1 mL) and 15% NaOH aqueous solution (1 mL). Then 20 g of sodium sulfate was added to the mixture. The solid was filtered off. The filtrate was concentrated in vacuum. The residue was purified by silica gel column chromatography and eluted with ethyl acetate/petroleum ether=l:3) to give the title compound (6-(benzyloxy)-2,3-dihydrobenzofuran-2,2- diyl)dimethanol (0.6 g, 1.886 mmol, 58.2 % yield) as a white solid LCMS: ESI-MS: m/z: 287 [M + H]+; Rt = 2.87 min. (Method B)

6. Synthesis of compound 7

6 7

To a solution of (6-(benzyloxy)-2,3-dihydrobenzofuran-2,2-diyl)dimethanol (3.0 g, 10.48 mmol) in acetonitrile (10 mL) was added trifluoromethanesulfonic anhydride (3.72 mL, 22.00 mmol) at -20 °C, followed by DIPEA (4.57 mL, 26.2 mmol). After stirred for 0.5 hour, benzylamine (2.005 mL, 18.34 mmol) was added at -20 °C. The mixture was stirred at70 °C for 2 hours. The mixture was diluted with 100 mL of ethyl acetate andlOO mL of saturated NaCl. The organic layer was dried over Na2S04, filtered and concentrated. The residue was purified by silica gel chromatography column and eluted with ethyl acetate/petroleum ether=l:3 to give the title compound l-benzyl-6'-(benzyloxy)-3'H-spiro[azetidine-3,2'-benzofuran] (2 g, 4.48 mmol, 42.7 % yield) as a yellow solid.

LCMS: ESI-MS: m/z: 358 [M + H] ⁺ ; Rt = 2.19 min. (Method B)

7. Synthesis of 3'H-spiro[azetidine-3,2'-benzofuran]-6'-ol

7

To a solution of l-benzyl-6'-(benzyloxy)-3'H-spiro[azetidine-3,2'-benzofuran] (9.0 g, 25.2 mmol) in ethyl acetate (500 mL) was added Pd-C (2.68 g, 25.2 mmol). The mixture was attached to a hydrogenation apparatus. The system was evacuated and then refilled with hydrogen several times. The mixture was stirred and hydrogenated at 26 °C for 10 hours. The mixture was filtered and concentrated in vacuum. The residue was purified by silica gel column chromatography and eluted with ethyl acetate/petroleum ether=l:3 to give title compound 3'H-spiro[azetidine- 3,2'-benzofuran]-6'-ol (1.35 g, 7.01 mmol, 27.8 % yield).

LCMS: ESI-MS: m/z: 178[M + H]+; Rt = 0.55 min. (Method A) NMR (400 MHz, MeOD-d ₄ ): δ 6.971-6.950 (d, J = 8 Hz, 1 H), 6.314- 6.294 (d, J Hz, 1 H), 6.229 (s, 1 H), 3.939-3.914 (d, J=10 Hz, 2 H), 3.645-3.620 (d, J=10 Hz H) 3.306 (s, 2 H)

Reference: WO2006/40178

Synthetic Scheme 2

Procedures of Synthetic Scheme 2:

Below the procedure of synthetic scheme 2 is described in detail for compounds wherein R4 is H. Appropriately substituted starting compound 1 can be used to prepare the corresponding substituted l',3'-dihydrospiro[azetidine-3,2'-inden]-5'-ol. In brief, R4- substituted 4-methoxy-l,2-dimethylbenzene can be dibrominated in the two benzylic positions to give the corresponding l,2-bis(bromomethyl)-4- methoxybenzene. Alternatively an R4- substituted 4-methoxyphthalate can be reduced (e.g. lithium aluminium hydride) to the corresponding diol which can be converted under Appel reaction conditions to the equivalent R4-substituted 1,2- bis(bromomethyl)-4-methoxybenzene. Reaction with 2-cyanoacetate under basic conditions yields the corresponding R4-substituted ethyl 2-cyano-5-methoxy-2,3- dihydro-lH-indene-2-carboxylate. Hydrogenation (e.g. Raney Ni) gives the corresponding ethyl 2-(aminomethyl)-5-methoxy-2,3-dihydro-lH-indene-2- carboxylate. Reductive amination with benzyaldehyde gives the corresponding R4- substituted ethyl 2-((benzylamino)methyl)-5-methoxy-2,3-dihydro-lH-indene-2- carboxylate. Saponification (e.g. NaOH) followed by intramolecular amide formation (e.g. Mitsunobu conditions) yields the R4-substituted l-benzyl-5'- methoxy-l',3'-dihydrospiro[azetidine-3,2'-inden]-2-one. Reduction of the amide carbonyl (e.g. LAH, AICI3) gives the corresponding l-benzyl-5'-methoxy-l',3'- dihydrospiro[azetidine-3,2'-indene] . Demethylation (e.g. ΒΒη) gives the

corresponding l-benzyl-l',3'-dihydrospiro[azetidine-3,2'-inden]-5'-ol and

hydrogenation (e.g. Pd/C) could yield the R4-substituted ,3'- dihy drospiro [azetidine- 3 , 2' -inden] - 5'-ol.

Detailed procedure of synthetic scheme 2 for compounds wherein R4 is H:

1 Synthesis of l,2-bis(bromomethyl)-4-methoxybenzene (compound 2):

r r A mixture of 4-methoxy-l, 2-dimethylbenzene (50.0 g, 367 mmol), NBS (137 g, 771 mmol), and AIBN (1.21 g, 7.34 mmol) in CCU (600 mL) was refluxed for 5 h under N2. The resulting succinimide was removed by filtration, and the filtrate was concentrated in vacuo. The residue was chromatographed on silica gel (petroleum ether/dichloromethane = 8/1) to give the desired product (35.7 g, 367 mmol, 33.1 % yield) as a white solid.

Ή NMR: (400 MHz, CDCL3) δ: 7.31 (d, J=8.4 Hz, 1H), 6.92 (d, J=2.5 Hz, 1H), 6.85 (dd, J=8.4 2.8 Hz, 1H), 4.68 (s, 2H), 4.65 (s, 2H), 3.84 (s, 3H). 2 Synthesis of ethyl 2-cyano-5-methoxy-2,3-dihydro-lH-indene-2- carboxylate (compound 3):

To a mixture of sodium ethoxide (19.83 g, 291 mmol) and THF (200 ml) was added ethyl 2-cyanoacetate (16.48 g, 146 mmol) and a solution of l,2-bis(bromomethyl)-4- methoxybenzene (35.7 g, 121 mmol) in THF (50 ml) under Nitrogen at 0 °C. The mixture was stirred at 25 °C for 3 hr. To the mixture was added H2O (100 mL) and the mixture was stirred for 5 min. The mixture was extracted with ethyl acetate (300 mL * 3). The organic layers were combined, washed with saturated NaCl (100 mL), dried over anhydrous NaiSC , concentrated in vacuo. The residue was purified via column chromatography (petroleum ether/ethyl acetate = 10/1) to afford the desired product ethyl 2-cyano-5-methoxy-2,3-dihydro-lH-indene-2- carboxylate (16.6 g, 51.0 mmol, 42.0 % yield) as a white solid.

LC-MS: m/z 246.1 (M+H ₂ 0) ⁺ , RT= 1.969 min/ 3.0 min (Method B);

Ή NMR: (400 MHz, CDCI3) δ: 7.14 (d, J=8.4 Hz, 1H), 6.82-6.79 (m, 2H , 4.32 (q, J=7.2 Hz, 2H), 3.81 (s, 3H), 3.72-3.62 (m, 2H), 3.56-3.51 (m, 2H), 1.36 (t, J=7.2 Hz, 3H).

3 Synthesis of ethyl 2-(aminomethyl)-5-methoxy-2,3-dihydro-lH- indene-2-carboxylate (compound 4):

To a solution ethyl 2-cyano-5-methoxy-2,3-dihydro-lH-indene-2-carboxylate (24.66 g, 101 mmol) in Ethanol (500 ml) was added Raney Nickel (35.4 g, 302 mmol). The mixture was stirred under Hydrogen at 25 °C for 16 hr. The mixture was filtered and the filtrate was concentrated in vacuo to afford the desired product ethyl 2- (aminomethyl)-5-methoxy-2,3-dihydro-lH-indene-2-carboxylate (21.5 g, 86 mmol, 86 % yield) as a yellow oil.

LC-MS: m/z 250.2 (M+l) +, RT= 1.731 min/3.0 min (Method B);

Ή NMR: (400 MHz, DMSO-de) δ: 7.06 (d, J=8.4 Hz, 1H), 6.76 (d, J=2.0 Hz, 1H), 6.69 (dd , J=8.0 2.0 Hz, 2H), 4.09 (q, J=7.2 Hz, 2H), 3.69 (s, 3H), 3.24-3.13 (m, 2H), 2.96-3.73 (m, 4 H), 1.18 (t, J=7.2Hz, 3H).

4 Synthesis of ethyl 2-((benzylamino)methyl)-5-methoxy-2,3-dihydro- lH-indene-2-carboxylate (compound 5):

To a solution of ethyl 2-(aminomethyl)-5-methoxy-2,3-dihydro-lH-indene-2- carboxylate (21.5 g, 86 mmol) in Ethanol 150 ml) was added benzaldehyde (8.74 ml, 86 mmol) at 25 °C . The mixture was stirred at 25 °C for 1 hr. The mixture was cooled to 0 °C and to it was added sodium borohydride (9.79 g, 259 mmol) portionwise. The mixture was stirred at 0 °C for 1 hr. The mixture was neutralized with 1 N HC1. The mixture was concentrated in vacuo. The residue was extracted with ethyl acetate (200 mL * 3). The organic layers were combined, washed with saturated NaCl (100 mL), dried over anhydrous Na2S04, concentrated in vacuo. The residue was purified via flash chromatography (petroleum ether/ethyl acetate = 5/1 ) to afford the desired product ethyl 2-((benzylamino)methyl)-5-methoxy-2,3- dihydro-lH-indene-2-carboxylate (14.0 g, 37.6 mmol, 43.6 % yield) as a colorless oil. LC-MS: m/z 340.1 (M+l) ⁺ , RT= 1.55 min/3.0 min (Method B); Ή NMR: (400 MHz, CDC1 ₃ ) δ: 7.40-7.24 (m, 2H), 7.48-7.38 (m, 3H), 7.07 (d, J=8.0 Hz, 1H), 6.74-6.70 (m, 2H), 4.21-4.15 (m, 2H), 3.79 (s, 3H), 3.45-3.35 (m, 2H), 3.05- 2.81 (m, 4 H), 1.26 (t, J=7.2Hz, 3H).

Synthesis of 2-((benzylamino)methyl)-5-methoxy-2,3-dihyd:

indene-2-carboxylic acid (compound 6):

To a solution of ethyl 2-((benzylamino)methyl)-5-methoxy-2,3-dihydro-lH-indene-2- carboxylate (14.0 g, 41.2 mmol) in Ethanol (80 ml) was added 2 M sodium hydroxide (80 ml, 160 mmol) at RT. The mixture was refluxed for 2 hr. The mixture was cooled to RT. To the mixture was added 1 N HC1 to adjust PH = 7. The organic solvent was evaporated and the resulted mixture was extracted with

dichloromethane: methanol (v:v = 10: 1, 150 mL * 3). The organic layers were combined, washed with H2O (80 mL), saturated NaCl (50 mL), dried over anhydrous NaiSC , concentrated in vacuo to afford the crude product 2-

((benzylamino)methyl)-5-methoxy-2,3-dihydro-lH-indene-2-c arboxylic acid (9.7 g, 30.0 mmol, 72.7 % yield) as a white foam.

LC-MS: m/z 312.1 (M+l) ⁺ , RT= 1.477 min/3.0 min (Method B);

Ή NMR: (400 MHz, DMSO-de) δ: 9.32 (brs, 1 H), 7.35-7.27 (m, 5H), 7.04 (d, J=8.4 Hz, 1H), 6.67 (dd, J=8.0 2.4 Hz, 1H), 3.83 (s, 2H), 3.70 (s, 3H), 3.28-3.16 (m, 2H), 2.88-2.76 (m, 4 H), 1.26 (t, J=7.2Hz, 3H).

6 Synthesis of l-benzyl-5'-methoxy-l',3'-dihydrospiro[azetidine-3,2'- i

To a mixture of 2-((benzylamino)methyl)-5-methoxy-2,3-dihydro- lH-indene-2- carboxylic acid (9.85 g, 31.6 mmol), triphenylphosphine (9.96 g, 38.0 mmol) and acetonitrile (20 ml) was added CC1 ₄ (6.11 mL, 63.3 mmol) and TEA (5.29 ml, 38.0 mmol) under Nitrogen at RT. The mixture wa refluxed at 90 °C under Nitrogen for 5 hr. The mixture was concentrated in vacuo. The residue was purified via column chromatography (petroleum ether:ethyl acetate = 3:1) to afford the desired product l-benzyl-5'-methoxy-l',3'-dihydrospiro[azetidine-3,2'-inden] -2-one (7.7 g, 25.4 mmol, 80 % yield) as a yellow oil.

LC-MS: m/z 294.1 (M+l) ⁺ , RT= 1.998 min/3.0 min (Method B);

Ή NMR: (400MHz, CDC1 ₃ ) δ: 7.41-7.27 (m, 5H), 7.10 (d, J=8.4 Hz, 1H), 6.79-6.73

(m, 2H), 4.45 (s, 2H), 3.79 (s, 3H), 3.52-3.43 (m, 2H), 3.19 (s, 2H), 3.10-3.03 (m, 2H). 7 Synthesis of l-benzyl-5'-methoxy-l',3'-dihydrospiro[azetidine-3,2'- indene] (compound 8):

To a solution of aluminum chloride (7.00 g, 52.5 mmol) in THF (100 mL) was added lithium aluminum hydride (2.99 g, 79 mmol) at 0 °C under Nitrogen. The mixture was stirred at 0 °C for 5 min. To the mixture was added a solution of l-benzyl-5'- methoxy-l',3'-dihydrospiro[azetidine-3,2'-inden]-2-one (7.7 g, 26.2 mmol) in THF (10 mL) dropwise at 0 °C under Nitrogen. The mixture was stirred at 25 °C for 16 hr. To the mixture was added H2O (50 mL), 15% aq NaOH (50 mL), H2O (150 mL) dropwise at 0 °C and the mixture was stirred at 0 °C for 10 min.To the mixture was added ethyl acetate (100 mL) and the mixture was filtered through celite. The organic layer of the filtrate was separated and the aqueous layer was extracted with ethyl acetate (100 mL * 2). The organic layers were combined, washed with H2O (50 mL), saturated NaCl (50 mL), dried over anhydrous NaiSC , concentrated in vacuo to afford the desired product l-benzyl-5'-methoxy-l',3'- dihydrospiro[azetidine-3,2'-indene] (6.5 g, 21.74 mmol, 83 % yield) as a colorless oil. LC-MS: m/z 280.1 (M+l) ⁺ , RT= 1.508 min/3.0 min (Method B);

Ή NMR: (400MHz, CDCI3) δ: 7.35-7.24 (m, 5H), 7.09 (d, J=8.0 Hz, 1H), 6.76 (s, 1H), 6.71 (dd, J=8.4 2.8 Hz, 2H), 3.79 (s, 3H), 3.67 (s, 2H), 3.26 (s, 4H), 3.13(s, 2H), 3.08 (s, 2H). 8 Synthesis of l-benzyl-l',3'-dihydrospiro[azetidine-3,2'-inden]-5'-ol (compound 9):

To a solution of l-benzyl-5'-methoxy-l',3'-dihydrospiro[azetidine-3,2'-indene ] (6.50 g, 23.27 mmol) in CH2CI2 (200 ml) was added HCl/Dioxane (20 ml) dropwise at 0 °C. The mixture was stirred at 0 °C for 5 min. The mixture was concentrated in vacuo. To the solution of residue in CH2CI2 (200 ml) was added BBr3 (3.30 ml, 34.9 mmol) dropwise at -78 °C under Nitrogen. The mixture was stirred at 25 °C for 16 hr. To the mixture was added sat. NaHC03 (25 mL) and the mixture was stirred for 15 min. The organic was separated and the aqueous layer was extracted with dichloromethane/methanol (60 mL/6 mL * 3). The organic layers were combined and washed with H2O (20 mL), saturated NaCl (20 mL), dried over anhydrous Na2S04, concentrated in vacuo. The residue was purified via flash chromatography (dichloromethane:methanol = 45:1 to 30:1) to afford the desired product 1-benzyl- l',3'-dihydrospiro[azetidine-3,2'-inden]-5'-ol (4.05 g, 15.26 mmol, 65.6 % yield) as a white solid.

LC-MS: m/z 266.1 (M+l) +, RT= 1.394 min/3.0 min (Method B);

Ή NMR: (400MHz, DMSO-de) δ: 9.15 (s, 1H), 7.48-7.42 (m, 5H), 6.98 (d, J=8.0Hz, 1H), 6.60 (s, 1H), 6.54 (dd, J=8.0 2.4Hz, 1H), 4.27 (brs, 1H), 3.92 (brs, 4H), 3.11(s, 2H), 3.07 (s, 2H).

9 Synthesis of compound l',3'-dihydrospiro[azetidine-3,2'-inden]-5'-ol:

To a solution of l-benzyl-l',3'-dihydrospiro[azetidine-3,2'-inden]-5'-ol (8.10 g, 30.5 mmol) in methanol (200 ml) was added 10% Pd/C (24.3 g, 228 mmol) under Nitrogen. The mixture was stirred under hydrogen bag at 25 °C for 3 hr. The mixture was filtered, washed with methanol (100 mL). The filtrate was concentrated in vacuo to afford the desired product l',3'-dihydrospiro[azetidine-3,2'- inden]-5'-ol (4.9228 g, 28.1 mmol, 92 % yield) as a white solid.

LC-MS: m/z 176 (M-55) ⁺ , RT= 0.802 min 3.0 min (Method A);

Ή NMR: (400MHz, Methanol-de) δ: 7.03 (d, J=8.0 Hz, 1H), 6.67 (s, 1H), 6.62 (dd, J=8.4 2.4Hz, 1H), 4.07 (s, 4H), 3.20(s, 2H), 3.17 (s, 2H).

Reference:

> J. Org. Chem. 1997, 62, 6598-6602;

> Canadian Journal of Research, Section B: Chemical Sciences; vol. 26; (1948); p. 503,509;

> Synthetic Communications, 18(3), 247-252 (1988);

> WO2013/11285, (2013)

61

Intermediates leading to compounds of formula I (m = 0, 1; X = C) are commercially available or can be prepared in accordance with Synthetic Scheme 3.

Procedures of Synthetic Scheme 3:

N-protected (PG = protection group) pyrollidine 3-carboxylic ester derivatives (m = 0) or N-protected piperidine 4-carboxylic ester derivatives (m = 1) can be

deprotonated with e.g. lithium diisopropyl amine at low temperature (e.g. -78°C) and then can be alkylated in the alpha-position to the ester moiety with a para- alkoxy benzylhalide derivative (e.g. substituted para-methoxy benzyl bromide). Reaction with a strong dehydrating agent (e.g. phosphorus pentoxide) affords the corresponding spiro- 2,3-dihydro-lH-inden-l-one derivative. The carbonyl moiety of the obtained 2,3-dihydro-lH-inden-l-one derivative can be reduced in two steps, e.g. 1) sodium borohydride in ethanol; 2) triethylsilane, trifluoro acetic acid in dichloromethane) to give the corresponding spiro indanyl derivative. Deprotection of the alkoxy indanyl derivative (e.g. with boron tribromide in the case of a methoxy indanyl) yields the corresponding phenol derivative. In case of a benzyl moiety as N-protection group this protection group could be cleaved, e.g. under hydrogenating conditions using hydrogen and Pd C as catalyst to give the corresponding amino phenol spiro derivative.

Scheme 4

AcOH or TFA Rl-moieties can be introduced starting from the corresponding azetidines, wherein X is O or CH2 (see synthetic schemes 1 and 2), using alkylating or reductive amination conditions as depicted in scheme 4 above. When the Rl-moiety contains an ester the corresponding acid can be obtained by saponification under basic (e.g. NaOH) or acidic (e.g. TFA) conditions. Scheme 4 shows a number of routes starting from R4 substituted 3'H-spiro[azetidine-3,2'-benzofuran]-6'-ol or ,3'- dihydrospiro[azetidine-3,2'-inden]-5'-ol. It is clear to a person skilled in the art that these routes are suitable to introduce alternative substituents in these azetindine- containing compounds using the appropriate reagent(s), as well as in the corresponding pyrrolidine- or piperidine-containing compounds.

heme 5

base, e.g. DIPEA

2) Sonogashira reaction,

e.g. Pd(OAc) ₂ , PPh ₃ ,

K ₃ P0 ₄ „ __

R ³ -L- is

Mitsunobu reaction or DEAD, PPh ₃ , R-CH ₂ -O- R-CH ₂ -OH

R3-L-moieties can be introduced starting from the corresponding phenols via the corresponding nonaflates or triflates followed by Sonogashira reaction with an substituted alkyne or by the same protocol followed by hydrogenation which can yield the corresponding ethenyl derivative as shown in scheme 5. R3-L-moieties that contain a phenyl ether can be obtained under alkylating conditions using the corresponding alkylhalide precursors or under Mitsunobu conditions using the corresponding alkyl alcohols.

When the Rl-moiety contains an ester the corresponding acid can be obtained by saponification under basic (e.g. NaOH) or acidic (e.g. TFA) conditions.

Scheme 5 shows a number of routes starting from R4 substituted 3Ή- spiro[azetidine-3,2'-benzofuran]-6'-ol or l',3'-dihydrospiro[azetidine-3,2'-inden]-5'- ol. It is clear to a person skilled in the art that these routes are suitable to introduce R3-L-moieties in in the corresponding pyrrolidine- or piperidine- containing compounds as well.

In section 3. Synthesis of compounds according to the invention below, the introduction of alternative linkers L and R3-L-moieties is described. It is clear to a skilled person that the routes described for specific compounds can be used to introduce the same linker L and R3-L- moieties in other compounds according to the invention.

3. Synthesis of compounds according to the invention

Example 1. l-((5'-((4-ethoxyphenyl)ethynyl)-l',3'-dihydrospiro[azetidin e-3,2'- inden]-l-yl)methyl)cyclopropanecarboxylic acid compound with 2,2,2-trifluoroacetic acid (1:1)

In a 100 mL 3neck flask was methyl l-((5'-hydroxy-l\3'-dihydrospiro[azetidine-3,2'- inden]-l-yl)methyl)cyclopropanecarboxylate (650 mg, 2.262 mmol, prepared as described for example 28) in CH2CI2 (20 mL) to give a light yellow solution.

Pyridine (0.45 mL, 5.56 mmol) was added. The mixture was cooled to 0°C and at this temperature trifluoromethanesulfonic anhydride (2.488 mL, 2.488 mmol) was added dropwise. The color of the solution turned to yellow.

The reaction mixture was diluted with CH2CI2 and washed 2x with sat. NH4CI- solution and lx with saturated NaCl. The organic layer was dried over MgS04, filtered and evaporated. The residue was purified using the Isco-Combiflash (12 g, 0-10% MeOH in CH2CI2, 30mL/min).

Yield: 680 mg (yellow oil)

In a Schlenck flask were triphenylphosphine (8 mg, 0,031 mmol), palladium(II) acetate (2 mg, 8.91 μιηοΐ) and potassium phosphate tribasic monohydrate (40 mg, 0.174 mmol) dried for 30 min under Argon. In a second flask were 4- ethoxyphenylacetylene (25.1 mg, 0.172 mmol) and methyl l-((5'- (((trifluoromethyl)sulfonyl)oxy)-l',3'-dihydrospiro [azetidine-3,2'-inden]-l- yl)methyl)cyclopropanecarboxylate (60 mg, 0.143 mmol) dissolved in DMSO (2 ml and dried under Argon for 30min. This solution was put into the Schlenck flask via syringe and heated to 80°C for lh.

The reaction mixture was diluted with CH2CI2 and washed 2x with water and lx with saturated NaCl. The organic layer was dried over a Chromabond PTS- cartridge and evaporated. The residue was purified using the Isco-Combiflash (12 g, 0-10% MeOH in CH2CI2, 30mL/min). The crude product contained some DMSO and was used in next step.

Yield: 290 mg (brown oil)

In a 50 mL round-bottomed flask (t=g) was methyl l-((5'-((4-ethoxyphenyl)ethynyl)- l',3'-dihydrospiro[azetidine-3,2'-inden]-l-yl)methyl)cyclopr opanecarboxylate (290 mg, 0,140 mmol) in MeOH (1 mL) and THF (1 mL) to give a brown solution.

Sodium hydroxide (0.349 mL, 2 mol) was added. The reaction mixture was stirred at RT overnight. The reaction mixture was evaporated and the residue was purified by HPLC.

Yield: 6.8 mg (yellow oil)

Ή NMR (600 MHz, Chloroform-d) 5 11.60 (s, OH), 7.43 (d, J = 9.5 Hz, 1H), 7.38 - 7.28 (m, 1H), 7.18 (d, J = 7.8 Hz, OH), 6.88 - 6.83 (m, 1H), 4.53 (d, J = 10.3 Hz, 1H), 4.08 - 3.97 (m, 2H), 3.32 (d, J = 19.2 Hz, 2H), 3.13 (d, J = 5.9 Hz, 1H), 1.50 (q, J = 4.7 Hz, 1H), 1.42 (t, J = 7.0 Hz, 2H), 1.03 (q, J = 4.7 Hz, 1H).

MS: Calculated mass (C26H27N03): 401.20, found mass: M+H=402

Example 2. l-((5'-((2-methoxy-4-propylbenzyl)oxy)-l',3'-dihydrospiro[az etidine- 3,2'-inden]-l-yl)methyl)cyclopropanecarboxylic acid

In a 50 mL round-bottomed flask methyl l-((5'-hydroxy-l',3'- dihydrospiro[azetidine-3,2'-inden]-l-yl)methyl)cyclopropanec arboxylate (50 mg, 0,174 mmol, prepared as described for example 28) was dissolved in DMF (3 mL) to give a colorless solution. Cesium carbonate (70 mg, 0.215 mmol) and 1-

(chloromethyl)-2-methoxy-4-propylbenzene (40 mg, 0.201 mmol) were added. The reaction mixture was stirred at RT overnight.

The reaction mixture was evaporated. The residue was extracted with CH2CI2 and water. After phase separation with a Chromabond PTS-cartridge the organic layer was evaporated. The residue was purified by using the Isco-Combiflash (4 g, 0-10% MeOH in CH2CI2, 18 mL/min)

Yield: 50 mg (colorless oil)

In a 10 mL flask was methyl l-((5'-((2-methoxy-4-propylbenzyl)oxy)-l',3'- dihydrospiro[azetidine-3,2'-inden]-l-yl)methyl)cyclopropanec arboxylate (50 mg, 0.111 mmol) dissolved in THF (0.5 mL) and MeOH (0.5 mL) to give a colorless solution. NaOH (0.5 mL, 1.0 mmol) was added. The reaction mixture was stirred at RT overnight.

The reaction mixture was evaporated. The residue was dissolved in water and neutralized with 0.5 mL 2N HC1. The precipitate was filtered, washed with water and dried overnight at 40°C under vacuum.

Yield: 39 mg (colorless solid)

Ή NMR (600 MHz, DMSO-de) δ 7.25 (d, J= 7.6 Hz, 1H), 7.09 (d, J= 8.1 Hz, 1H), 6.86 (dd, J= 7.7, 1.9 Hz, 2H), 6.75 (ddd, J = 26.5, 7.9, 2.0 Hz, 2H), 4.94 (s, 2H), 3.80 (s, 3H), 3.48 (s, 5H), 3.07 (s, 2H), 3.02 (s, 2H), 2.77 (s, 2H), 2.58 - 2.51 (m, 6H), 1.64 - 1.57 (m, 2H), 0.93 - 0.88 (m, 5H), 0.62 (q, J= 3.7 Hz, 2H).

MS: Calculated mass (C27H33N04): 435.24, found mass: M+H=436 Example 3. 2-(5'-((4-butyl-2-chlorobenzyl)oxy)-l',3'-dihydrospiro[azeti dine-3,2'- inden]-l-yl)acetic acid

In a lOOmL round-bottom flask ethyl 2-(5'-hydroxy-l',3'-dihydrospiro[azetidine-3,2'- inden]-l-yl)acetate (150 mg, 0.574 mmol, prepared as described for example 8) was dissolved in DMF (10 mL) to give a colorless solution. Cesium carbonate (230 mg, 0.706 mmol) and 4-bromo-l-(bromomethyl)-2-chlorobenzene (180 mg, 0.633 mmol) were added. The reaction mixture was stirred at RT overnight.

The reaction mixture was evaporated. The residue was dissolved in CH2CI2 and washed lx with water. After phase separation with a Chromabond PTS-cartridge the organic layer was evaporated. The residue was purified using the Isco- Combiflash (12 g, 0-10% MeOH in CH2CI2)

Yield: 133 mg (yellow oil)

Under an atmosphere of argon ethyl 2-(5'-((4-bromo-2-chlorobenzyl)oxy)-l',3'- dihydrospiro[azetidine-3,2'-inden]-l-yl)acetate (30 mg, 0.065 mmol) was dissolved in Toluene (PI1CH3) (2 mL) in a microwave flask, n-butylboronic acid (10 mg, 0.098 mmol) and sodium carbonate (0.2 ml, 0.208 mmol) were added to give a yellow suspension. The reaction mixture was stirred for 30 min under argon atmosphere. Tetrakis(triphenylphosphine)palladium(0) (8 mg, 6.92 μιηοΐ) was added. The mixture was stirred for 30 min at 100°C in the Biotage microwave. LC/MS showed conversion, but the main peak was the reactant. The mixture was stirred for further 30 min at 120°C in the Biotage micowave, LC/MS showed a better conversion rate. The reaction mixture was stirred for further 60 min at 120°C in the Biotage microwave.

The reaction mixture was evaporated. The residue was dissolved in CH2CI2 and washed lx with water. After phase separation with a Chromabond PTS Cartridge the organic layer was evaporated. The residue was purified using the Isco- Combiflash (4 g, 0-10% MeOH in CH2CI2).

Yield: 23 mg (yellow oil)

In a 25 mL round-bottomed flask ethyl 2-(5'-((4-butyl-2-chlorobenzyl)oxy)-l',3'- dihydrospiro[azetidine-3,2'-inden]-l-yl)acetate (23 mg, 0.052 mmol) was dissolved in MeOH (0.5 mL) and THF (0.5 mL) to give a colorless solution. 2M NaOH (100 μL, 0.200 mmol) was added. The reaction mixture was stirred overnight.

The reaction mixture was evaporated. The residue was dissolved in water and 100 μΐ 2N HCl were added. The mixture was stirred for 10 min and CH2CI2 was added. After phase separation with a Chromabond- PTS-cartridge the organic layer was evaporated. The residue was purified using the Isco-Combiflash (4 g, 0-60% MeOH

Yield: 2.6 mg (colorless oil)

Ή NMR (500 MHz, DMSO-de) δ 7.46 (d, J= 7.9 Hz, 1H), 7.34 (d, J= 1.7 Hz, 1H), 7.20 (dd, J= 7.9, 1.7 Hz, 1H), 7.12 (d, J= 8.2 Hz, 1H), 6.91 (d, J = 2.4 Hz, 1H), 6.79 (dd, J= 8.2, 2.6 Hz, 1H), 5.05 (s, 2H), 4.00 (s, 4H), 3.89 (s, 2H), 3.18 (s, 2H), 3.13 (s, 2H), 2.64 - 2.52 (m, 3H), 2.45 (s, 1H), 1.60 - 1.50 (m, 2H), 1.34 - 1.22 (m, 2H), 0.89 (t, J= 7.4 Hz, 3H).

MS: Calculated mass (C24H28C1N03): 413.18, found mass: M+H=414/416

Example 4. 2-(5'-((2-chloro-4-ethylbenzyl)oxy)-l',3'-dihydrospiro[azeti dine-3,2'- ind -l-yl)acetic acid

In a 100 mL round-bottomed flask (t=g) was l',3'-dihydrospiro[azetidine-3,2'- inden]-5'-ol (1 g, 5,71 mmol) in DMF (40 mL) to give a colorless solution. DBU (1.3 mL, 8.62 mmol) and ethyl bromoacetate (800 μL, 7.21 mmol) were added. The reaction mixture was stirred at RT for 1 hour.

The reaction mixture was evaporated, the residue was dissolved in Ethylacetate and washed 2x with sat. NH4Cl-solution, lx with saturated NaCl, the organic layer was dried with MgS04, filtered and evaporated. The residue was purified using the Isco-Combiflash (12g, 0-20% MeOH in CH2CI2, 30mL/min)

Yield: 633mg (light brown oil).

Cs ⁺ In a lOOmL round-bottom flask was ethyl 2-(5'-hydroxy-l',3'- dihydrospiro[azetidine-3,2'-inden]-l-yl)acetate (150 mg, 0.574 mmol) in DMF (10 mL) to give a colorless solution. Cesium carbonate (230 mg, 0.706 mmol) and 4- bromo-l-(bromomethyl)-2-chlorobenzene (180 mg, 0.633 mmol) were added.The reaction mixture was stirred at RT overnight.

The reaction mixture was evaporated. The residue was dissolved in CH2CI2 and washed lx with water. After phase separation with a Chromabond PTS-cartridge the organic layer was evaporated. The residue was purified using the Isco- Combiflash (12 g, 0-10% MeOH in CH2CI2)

Yield = 133 mg yellow oil

In a microwave flask was ethyl 2-(5'-((4-bromo-2-chlorobenzyl)oxy)-l',3'- dihydrospiro[azetidine-3,2'-inden]-l-yl)acetate (mixture reactant and product ) (50 mg, 0.108 mmol) dissolved in Toluene (PI1CH3) (3 mL). Potassium

ethyltrifluoroborate (50 mg, 0.368 mmol) and sodium carbonate (0.3 mL, 0.311 mmol) were added to give a colorless suspension. The reaction mixture was stirred for 30min under an argon atmosphere. Tetrakis(triphenylphosphine)palladium(0) (20 mg, 0.017 mmol) was added. The reaction was stirred for 2h at 120°C in the microwave. LC/MS showed conversion to desired product.

The reaction mixture was evaporated. The residue was dissolved in CH2CI2 and washed lx with water, after phase separation with a Chromabond PTS Cartridge the organic layer was evaporated. The residue was purified using the Isco- Combiflash (4 g, 0-10% MeOH in CH2CI2).

Yield = 7 mg yellow oil

In a 4mL vial was ethyl 2-(5'-((2-chloro-4-ethylbenzyl)oxy)-l',3'- dihydrospiro[azetidine-3,2'-inden]-l-yl)acetate (7 mg, 0.017 mmol) dissolved in THF (0.2 mL) and MeOH (0.200 ml) to give a colorless solution. NaOH (0.042 mL,

0.085 mmol) was added. The reaction mixture was stirred overnight.

The reaction mixture was evaporated and the residue was purified by HPLC

(Waters XBridge C18 OBD, acetonitrile, water, 0.1 % TFA).

Yield: 1.4 mg clear oil (approx 70% purity by HPLC)

Ή NMR (500 MHz, Chloroform-d) 5 7.39 (dd, J = 21.0, 7.9 Hz, 1H), 7.19 (s, 1H),

7.08 (dd, J= 19.9, 8.0 Hz, 2H), 6.82 (d, J = 17.0 Hz, 1H), 6.74 (d, J = 7.8 Hz, 1H),

5.00 (s, 2H), 4.31 (s, 2H), 4.04 (s, 1H), 3.20 (d, J= 17.4 Hz, 1H), 2.67 - 2.55 (m,

2H), 1.28 - 1.16 (m, 6H)

MS: Calculated mass (C22H24C1N03): 385.14, found mass: M+H=386/388

Example 5. 3-(5'-((tetrahydro-2H-pyran-3-yl)methoxy)-l',3'-dihydrospiro [azetidine- '-inden]-l-yl)cyclobutanecarboxylic acid

In a 100 mL 3-neck round-bottomed flask l',3'-dihydrospiro[azetidine-3,2'-inden]- 5'-ol (2 g, 11,41 mmol) was suspended in THF (80 mL). Methyl 3- oxocyclobutanecarboxylate (2.92 g, 22.83 mmol) was added. The mixture was stirred for 60 min at RT. Sodium triacetoxyborohydride (4.84 g, 22.83 mmol) was added. The reaction mixture was stirred overnight at RT.

The reaction mixture was diluted with CH2CI2 and water and stirred for 30 min. CH2CI2 was added, the organic layer was washed 2x with NaHC03-solution, lx with saturated sodium chloride solution, dried over MgS04, filtered and evaporated Crude yield: 3.47 g light red solid

2.5 g of the crude product were absorbed on Celite XTR and purified using the Isco- Combiflash (12 g, 0-20% MeOH in CH2CI2, 35mL/min)

Yield: 1 g foam

In a 50 mL round-bottom flask was methyl 3-(5'-hydroxy-l',3'- dihydrospiro[azetidine-3,2'-inden]-l-yl)cyclobutanecarboxyla te (50 mg, 0.174 mmol) in DMF (3 mL) to give a colorless solution. Cesium carbonate (85 mg, 0.261 mmol) and 3-(bromomethyl)tetrahydro-2H-pyran (40 mg, 0.223 mmol) were added. The reaction mixture was stirred at RT overnight.

The reaction mixture was evaporated. The residue was dissolved in water and CH2CI2. After phase separation the organic layer was washed lx with water and lx with saturated sodium chloride solution. The organic layer was dried over MgSC , filtered and evaporated. The residue was purified using the Isco-Combiflash (4 g, 0-10% MeOH in CH2CI2, 18 mL/min)

Yield: 34 mg clear oil

In a 50mL round bottom flask was methyl 3-(5'-((tetrahydro-2H-pyran-3- yl)methoxy)-l',3'-dihydrospiro[azetidine-3,2'-inden]-l-yl)cy clobutanecarboxylate (34 mg, 0.088 mmol) dissolved in THF (0.5 mL) and MeOH (0.5 mL) to give a yellow solution. NaOH (0.25 mL, 0.500 mmol) was added. The reaction mixture was stirred at RT overnight.

The reaction mixture was evaporated. The residue was dissolved in water and neutralized with 0.25 mL 2n HCl. CH2CI2 was added, the mixture was stirred at RT for lh. After phase separation the organic layer was dried over MgSC , filtered and evaporated.

Yield: 27.7mg white foam

Ή NMR (600 MHz, Methanol-^) δ 7.10 (d, J = 8.2 Hz, 1H), 6.80 (d, J= 2.2 Hz, 1H), 6.72 (dd, J = 8.2, 2.4 Hz, 1H), 4.04 (s, 4H), 4.04 - 3.96 (m, 1H), 3.87 - 3.75 (m, 4H), 3.46 (ddd, J = 11.4, 10.0, 3.3 Hz, 1H), 3.35 (dd, J = 11.3, 9.2 Hz, 1H), 3.22 (s, 2H), 3.18 (s, 2H), 2.91 - 2.82 (m, 1H), 2.62 - 2.50 (m, 2H), 2.19 - 2.11 (m, 2H), 2.11 - 2.01 (m, 1H), 1.89 (dq, J= 12.9, 4.3 Hz, 1H), 1.72 - 1.58 (m, 2H), 1.45 (dtd, J = 13.1, 10.4, 4.6 Hz, 1H).

MS: Calculated mass (C22H29N04): 371.21, found mass: M+H=372

Example 6. 3-(5'-(benzyloxy)-l',3'-dihydrospiro[azetidine-3,2'-inden]-l -yl)propanoic acid hydrochloride

In a 50 mL round-bottomed flask l',3'-dihydrospiro[azetidine-3,2'-inden]-5'-ol hydrochloride (100 mg, 0.472 mmol) was dissolved in MeOH (5 mL) to give a colorless solution. DBU (0.5 mL, 3.32 mmol) and tert-butyl acrylate (0.5 mL, 3.41 mmol) were added. The reaction mixture was stirred at RT for 30 min. LC/MS showed complete conversion.

The reaction mixture was evaporated. The residue was dissolved in CH2CI2, the organic layer was washed 2x with sat. NH4CI- solution, lx with saturated sodium chloride solution, dried over MgS04, filtered and evaporated. The crude product (oil) was purified using the Isco-Combiflash (4g, 0-10% MeOH in CH ₂ C1 ₂ )

Yield: 99 mg clear oil

In a Schlenck flask tert-butyl 3-(5'-hydroxy-l\3'-dihydrospiro[azetidine-3,2'-inden]- l-yl)propanoate (50 mg, 0.165 mmol) was dissolved in DMF (2 mL) to give a colorless solution. The reaction mixture was cooled down to 0°C and was added. Stirred at 0°C for 30 min. Benzyl bromide (0.020 mL, 0.165 mmol) was added. After lh the reaction was finished.

0.5 mL sat. NH4CI- solution was added slowly to the mixture and after that the mixture was diluted with ethyl acetate. The organic layer was washed lx with water, after phase separation, the organic layer was dried over MgS04, filtered and evaporated. The residue was purified using the Isco-Combiflash (4 g, 0-10% MeOH

Yield: 41 mg oil

In a 25 mL round-bottomed flask tert-butyl 3-(5'-(benzyloxy)-l',3'- dihydrospiro[azetidine-3,2'-inden]-l-yl)propanoate (41 mg, 0.104 mmol) was dissolved in Methanol (1 mL) and Tetrahydrofuran (1 mL). NaOH (250 μΙ_, 0.500 mmol) was added. The reaction mixture was stirred at RT overnight. LC/MS showed that the conversion was not complete. 300μL 2n NaOH were added and stirred for further 4h at RT.

The reaction mixture was evaporated. The residue was dissolved in water and acidified with 2n HC1 (1 mL, pH-value 1-2). The precipitate was filtered, washed lx with water, dried overnight under vacuum at 40°C.

Yield: 33 mg white solid Ή NMR (600 MHz, DMSO-de) 5 12.74 (s, 1H), 10.21 (s, 1H), 7.46 - 7.40 (m, 2H), 7.39 (dd, J= 8.5, 6.7 Hz, 2H), 7.35 - 7.29 (m, 1H), 7.12 (d, J= 8.3 Hz, 1H), 6.91 (d, J = 2.5 Hz, 1H), 6.80 (dd, J= 8.3, 2.5 Hz, 1H), 5.05 (s, 2H), 4.05 (s, 4H), 3.14 (d, J = 29.5 Hz, 4H), 2.57 (t, J= 7.2 Hz, 2H).

MS: Calculated mass (C21H23N03): 337.17, found mass: M+H=338

Example 7 was prepared analogous to example 6:

Example 7. 3-(5'-((2-chloro-6-ethylbenzyl)oxy)-l',3'-dihydrospiro[azeti dine-3,2'- inden]-l-yl)propanoic acid hydrochloride

Ή NMR (600 MHz, DMSO-de) δ 12.78 (s, OH), 10.16 (s, OH), 7.42 - 7.33 (m, 2H), 7.28 (dd, J= 5.7, 3.3 Hz, 1H), 7.15 (d, J= 8.2 Hz, 1H), 6.97 (d, J= 2.4 Hz, 1H), 6.83 (dd, J= 8.2, 2.5 Hz, 1H), 5.10 (s, 2H), 4.07 (s, 4H), 3.16 (d, J = 32.9 Hz, 4H), 2.71 (q, J = 7.6 Hz, 2H), 2.57 (t, J = 7.2 Hz, 2H), 1.16 (t, J = 7.6 Hz, 3H).

MS: Calculated mass (C23H26C1N03): 399.16, found mass: M+H=400/402

Example 8. 2-(5'-(benzyloxy)-l',3'-dihydrospiro[azetidine-3,2'-inden]-l -yl)acetic acid

In a 50 mL round-bottomed flask l',3'-dihydrospiro[azetidine-3,2'-inden]-5'-ol hydrochloride (100 mg, 0.472 mmol) was dissolved in Acetonitrile (5 mL) to give a colorless solution. DBU (0.2 niL, 1.327 mmol) and ethyl bromoacetate (55 μϋι, 0.496 mmol) were added. The reaction mixture was stirred for lh at RT.

The reaction mixture was evaporated, the residue was dissolved in CH2CI2 and washed lx with sat. NH4Cl-solution, the phases were separated with a

Chromabond PTS-Cartridge and the organic layer was evaporated. The residue was purified by flash chromatography (silica 4 g, 0-10% MeOH in CH2CI2)

Yield: 81 mg clear oil

In a Schlenck flask (ethyl 2-(5'-hydroxy-l',3'-dihydrospiro[azetidine-3,2'-inden]-l- yl)acetate (40 mg, 0.153 mmol) was dissolved in DMF (2 mL) to give a colorless solution. The reaction mixture was cooled to 0°C and potassium tert-butoxide (20 mg, 0.178 mmol) was added. The reaction mixture was stirred at 0°C for 30min. benzyl bromide (20 μϋι, 0.168 mmol) was added.

(0,5mL sat. NH4Cl-solution was added slowly to the mixture and after that the mixture was diluted with ethyl acetate. The organic layer was washed lx with water, after phase separation, the organic layer was dried over MgS04, filtered and evaporated. The residue was absorbed on Celite XTR and purified using the Isco- Combiflash (4 g, 0-10% MeOH in CH2CI2)

Yield: 25 mg clear oil

In a 25 mL round-bottomed flask ethyl 2-(5'-(benzyloxy)-l',3'- dihydrospiro[azetidine-3,2'-inden]-l-yl)acetate (25 mg, 0.071 mmol) was dissolved in MeOH (1 mL) and THF (1 mL) to give a colorless solution. NaOH (0.2 mL, 0.400 mmol) was added. The reaction mixture was stirred at RT overnight. The reaction mixture was evaporated. The residue was dissolved in water and neutralized with HOAc (to pH value 6).50 mL CH2CI2 were added. After phase separation with a Chromabond PTS cartridge, the organic layer was evaporated and purified by flash chromatography (silica 4 g, 0-30% MeOH in CH2CI2)

The product was dried at 40°C under vacuum. Yield: 17.7mg white solid

Ή NMR (600 MHz, DMSO-de) δ 12.78 (s, OH), 10.16 (s, OH), 7.42 - 7.33 (m, 2H), 7.28 (dd, J= 5.7, 3.3 Hz, 1H), 7.15 (d, J= 8.2 Hz, 1H), 6.97 (d, J= 2.4 Hz, 1H), 6.83 (dd, J= 8.2, 2.5 Hz, 1H), 5.10 (s, 2H), 4.07 (s, 4H), 3.16 (d, J = 32.9 Hz, 4H), 2.71 (q, J = 7.6 Hz, 2H), 2.57 (t, J = 7.2 Hz, 2H), 1.16 (t, J = 7.6 Hz, 3H).

MS: Calculated mass (C20H21NO3): 323.15, found mass: M+H+=324

Examples 9 - 27 were prepared analogous to example 8:

Example 9. 2,2,2-trifluoroacetic acid compound with 2-(5'-((2-chloro-6- methoxybenzyl)oxy)-l',3'-dihydrospiro[azetidine-3,2'-inden]- l-yl)acetic acid (1:1)

Ή NMR (600 MHz, DMSO-de) δ 10.51 (s, 1H), 7.41 (t, J = 8.2 Hz, 1H), 7.19 - 7.05 (m, 3H), 6.93 (d, J = 2.3 Hz, 1H), 6.80 (dd, J = 8.2, 2.5 Hz, 1H), 5.04 (s, 2H), 4.22 (s 2H), 4.19 - 4.10 (m, 4H), 3.21 (s, 3H), 3.16 (s, 2H).

MS: Calculated mass (C21H22C1N04): 387.12, found mass: M+H=388/390

Example 10. 2,2,2-trifluoroacetic acid compound with 2-(5'-((2-fluoro-6- methoxybenzyl)oxy -l',3'-dihydrospiro[azetidine-3,2'-inden]-l-yl)acetic acid (1:1)

Ή NMR (500 MHz, DMSO-de) δ 7.42 (td, J= 8.5, 6.9 Hz, 1H), 7.12 (d, J = 8.2 Hz, 1H), 6.98 - 6.90 (m, 2H), 6.85 (t, J = 8.8 Hz, 1H), 6.78 (dd, J= 8.2, 2.5 Hz, 1H), 4.97 (d, J = 1.5 Hz, 2H), 4.19 (s, 2H), 4.13 (d, J = 1.5 Hz, 4H), 3.83 (s, 3H), 3.20 (s, 2H), 3.15 (s, 2H).

MS: Calculated mass (C21H22FN04): 371.15, found mass: M+H=372

Example 11. 2-(5'-((4-chlorobenzyl)oxy)-l',3'-dihydrospiro[azetidine-3,2 '-inden]-l yl) acetic acid

Ή NMR (600 MHz, DMSO-de) 5 7.45 (s, 4H), 7.10 (d, J = 8.2 Hz, 1H), 6.88 (d, J = 2.3 Hz, 1H), 6.76 (dd, J= 8.2, 2.5 Hz, 1H), 5.05 (s, 2H), 3.75 (s, 4H), 3.12 (s, 2H), 3.07 (s, 2H).

MS: Calculated mass (C20H20C1NO3): 357.11, found mass: M+H=358/360

Example 12. 2,2,2-trifluoroacetic acid compound with 2-(5'-((2- (trifluoromethyl)benzyl)oxy)-l',3'-dihydrospiro[azetidine-3, 2'-inden]-l-yl)acetic acid (1:1)

Ή NMR (500 MHz, DMSO-de) δ 7.80 (d, J= 7.8 Hz, 1H), 7.77 - 7.69 (m, 2H), 7.59 (t, J= 7.4 Hz, 1H), 7.14 (d, J= 8.2 Hz, 1H), 6.91 (d, J = 2.4 Hz, 1H), 6.79 (dd, J = 8.3, 2.5 Hz, 1H), 5.18 (s, 2H), 4.16 (s, 1H), 4.12 (s, 4H), 3.20 (s, 2H), 3.15 (s, 2H). MS: Calculated mass (C21H20F3NO3): 391.14, found mass: M+H=392

Example 13. 2,2,2-trifluoroacetic acid compound with 2-(5'-((2,6- difluorobenzyl)oxy)-l',3'-dihydrospiro[azetidine-3,2'-inden] -l-yl)acetic acid (1:1)

Ή NMR (500 MHz, DMSO-de) δ 7.52 (tt, J = 8.5, 6.7 Hz, 1H), 7.17 (t, J= 8.0 Hz, 2H), 7.10 (d, J= 8.2 Hz, 1H), 6.89 (d, J = 2.6 Hz, 1H), 6.76 (dd, J = 8.2, 2.4 Hz, 1H), 5.04 (s, 2H), 3.08 - 2.97 (m, 6H).

MS: Calculated mass (C20H19F2NO3): 359.13, found mass: M+H=360

Example 14. 2-(5'-((3,5-difluorobenzyl)oxy)-l',3'-dihydrospiro[azetidine -3,2'-inden]- 1-yl) acetic acid

Ή NMR (600 MHz, DMSO-de) δ 7.22 - 7.13 (m, 3H), 7.11 (d, J = 8.2 Hz, 1H), 6.89 (d, J = 2.4 Hz, 1H), 6.78 (dd, J = 8.2, 2.5 Hz, 1H), 5.09 (s, 2H), 3.77 (s, 4H), 3.40 (s, 2H), 3.13 (s, 2H), 3.08 (s, 2H).

MS: Calculated mass (C20H19F2NO3): 359.13, found mass: M+H=360

Example 15. 2-(5'-((2-chloro-6-cyclopropylbenzyl)oxy)-l',3'-dihydrospiro [azetidine- 3,2'-inden]-l-yl)acetic ac

Ή NMR (600 MHz, DMSO-de) δ 7.39 - 7.28 (m, 2H), 7.14 (d, J = 8.2 Hz, 1H), 7.04 (d, J = 7.3 Hz, 1H), 6.97 (d, J = 2.3 Hz, 1H), 6.84 (dd, J = 8.2, 2.4 Hz, 1H), 5.26 (s, 2H), 3.92 - 3.85 (m, 4H), 3.56 (s, 2H), 3.18 (s, 2H), 3.12 (s, 2H), 2.06 (ddd, J = 13.7, 8.6, 5.3 Hz, 1H), 0.96 - 0.88 (m, 2H), 0.70 (q, J = 5.3 Hz, 2H).

MS: Calculated mass (C23H24C1N03): 397.14, found mass: M+H=398/400

Example 16. 2-(5'-((3-chlorobenzyl)oxy)-l',3'-dihydrospiro[azetidine-3,2 '-inden]-l- yl)acetic acid compound with acetic acid (1:1)

Ή NMR (600 MHz, DMSO-de) δ 11.78 (s, 2H), 7.49 (t, J = 1.7 Hz, 1H), 7.44 - 7.37 (m, 3H), 7.10 (d, J = 8.2 Hz, 1H), 6.89 (d, J = 2.4 Hz, 1H), 6.78 (dd, J = 8.2, 2.5 Hz, 1H), 5.07 (s, 2H), 3.78 (s, 4H), 3.41 (s, 2H), 3.13 (s, 2H), 3.08 (s, 2H), 1.91 (s, 6H). MS: Calculated mass (C20H20C1NO3): 357.11, found mass: M+H=358/360

Example 17. 2,2,2-trifluoroacetic acid compound with 2-(5'-((2-fluoro-6- methylbenzyl)oxy -l',3'-dihydrospiro[azetidine-3,2'-inden]-l-yl)acetic acid (1:1)

Ή NMR (500 MHz, DMSO-de) δ 10.52 (s, 1H), 7.32 (td, J= 8.0, 5.9 Hz, 1H), 7.16 - 7.04 (m, 3H), 6.94 (d, J= 2.6 Hz, 1H), 6.82 (dd, J = 8.2, 2.5 Hz, 1H), 5.04 (d, J = 1.7 Hz, 2H), 4.21 (s, 2H), 4.15 (d, J = 1.5 Hz, 4H), 3.21 (s, 2H), 3.16 (s, 2H), 2.36 (s, 4H). MS: Calculated mass (C21H22FN03): 355.16, found mass: M+H=356

Example 18. 2,2,2-trifluoroacetic acid compound with 2-(5'-((2-chloro-6- fluorobenzyl)oxy)-l' '-dihydrospiro[azetidine-3,2'-inden]-l-yl)acetic acid (1:1)

Ή NMR (500 MHz, DMSO-de) δ 7.51 (td, J= 8.3, 6.2 Hz, 1H), 7.42 (d, J = 8.1 Hz, 1H), 7.31 (t, J = 8.8 Hz, 1H), 7.14 (d, J = 8.2 Hz, 1H), 6.95 (d, J= 2.4 Hz, 1H), 6.82 (dd, J = 8.2, 2.4 Hz, 1H), 5.09 (d, J = 1.9 Hz, 2H), 4.04 (s, 4H), 3.96 (s, 2H), 3.19 (s, 2H), 3.14 (s, 2H).

MS: Calculated mass (C20H19C1FNO3): 375.10, found mass: M+H=376/378 Example 19. 2-(5'-((2-fluoro-6-(trifluoromethyl)benzyl)oxy)-l',3'- dihy drospiro [azetidine- ' -inden] - 1 -yl)acetic acid

Ή NMR (500 MHz, DMSO-de) δ 7.80 (d, J= 7.8 Hz, 1H), 7.77 - 7.69 (m, 2H), 7.59 (t, J= 7.4 Hz, 1H), 7.14 (d, J= 8.2 Hz, 1H), 6.91 (d, J = 2.4 Hz, 1H), 6.79 (dd, J = 8.3, 2.5 Hz, 1H), 5.18 (s, 2H), 4.14 (d, J = 20.4 Hz, 6H), 3.20 (s, 2H), 3.15 (s, 2H). MS: Calculated mass (C21H19F4N03): 409.13, found mass: M+H=410

Example 20. 2,2,2-trifluoroacetic acid compound with 2-(5'-((2-chloro-6- (trifluoromethyl)benzyl)oxy)-l',3'-dihydrospiro[azetidine-3, 2'-inden]-l-yl)acetic acid (1:1)

Ή NMR (500 MHz, DMSO-de) δ 13.89 (s, OH), 10.57 (s, 1H), 7.92 (d, J= 8.1 Hz, 1H), 7.84 (d, J= 7.9 Hz, 1H), 7.69 (t, J= 8.0 Hz, 1H), 7.15 (d, J= 8.2 Hz, 1H), 6.97 (d, J = 2.3 Hz, 1H), 6.83 (dd, J = 8.2, 2.5 Hz, 1H), 5.14 (s, 2H), 4.23 (s, 2H), 4.21 - 4.12 (m, 4H), 3.23 (s, 2H), 3.17 (s, 2H).

MS: Calculated mass (C21H19C1F3N03): 425.10, found mass: M+H=426/428

Example 21. 2-(5'-((2-ethyl-6-fluorobenzyl)oxy)-l',3'-dihydrospiro[azeti dine-3,2'- inden] -l-yl)acetic acid

Ή NMR (600 MHz, DMSO-de) δ 7.38 (td, J= 8.0, 6.0 Hz, 1H), 7.17 - 7.11 (m, 2H), 7.08 (ddd, J= 9.6, 8.2, 1.1 Hz, 1H), 6.93 (d, J = 2.3 Hz, 1H), 6.79 (dd, J= 8.2, 2.5 Hz, 1H), 5.02 (d, J = 1.7 Hz, 2H), 3.77 (d, J = 2.2 Hz, 5H), 3.14 (s, 3H), 3.09 (s, 2H), 2.70 (q, J = 7.5 Hz, 2H).

MS: Calculated mass (C22H24FN03): 369.17, found mass: M+H=370 Example 22. 2-(5'-((4-bromo-2-chlorobenzyl)oxy)-l',3'-dihydrospiro[azeti dine-3,2'- inden]-l-yl)acetic acid

Ή NMR (600 MHz, DMSO-de) δ 7.81 (d, J= 2.0 Hz, 1H), 7.61 (dd, J= 8.2, 2.0 Hz, 1H), 7.52 (d, J= 8.3 Hz, 1H), 7.13 (d, J = 8.3 Hz, 1H), 6.91 (d, J = 2.4 Hz, 1H), 6.79 (dd, J = 8.2, 2.5 Hz, 1H), 5.07 (s, 2H), 3.90 (s, 4H), 3.16 (s, 2H), 3.11 (s, 2H).

MS: Calculated mass (C20H19BrClNO3): 435.02, found mass: M+H=436/438

Example 23. 2,2,2-trifluoroacetic acid compound with 2-(5'-((2,5- dichlorobenzyl)ox -l',3'-dihydrospiro[azetidine-3,2'-inden]-l-yl)acetic acid (1:1)

Ή NMR (500 MHz, DMSO-de) δ 7.64 (d, J= 2.7 Hz, 1H), 7.56 (d, J= 8.5 Hz, 1H), 7.47 (dd, J= 8.6, 2.7 Hz, 1H), 7.15 (d, J= 8.3 Hz, 1H), 6.95 (d, J = 2.4 Hz, 1H), 6.83 (dd, J= 8.2, 2.5 Hz, 1H), 5.10 (s, 2H), 4.08 (s, 5H), 3.20 (s, 2H), 3.15 (s, 2H).

MS: Calculated mass (C20H19C12NO3): 391.07, found mass: M+H=392/394/396

Example 24. 2,2,2-trifluoroacetic acid compound with 2-(5'-((2-chloro-6- ethylbenzyl)oxy)-l',3'-dihydrospiro[azetidine-3,2'-inden]-l- yl)acetic acid (1:1)

Ή NMR (500 MHz, DMSO-de) δ 7.37 - 7.35 (m, 2H), 7.28 (dd, J = 5.4, 3.7 Hz, 1H), 7.15 (d, J = 8.3 Hz, 1H), 6.96 (d, J= 2.4 Hz, 1H), 6.83 (dd, J = 8.2, 2.5 Hz, 1H), 5.10 (s, 2H), 4.20 - 4.10 (m, 6H), 3.22 (s, 2H), 3.16 (s, 2H), 2.71 (q, J = 7.5 Hz, 2H), 1.16 (t, J= 7.5 Hz, 3H).

MS: Calculated mass (C22H24C1N03): 385.14, found mass: M+H=386/388 Example 25. 2,2,2-trifluoroacetic acid compound with 2-(5'-((3,4- dichlorobenzyl)oxy)-l',3'-dihydrospiro[azetidine-3,2'-inden] -l-yl)acetic acid (1:1)

Ή NMR (500 MHz, DMSO-de) δ 7.69 (d, J= 2.1 Hz, 1H), 7.66 (d, J= 8.3 Hz, 1H), 7.42 (dd, J= 8.3, 2.1 Hz, 1H), 7.12 (d, J= 8.3 Hz, 1H), 6.90 (d, J = 2.4 Hz, 1H), 6.79 (dd, J= 8.3, 2.5 Hz, 1H), 5.08 (s, 2H), 4.06 (d, J= 6.4 Hz, 5H), 3.18 (s, 2H), 3.13 (s, 2H).

MS: Calculated mass (C20H19C12NO3): 391.07, found mass: M+H=392/394/396

Example 26. 2-(5'-((2,6-dimethylbenzyl)oxy)-l',3'-dihydrospiro[azetidine -3,2'- inden]-l-yl)acetic acid

Ή NMR (600 MHz, DMSO-de) δ 7.14 (dt, J= 15.7, 7.9 Hz, 2H), 7.06 (d, J = 7.6 Hz, 2H), 6.94 (d, J= 2.5 Hz, 1H), 6.80 (dd, J= 8.2, 2.5 Hz, 1H), 3.78 (d, J= 2.0 Hz, 4H), 3.40 (s, 2H), 3.15 (s, 2H), 3.09 (s, 2H), 2.31 (s, 6H).

MS: Calculated mass (C22H25N03): 351.18, found mass: M+H=352

Example 27. 2-(5'-((5-fluoro-2-(trifluoromethyl)benzyl)oxy)-l',3'- dihydrospiro [azetidine- 3 , 2' -inden] - 1 -yl)acetic acid

Ή NMR (600 MHz, DMSO-de) δ 7.88 (dd, J= 8.8, 5.4 Hz, 1H), 7.61 (dd, J= 9.7, 2.7 Hz, 1H), 7.45 - 7.39 (m, 1H), 7.09 (d, J= 8.2 Hz, 1H), 6.88 (d, J= 2.4 Hz, 1H), 6.74 (dd, J = 8.2, 2.5 Hz, 1H), 5.18 (s, 2H), 3.05 (s, 4H), 2.98 (s, 2H), 2.93 (s, 2H), 2.66 (s, 2H).

MS: Calculated mass (C21H19F4N03): 409.13, found mass: M+H=410

Example 28. l-((5'-((2-chloro-6-ethylbenzyl)oxy)-l',3'-dihydrospiro[azet idine-3,2'- inden]-l-yl)methyl)cyclopropanecarboxylic acid

In a 50 mL round-bottomed flask l',3'-dihydrospiro[azetidine-3,2'-inden]-5'-ol hydrochloride (100 mg, 0.472 mmol) was dissolved in DMF (3 mL) to give a colorless solution. DBU (0.2 mL, 1.327 mmol) and methyl 1-

(bromomethyl)cyclopropanecarboxylate (119 mg, 0.614 mmol) were added. The reaction mixture was stirred at RT for lh.

The reaction mixture was evaporated, the residue was dissolved in CH2CI2 and washed lx with sat. NH4Cl-solution, the phases were separated with a

Chromabond PTS- Cartridge and the organic layer was evaporated. The residue was purified using the Isco-Combiflash (4 g, 0-10% MeOH in CH2CI2)

Yield: 109 mg colorless oil

In a 50 mL round-bottomed flask methyl l-((5'-hydroxy-l',3'- dihydrospiro[azetidine-3,2'-inden]-l-yl)methyl)cyclopropanec arboxylate (50 mg, 0.174 mmol) was dissolved in DMF (2 mL) to give a colorless solution. The reaction mixture was cooled down to 0°C and potassium tert-butoxide (20 mg, 0.178 mmol) was added. The reaction mixture was stirred at 0°C for 30 min. 2-(Bromomethyl)-l- chloro-3-ethylbenzene (41 mg, 0.176 mmol) was added. The reaction mixture was stirred overnight at RT.

lm L water was added to the mixture and after that the mixture was diluted with CH2CI2. The phases were separated using a Chromabond PTS-cartridge and the organic layer was evaporated. The residue was purified using the Isco-Combiflash (4 g, 0-10% MeOH in CH2CI2).

Yield: 42 mg clear oil

In a 25 mL round-bottomed flask methyl l-((5'-((2-chloro-6-ethylbenzyl)oxy)-l',3'- dihydrospiro[azetidine-3,2'-inden]-l-yl)methyl)cyclopropanec arboxylate (42 mg, 0.095 mmol) was dissolved in MeOH (1 mL) and THF (1 mL) to give a colorless solution. NaOH (0.3 mL, 0.600 mmol) was added. The reaction mixture was stirred at RT overnight.

The reaction mixture was evaporated. The residue was dissolved in water and neutralized with HOAc (to pH value 6).50 mL CH2CI2 were added. After phase separation the organic layer was dried over a GoreTex cartridge, the organic layer was evaporated. The residue was dried under vacuum at 40°C. Yield: 45 mg oil

Ή NMR (600 MHz, DMSO-de) δ 7.39 - 7.34 (m, 2H), 7.28 (dd, J = 6.0, 2.9 Hz, 1H), 7.13 (d, J = 8.3 Hz, 1H), 6.95 (d, J= 2.5 Hz, 1H), 6.81 (dd, J = 8.2, 2.5 Hz, 1H), 5.09 (s, 2H), 3.51 (s, 4H), 3.10 (s, 2H), 3.05 (s, 2H), 2.79 (s, 2H), 2.71 (q, J = 7.5 Hz, 2H), 1.16 (t, J= 7.6 Hz, 3H), 0.92 (q, J= 3.7 Hz, 2H), 0.64 (q, J= 3.7 Hz, 2H). MS: Calculated mass (C25H28C1N03): 425.18, found mass: M+H=426/428

Examples 29 - 49 were prepared analogous to example 28: Example 29. l-((5'-(benzyloxy)-l',3'-dihydrospiro[azetidine-3,2'-inden]- l- yl)methyl)cyclopropanecarboxylic acid

Ή NMR (600 MHz, DMSO-de) δ 7.45 - 7.41 (m, 2H), 7.38 (t, J= 7.6 Hz, 2H), 7.34 - 7.29 (m, 1H), 7.09 (d, J= 8.3 Hz, 1H), 6.88 (d, J= 2.3 Hz, 1H), 6.76 (dd, J= 8.2, 2.5 Hz, 1H), 5.04 (s, 2H), 3.41 (s, 4H), 3.05 (s, 2H), 3.00 (s, 2H), 2.74 (s, 2H), 0.86 (q, J = 3.5 Hz, 2H), 0.57 (q, J= 3.6 Hz, 2H).

MS: Calculated mass (C23H25N03): 363.18, found mass: M+H=364

Example 30. l-((5'-((2-fluoro-6-methoxybenzyl)oxy)-l',3'-dihydrospiro[az etidine- 3,2'-inden]-l-yl)methyl)cyclopropanecarboxylic acid compound with 2,2,2- trifluoroacetic ac

Ή NMR (500 MHz, DMSO-d ₆ ) δ 12.90 (d, J =40.4 Hz, 1H), 9.60 (s, 1H), 7.42 (td, J 8.4, 6.9 Hz, 1H), 7.12 (dd, J = 19.6, 8.3 Hz, 1H), 7.01 -6.54 (m, 5H), 4.97 (s, 2H), 4.18 (d, J = 6.1 Hz, 4H), 3.83 (s, 3H), 1.23 - 1.05 (m, 4H).

MS: Calculated mass (C24H26FN04): 411.18, found mass: M+H=412

Example 31. l-((5'-((2-chloro-6-methoxybenzyl)oxy)-l',3'-dihydrospiro[az etidine- 3,2'-inden]-l-yl)methyl)cyclopropanecarboxylic acid compound with 2,2,2- trifluoroacetic acid (1:1)

Ή NMR (500 MHz, DMSO-de) 5 12.93 (s, 1H), 9.66 (s, 1H), 7.41 (t, J= 8.2 Hz, 1H), 7.09 (dd, J= 12.4, 8.2 Hz, 3H), 6.93 (d, J = 23.2 Hz, 1H), 6.79 (dd, J= 8.2, 2.4 Hz, 1H), 5.05 (s, 2H), 4.19 (d, J = 6.2 Hz, 4H), 3.82 (s, 2H), 3.23 (d, J = 27.7 Hz, 2H), 3.12 (d, J = 26.0 Hz, 2H), 1.22 (q, J= 4.1, 3.7 Hz, 2H), 1.10 (q, J= 4.1 Hz, 2H). MS: Calculated mass (C24H26C1N04): 427.16, found mass: M+H=428

Example 32. l-((5'-((2-chloro-4-ethoxybenzyl)oxy)-l',3'-dihydrospiro[aze tidine-3,2'- inden] - 1 - yl) methyl) cycloprop anecarb oxylic acid

Ή NMR (600 MHz, DMSO-de) δ 7.47 (d, J= 8.5 Hz, 1H), 7.11 (d, J = 8.3 Hz, 1H), 7.07 (d, J = 2.6 Hz, 1H), 6.94 (dd, J = 8.5, 2.6 Hz, 1H), 6.89 (d, J = 2.4 Hz, 1H), 6.77 (dd, J= 8.2, 2.5 Hz, 1H), 5.00 (s, 2H), 4.06 (q, J= 7.0 Hz, 2H), 3.08 (s, 2H), 3.03 (s, 2H), 2.78 (d, J = 2.4 Hz, 2H), 1.33 (t, J = 7.0 Hz, 3H), 0.89 (q, J = 3.5 Hz, 2H), 0.61 (p, J = 3.8, 3.2 Hz, 2H).

MS: Calculated mass (C25H28C1N04): 441.17, found mass: M+H=442/444

Example 33. l-((5'-((4-chlorobenzyl)oxy)-l',3'-dihydrospiro[azetidine-3, 2'-inden]-l- yl)methyl)cyclopropanecarboxylic acid

Ή NMR (600 MHz, DMSO-de) 5 7.45 (s, 4H), 7.10 (d, J = 8.2 Hz, 1H), 6.88 (d, J = 2.4 Hz, 1H), 6.76 (dd, J= 8.2, 2.5 Hz, 1H), 5.05 (s, 2H), 3.45 (s, 4H), 3.06 (s, 2H), 3.01 (s, 2H), 2.76 (s, 2H), 0.89 (q, J = 3.6 Hz, 2H), 0.61 (q, J = 3.7 Hz, 2H).

MS: Calculated mass (C23H24C1N03): 397.14, found mass: M+H=398/400 Example 34. l-((5'-((2-chloro-6-fluorobenzyl)oxy)-l',3'-dihydrospiro[aze tidine-3,2'- inden]-l-yl)methyl)cyclopropanecarboxylic acid compound with 2,2,2-trifluoroacetic acid (1:1)

Ή NMR (500 MHz, DMSO-d ₆ ) δ 12.91 (s,lH), 9.61 (s, 1H), 7.51 (td, J = 8.3, 6.2 Hz, 1H), 7.42 (d, J = 8.1 Hz, 1H), 7.36 - 7.27 (m, 1H), 7.20 - 7.10 (m, 1H), 6.95 (d, J =22.6 Hz, 1H), 6.83 (dd, J = 8.5, 2.2 Hz, 1H), 4.19 (d, J = 6.2 Hz, 4H), 3.45 (d, J= 5.2 Hz, 2H), 3.24 - 3.08 (m, 4H), 1.27 - 1.06(m, 4H).

MS: Calculated mass (C23H23C1FN03): 415.14, found mass: M+H=416/418

Example 35. l-((5'-((4-ethoxybenzyl)oxy)-l',3'-dihydrospiro[azetidine-3, 2'-inden]-l- yl)methyl)cyclopropanecarboxylic acid

Ή NMR (600 MHz, DMSO-de) δ 7.35 - 7.31 (m, 2H), 7.09 (d, J = 8.3 Hz, 1H), 6.94 - 6.90 (m, 2H), 6.86 (d, J= 2.3 Hz, 1H), 6.75 (dd, J = 8.2, 2.5 Hz, 1H), 4.95 (s, 2H), 4.01 (q, J = 7.0 Hz, 2H), 3.48 (s, 4H), 3.06 (s, 2H), 3.02 (s, 2H), 2.77 (s, 2H), 1.32 (t, J = 7.0 Hz, 3H), 0.91 (q, J= 3.7 Hz, 2H), 0.63 (q, J= 3.7 Hz, 2H).

MS: Calculated mass (C25H29N04): 407.21, found mass: M+H=408 Example 36. l-((5'-((2,5-dichlorobenzyl)oxy)-l',3'-dihydrospiro[azetidin e-3,2'- inden]-l-yl)methyl)cyclopropanecarboxylic acid compound with acetic acid (1:1)

Ή NMR (600 MHz, DMSO-de) δ 12.05 (s, 3H), 7.65 (d, J= 2.7 Hz, 1H), 7.56 (d, J = 8.5 Hz, 1H), 7.48 (dd, J= 8.5, 2.6 Hz, 1H), 7.14 (d, J= 8.3 Hz, 1H), 6.93 (d, J= 2.4 Hz, 1H), 6.81 (dd, J= 8.2, 2.5 Hz, 1H), 5.10 (s, 2H), 3.53 (s, 4H), 3.10 (s, 2H), 3.05 (s, 2H), 2.80 (s, 2H), 1.92 (s, 11H), 0.92 (q, J = 3.7 Hz, 2H), 0.64 (q, J = 3.7 Hz, 2H). MS: Calculated mass (C23H23C12N03): 431.11, found mass: M+H=432/434/436 Example 37. l-((5'-((2,6-difluorobenzyl)oxy)-l',3'-dihydrospiro[azetidin e-3,2'- inden]-l-yl)methyl)cyclopropanecarboxylic acid compound with 2,2,2-trifluoroacetic acid (1:1)

Ή NMR (600 MHz, DMSO-de) δ 12.05 (s, 3H), 7.65 (d, J= 2.7 Hz, 1H), 7.56 (d, J = 8.5 Hz, 1H), 7.48 (dd, J= 8.5, 2.6 Hz, 1H), 7.14 (d, J= 8.3 Hz, 1H), 6.93 (d, J= 2.4 Hz, 1H), 6.81 (dd, J = 8.2, 2.5 Hz, 1H), 5.10 (s, 2H), 3.53 (s, 4H), 3.10 (s, 2H), 3.05 (s, 2H), 2.80 (s, 2H), 1.92 (s, 11H), 0.92 (q, J = 3.7 Hz, 2H), 0.64 (q, J = 3.7 Hz, 2H). MS: Calculated mass (C23H23F2N03): 399.16, found mass: M+H=400 Example 38. l-((5'-((2,4-dichlorobenzyl)oxy)-l',3'-dihydrospiro[azetidin e-3,2'- inden] - 1 - yl) methyl) cycloprop anecarb oxylic acid

Ή NMR (600 MHz, DMSO-de) δ 7.70 (d, J= 2.2 Hz, 1H), 7.60 (d, J= 8.3 Hz, 1H), 7.48 (dd, J= 8.3, 2.2 Hz, 1H), 7.12 (d, J= 8.2 Hz, 1H), 6.91 (d, J = 2.4 Hz, 1H), 6.79 (dd, J= 8.2, 2.5 Hz, 1H), 5.09 (s, 2H), 3.46 (s, 6H), 3.08 (s, 2H), 3.03 (s, 2H), 2.77 (s, 2H), 0.89 (q, J = 3.7 Hz, 2H), 0.60 (q, J = 3.7 Hz, 2H).

MS: Calculated mass (C23H23C12N03): 431.11, found mass: M+H=432/434/436

Example 39. l-((5'-((2,6-dimethylbenzyl)oxy)-l',3'-dihydrospiro[azetidin e-3,2'- inden]-l-yl)methyl)cyclopropanecarboxylic acid compound with 2,2,2-trifluoroacetic acid (1:1)

Ή NMR (500 MHz, DMSO-de) δ 12.92 (s, 1H), 9.63 (s, 1H), 7.15 (td, J = 14.0, 13.5, 7.5 Hz, 2H), 7.07 (t, J = 6.1 Hz, 2H), 6.99 - 6.92 (m, 1H), 6.83 (dd, J = 8.1, 2.4 Hz, 1H), 4.98 (s, 2H), 4.19 (d, J = 6.2 Hz, 4H), 3.45 (d, J = 5.3 Hz, 2H), 3.24 (d, J = 28.2 Hz, 2H), 3.13 (d, J = 25.5 Hz, 2H), 1.22 (q, J = 4.1 Hz, 2H), 1.10 (q, J = 4.5, 4.1 Hz, 2H).

MS: Calculated mass (C25H29N03): 391.21, found mass: M+H=392

Example 40. l-((5'-((2-chloro-4-methoxybenzyl)oxy)-l',3'-dihydrospiro[az etidine- 3,2'-inden]-l-yl)methyl)cyclopropanecarboxylic acid

Ή NMR (600 MHz, DMSO-de) δ 7.48 (d, J = 8.6 Hz, 1H), 7.11 (d, J = 8.4 Hz, 1H), 7.09 (d, J = 2.6 Hz, 1H), 6.95 (dd, J = 8.5, 2.6 Hz, 1H), 6.89 (d, J = 2.4 Hz, 1H), 6.77 (dd, J = 8.2, 2.5 Hz, 1H), 5.01 (s, 2H), 3.79 (s, 3H), 3.48 (s, 4H), 3.08 (s, 2H), 3.03 (s, 2H), 2.77 (s, 2H), 0.91 (q, J = 3.7 Hz, 2H), 0.63 (q, J = 3.7 Hz, 2H).

MS: Calculated mass (C24H26C1N04): 427.16, found mass: M+H=428/430

Example 41. l-((5'-((2-(trifluoromethyl)benzyl)oxy)-l',3'-dihydrospiro[a zetidine- 3,2'-inden]-l-yl)methyl)cyclopropanecarboxylic acid compound with 2,2,2- trifluoroacetic acid (1:1)

Ή NMR (500 MHz, DMSO-d ₆ ) δ 12.91 (s,lH), 9.61 (s, 1H), 7.83 - 7.66 (m, 3H), 7.63 - 7.53 (m, 1H), 7.14 (s, 1H), 6.91 (d, J = 22.5 Ηζ,ΙΗ), 6.79 (dd, J = 8.2, 2.5 Hz, 1H), 5.22 - 5.14(m, 2H), 4.26 - 4.09 (m, 4H), 3.23 - 3.06 (m, 4H), 1.25 - 1.07 (m,4H). MS: Calculated mass (C24H24F3N03): 431.17, found mass: M+H=432 Example 42. l-((5'-((2-fluoro-6-methylbenzyl)oxy)-l',3'-dihydrospiro[aze tidine-3,2'- inden]-l-yl)methyl)cyclopropanecarboxylic acid compound with 2,2,2-trifluoroacetic acid (1:1)

Ή NMR (500 MHz, DMSO-de) δ 12.92 (s, 1H), 9.62 (s, 1H), 7.33 (td, J= 7.9, 5.9 Hz, 1H), 7.19 - 7.04 (m, 3H), 6.95 (d, J= 23.7 Hz, 1H), 6.82 (dd, J = 8.3, 2.4 Hz, 1H), 5.04 (s, 2H), 4.19 (d, J= 6.4 Hz, 4H), 3.45 (d, J= 5.3 Hz, 2H), 3.23 (d, J = 27.6 Hz, 2H), 3.12 (d, J= 25.7 Hz, 2H), 2.36 (d, J = 2.1 Hz, 3H), 1.22 (q, J = 4.1 Hz, 2H), 1.10 (q, J = 4.1 Hz, 2H).

MS: Calculated mass (C24H26FN03): 395.19, found mass: M+H=396

Example 43. l-((5'-((5-fluoro-2-(trifluoromethyl)benzyl)oxy)-l',3'- dihydrospiro [azetidine- 3 , 2' -inden] - 1 -yl)methyl)cyclopropanecarboxylic acid compound with -trifluoroacetic acid (1:1)

Ή NMR (500 MHz, DMSO-de) δ 9.67 (s, 1H), 7.89 (dd, J = 8.8, 5.3 Hz, 1H), 7.60 (dd, J= 9.9, 2.9 Hz, 1H), 7.44 (td, J= 8.5, 2.7 Hz, 1H), 7.17 (d, J= 13.2 Hz, 1H), 6.93 (d, J = 22.7 Hz, 1H), 6.82 (dd, J= 8.2, 2.5 Hz, 1H), 5.20 (s, 2H), 4.19 (d, J = 4 Hz, 4H), 3.45 (d, J = 3.5 Hz, 3H), 3.24 (d, J = 28.4 Hz, 2H), 3.13 (d, J = 25.1 Hz, 2H), 1.22 (q, J= 4.1 Hz, 2H), 1.10 (q, J= 4.1 Hz, 2H).

MS: Calculated mass (C24H23F4N03): 449.16, found mass: M+H=450

Example 44. l-((5'-((2-chloro-6-cyclopropylbenzyl)oxy)-l',3'-dihydrospir o[azetidine- 3,2'-inden]-l-yl)methyl)cyclopropanecarboxylic acid compound with acetic acid (1:1)

Ή NMR (600 MHz, DMSO-de) δ 7.36 - 7.30 (m, 2H), 7.13 (d, J = 8.2 Hz, 1H), 7.04 (dd, J= 7.4, 1.6 Hz, 1H), 6.97 (d, J= 2.4 Hz, 1H), 6.83 (dd, J= 8.2, 2.5 Hz, 1H), 5.26 (s, 2H), 3.56 (s, 4H), 3.11 (s, 2H), 3.06 (s, 2H), 2.06 (tt, J= 8.5, 5.3 Hz, 1H), 1.92 (s, 3H), 0.94 - 0.90 (m, 4H), 0.72 - 0.68 (m, 2H), 0.65 (q, J= 3.7 Hz, 2H).

MS: Calculated mass (C26H28C1N03): 437.18, found mass: M+H=438/440

Example 45. l-((5'-((3-chlorobenzyl)oxy)-l',3'-dihydrospiro[azetidine-3, 2'-inden]-l- yl)methyl)cyclopropanecarboxylic acid

Ή NMR (600 MHz, DMSO-de) δ 7.49 (t, J = 1.8 Hz, 1H), 7.44 - 7.36 (m, 3H), 7.10 (d, J = 8.1 Hz, 1H), 6.89 (d, J = 2.3 Hz, 1H), 6.77 (dd, J = 8.2, 2.5 Hz, 1H), 5.07 (s, 2H), 3.45 (s, 4H), 3.07 (s, 2H), 3.02 (s, 2H), 2.76 (s, 2H), 0.89 (q, J = 3.7 Hz, 2H), 0.61 (q, J = 3.7 Hz, 2H).

MS: Calculated mass (C23H24C1N03): 397.14, found mass: M+H=398/400

Example 46. l-((5'-((2,6-dichlorobenzyl)oxy)-l',3'-dihydrospiro[azetidin e-3,2'- inden] - 1 - yl) methyl) cycloprop anecarb oxylic acid

Ή NMR (600 MHz, DMSO-de) δ 7.57 (d, J= 8.1 Hz, 2H), 7.47 (dd, J= 8.7, 7.5 Hz, 1H), 7.13 (d, J= 8.2 Hz, 1H), 6.94 (d, J = 2.4 Hz, 1H), 6.81 (dd, J = 8.2, 2.5 Hz, 1H), 5.17 (s, 2H), 3.08 (s, 2H), 3.03 (s, 2H), 2.76 (s, 2H), 0.85 (q, J = 3.3 Hz, 2H), 0.56 (q, J = 3.3 Hz, 2H). MS: Calculated mass (C23H23C12N03): 431.11, found mass: M+H=432/434/436

Example 47. l-((5'-((2-chloro-6-(trifluoromethyl)benzyl)oxy)-l',3'- dihydrospiro[azetidine-3,2'-inden]-l-yl)methyl)cyclopropanec arboxylic acid compound with -trifluoroacetic acid (1:1)

Ή NMR (500 MHz, DMSO-de) δ 12.92 (s, 1H), 9.63 (s, 1H), 7.92 (d, J = 8.0 Hz, 1H), 7.84 (d, J = 7.8 Hz, 1H), 7.69 (t, J = 8.0 Hz, 1H), 7.15 (dd, J = 19.6, 8.3 Hz, 1H), 6.97 (d, J = 23.8 Hz, 1H), 6.86 - 6.81 (m, 1H), 5.14 (s, 2H), 4.19 (d, J= 6.0 Hz, 5H), 3.45 (d, J = 5.0 Hz, 2H), 3.25 (d, J= 29.1 Hz, 2H), 3.14 (d, J = 26.2 Hz, 2H), 1.22 (q, J = 4.1, 3.7 Hz, 2H), 1.10 (q, J = 4.1 Hz, 2H).

MS: Calculated mass (C24H23C1F3N03): 465.13, found mass: M+H=466/468

Example 48. l-((5'-((2-ethyl-6-fluorobenzyl)oxy)-l',3'-dihydrospiro[azet idine-3,2'- inden]-l-yl)methyl)cyclopropanecarboxylic acid

Ή NMR (600 MHz, DMSO-de) δ 7.38 (td, J= 8.0, 6.0 Hz, 1H), 7.16 - 7.12 (m, 2H), 7.09 (ddd, J= 9.5, 8.3, 1.1 Hz, 1H), 6.94 (d, J = 2.3 Hz, 1H), 6.81 (dd, J= 8.2, 2.5 Hz, 1H), 5.03 (d, J = 1.9 Hz, 2H), 3.85 (s, 4H), 3.13 (d, J= 30.7 Hz, 4H), 2.70 (q, J = 7.6 Hz, 2H), 1.17 (t, J = 7.6 Hz, 3H), 1.07 (t, J= 3.6 Hz, 2H), 0.88 (s, 2H).

MS: Calculated mass (C25H28FN03): 409.21, found mass: M+H=410

Example 49. l-((5'-((2-fluoro-6-(trifluoromethyl)benzyl)oxy)-l',3'- dihydrospiro [azetidine- 3 , 2' -inden] - 1 -yl)methyl)cyclopropanecarboxylic acid

Ή NMR (600 MHz, DMSO-de) δ 7.75 - 7.66 (m, 3H), 7.13 (d, J = 8.2 Hz, 1H), 6.92 (d, J = 2.3 Hz, 1H), 6.79 (dd, J = 8.2, 2.5 Hz, 1H), 5.09 (s, 2H), 3.49 (s, 4H), 3.09 (s, 2H), 3.05 (s, 2H), 2.78 (s, 2H), 0.91 (q, J = 3.7 Hz, 2H), 0.63 (q, J = 3.7 Hz, 2H). MS: Calculated mass (C24H23F4N03): 449.16, found mass: M+H=450

Example 50. l-((5'-(4-((3-fluorobenzyl)oxy)phenyl)-l',3'-dihydrospiro[az etidine-3,2'- in d - 1 - yl) methyl) cycloprop anecarb oxylic acid

In a 50 mL round-bottomed flask l',3'-dihydrospiro[azetidine-3,2'-inden]-5'-ol (700 mg, 3.99 mmol) was dissolved in DMF (10 mL) to give a colorless solution. DBU (660 yiL, 4.38 mmol) and methyl l-(bromomethyl)cyclopropanecarboxylate (1002 mg, 5.19 mmol) were added. The reaction mixture was stirred at RT for 1 h.

The reaction mixture was evaporated, the residue was dissolved in ethyl acetate and washed 2x with sat. NH4Cl-solution and lx with saturated sodium chloride solution, the organic layer was dried with MgS04, filtered and evaporated. The residue was purified using the Isco-Combiflash (12 g, 0-10% MeOH in CH2CI2). Yield: 650 mg yellow oil

In a 100 mL 3-neck flask methyl l-((5'-hydroxy-l',3'-dihydrospiro[azetidine-3,2'- inden]-l-yl)methyl)cyclopropanecarboxylate (650 mg, 2.262 mmol) was dissolved in CH2CI2 (20 mL) to give a light yellow solution. Pyridine (0.45 mL, 5.56 mmol) was added. The mixture was cooled to 0°C and at this temperature

trifluoromethanesulfomc anhydride (2.5 mL, 2.5 mmol) was added dropwise. The color of the solution turned to yellow.

The reaction mixture was diluted with CH2CI2 and washed 2x with sat. NH4CI- solution and lx with saturated sodium chloride solution. The organic layer was dried over MgS04, filtered and evaporated. The residue was purified using the Isco- Combiflash (12 g, 0-10% MeOH in CH2CI2, 30 mL/min).

Yield: 680 mg yellow oil

In a CEM microwave flask methyl l-((5'-(((trifluoromethyl)sulfonyl)oxy)-l',3'- dihydrospiro[azetidine-3,2'-inden]-l-yl)methyl)cyclopropanec arboxylate (630 mg, 1.502 mmol), potassium (4-benzyloxyphenyl)trifluoroborate (523 mg, 1.803 mmol) were dissolved in N,N-Dimethylformamide (15 mL). Sodium carbonate (3 mL, 3.11 mmol) was added. The reaction mixture was degassed with Argon for 30 min.

Tetrakis(triphenylphosphine)palladium(0) (87 mg, 0.075 mmol) was added. The reaction mixture was stirred for 60 min at 120°C in the CEM microwave. LC/MS showed product mass, the color of the reaction mixture changed during the reaction from yellow to black, reaction was stopped. The reaction mixture was evaporated. The residue was dissolved in CH2CI2 and washed 2x with water, lx with saturated sodium chloride solution, dried over MgS04, filtered and evaporated. The residue was purified using the Isco- Combiflash (12 g, 0-10% MeOH in CH2CI2, 30 mL/min)

Yield: 280 mg yellow solid (90% pure by HPLC)

In a 50 mL 2-neck round-bottomed flask methyl l-((5'-(4-(benzyloxy)phenyl)-l',3'- dihydrospiro[azetidine-3,2'-inden]-l-yl)methyl)cyclopropanec arboxylate (250 mg, 0.551 mmol) was dissolved in Tetrahydrofuran (5 mL) and MeOH (5 mL) to give a yellow solution. Pd-C (60 mg, 0.564 mmol) was added under Argon atmosphere. The reaction mixture was stirred at RT under hydrogen atmosphere.

The reaction mixture was filtered and the organic layer was evaporated.

Yield: 200 mg clear oil

In a 50 mL round-bottomed flask methyl l-((5'-(4-hydroxyphenyl)-l',3'- dihydrospiro[azetidine-3,2'-inden]-l-yl)methyl)cyclopropanec arboxylate (65 mg, 0.179 mmol) was dissolved in DMF (3 mL) to give a light yellow solution. Cesium carbonate (87 mg, 0.268 mmol) and 3-fluorobenzyl bromide (0.026 mL, 0.215 mmol) were added. The mixture was stirred overnight at RT.

The reaction mixture was evaporated. The residue was dissolved in CH2Cl2/water. After phase separation with a Chromabond PTS-cartridge, the organic layer was evaporated. The residue was purified using the Isco-Combiflash (4 g, 0-10% MeOH

Yield: 30 mg light brown solid

In a 50 mL round-bottomed flask methyl l-((5'-(4-((3-fluorobenzyl)oxy)phenyl)-l',3'- dihydrospiro[azetidine-3,2'-inden]-l-yl)methyl)cyclopropanec arboxylate (30 mg, 0.064 mmol) was dissolved in MeOH (1 mL) and THF (1 mL) to give a yellow solution, sodium hydroxide (0.159 mL, 0.318 mmol) was added. The mixture was stirred overnight.

The reaction mixture was neutralized with 318 μL In HC1 and concentrated under vacuum. A white precipitate was formed, the solid was filtered, washed with water and dried under vacuum at 50°C. Yield: 22 mg off-white solid

Ή NMR (600 MHz, DMSO-de) δ 7.58 - 7.54 (m, 2H), 7.45 (td, J = 8.0, 6.1 Hz, 2H), 7.37 (dd, J= 7.8, 1.7 Hz, 1H), 7.33 - 7.28 (m, 2H), 7.26 (d, J= 7.8 Hz, 1H), 7.17 (ddd, J= 10.5, 8.1, 2.6 Hz, 1H), 7.10 - 7.06 (m, 2H), 5.18 (s, 2H), 3.55 (s, 4H), 3.16 (s, 2H), 3.13 (s, 2H), 2.81 (s, 2H), 0.93 (q, J = 3.7 Hz, 2H), 0.66 (q, J = 3.8 Hz, 2H). MS: Calculated mass (C29H28FN03): 457.21, found mass: M+H=458

Examples 51 - 53 were prepared analogous to example 50:

Example 51. 1 - ((5' - (4- (cyclohexylmethoxy)phenyl) - 1 ', 3' - dihydrospiro [azetidine- 3,2'-inden]-l-yl)methyl)cyclopropanecarboxylic acid

Ή NMR (600 MHz, DMSO-de) δ 7.55 - 7.50 (m, 2H), 7.43 (d, J = 1.6 Hz, 1H), 7.36 (dd, J= 7.8, 1.8 Hz, 1H), 7.25 (d, J= 7.8 Hz, 1H), 6.99 - 6.96 (m, 2H), 3.80 (d, J =

6.4 Hz, 2H), 3.52 (s, 4H), 3.16 (s, 2H), 3.13 (s, 2H), 2.79 (s, 2H), 1.82 (dd, J= 12.6,

3.5 Hz, 2H), 1.77 - 1.62 (m, 4H), 1.31 - 1.13 (m, 3H), 1.05 (qd, J = 12.3, 3.4 Hz, 2H), 0.92 (q, J = 3.7 Hz, 2H), 0.65 (q, J = 3.8 Hz, 2H).

MS: Calculated mass (C29H35N03): 445.26, found mass: M+H=446 Example 52. l-((5'-(4-((3-chlorobenzyl)oxy)phenyl)-l',3'-dihydrospiro[az etidine-3,2'- in den] - 1 - yl) me

Ή NMR (600 MHz, DMSO-de) δ 7.58 - 7.53 (m, 3H), 7.44 (dt, J = 7.4, 2.9 Hz, 3H), 7.41 (dtd, J = 5.7, 3.7, 2.1 Hz, 1H), 7.37 (dd, J= 7.8, 1.7 Hz, 1H), 7.26 (d, J = 7.8 Hz, 1H), 7.09 - 7.06 (m, 2H), 5.17 (s, 2H), 3.59 (s, 4H), 3.17 (s, 2H), 3.14 (s, 2H), 2.86 (s, 2H), 0.95 (q, J= 3.7 Hz, 2H), 0.69 (q, J = 3.8 Hz, 2H).

MS: Calculated mass (C29H28C1N03): 473.18, found mass: M+H=474/476 Example 53. l-((5'-(4-(benzyloxy)phenyl)-l',3'-dihydrospiro[azetidine-3, 2'-inden]-l- yl)methyl)cyclopropanecarboxylic acid

Ή NMR (600 MHz, DMSO-de) δ 7.57 - 7.53 (m, 2H), 7.48 - 7.45 (m, 2H), 7.44 (d, J = 1.6 Hz, 1H), 7.43 - 7.39 (m, 2H), 7.38 - 7.32 (m, 2H), 7.25 (d, J = 7.8 Hz, 1H), 7.09 - 7.06 (m, 2H), 5.14 (s, 2H), 3.53 (s, 4H), 3.16 (s, 2H), 3.13 (s, 2H), 2.80 (s, 2H), 0.92 (q, J = 3.7 Hz, 2H), 0.65 (q, J = 3.7 Hz, 2H).

MS: Calculated mass (C29H29N03): 439.21, found mass: M+H=440

Example 54. l-((5'-phenethoxy-l',3'-dihydrospiro[azetidine-3,2'-inden]-l - yl)methyl)cyclopropanecarboxylic acid

In a 50 mL round-bottomed flask l',3'-dihydrospiro[azetidine-3,2'-inden]-5'-ol (1 g, 5.71 mmol) was dissolved in DMF (40 mL) to give a colorless solution. DBU (2.58 mL, 17.12 mmol) and methyl l-(bromomethyl)cyclopropanecarboxylate (1.432 g, 7.42 mmol) were added. The reaction mixture was stirred at RT for 2 days.

The reaction mixture was evaporated, the residue was dissolved in ethyl acetate and washed 2x with sat. Nl Cl-solution, the organic layer was dried with MgS04, filtrated and evaporated. The residue was purified using the Isco-Combiflash (40 g, 0-15% MeOH in CH2CI2, 40 mL/min).

Yield: 740 mg light yellow oil

Cs ⁺

In a 2 mL Microwave Tube methyl l-((5'-hydroxy-l',3'-dihydrospiro[azetidine-3,2'- inden]-l-yl)methyl)cyclopropanecarboxylate (50 mg, 0.174 mmol) was dissolved in

DMF (1 mL) to give a colorless solution. Cesium carbonate (125 mg, 0.383 mmol) and (2-bromoethyl)benzene (64.4 mg, 0.348 mmol) were added. The reaction mixture was stirred at 100°C for 20 minutes in a microwave.

The reaction mixture was evaporated. The residue was dissolved in CH2CI2 and water. After phase separation with a Chromabond PTS-cartridge, the organic layer was evaporated. The residue was purified using the Isco-Combiflash (4 g, 0-10%

MeOH in CH2CI2, 18 mL/min). Yield: 10.8 mg

In a 2 mL round-bottomed flask methyl l-((5'-phenethoxy-l',3'- dihydrospiro[azetidine-3,2'-inden]-l-yl)methyl)cyclopropanec arboxylate (10 mg, 0.026 mmol) was dissolved in MeOH (1 mL) and THF (2 mL) to give a colorless solution. 2M NaOH (64 μL, 0.128 mmol) were added. The mixture was stirred overnight. Additional 2M NaOH (128μ¾ was added and stirring was continued overnight.

The reaction mixture was evaporated. The residue was dissolved in water and neutralized with HCl (to pH value 7-8). CH2CI2 was added. The aqueous layer was extracted 2x with CH2CI2. After phase separation the combined organic layers were dried with MgSC , filtered and evaporated.

Yield: 8mg white solid

Ή NMR (600 MHz, DMSO-de) δ 7.33 - 7.28 (m, 4H), 7.22 (tt, J= 5.9, 3.0 Hz, 1H), 7.07 (d, J = 8.2 Hz, 1H), 6.80 (d, J = 2.3 Hz, 1H), 6.69 (dd, J = 8.2, 2.5 Hz, 1H), 4.13 (t, J= 6.9 Hz, 2H), 3.47 (s, 4H), 3.05 (s, 2H), 3.02 - 2.99 (m, 4H), 2.77 (s, 2H), 0.90 (q, J = 3.7 Hz, 2H), 0.63 (q, J = 3.7 Hz, 2H).

MS: Calculated mass (C24H27N03): 377.20, found mass: M+H=378

Examples 55 - 59 were prepared analogs to example 54:

Example 55. l-((5'-(4-chlorophenethoxy)-l',3'-dihydrospiro[azetidine-3,2 '-inden]-l- yl)methyl)cyclopropanecarboxylic acid

Ή NMR (600 MHz, DMSO-d ₆ ) δ 12.94 (s,lH), 7.41 - 7.29 (m, 4H), 7.09 (d,J = 8.3 Hz, 1H), 6.81 (d, J = 2.3 Hz, 1H), 6.70(dd, J = 8.2, 2.5 Hz, 1H), 4.21 - 4.05 (m,

6H),3.42 (s, 2H), 3.14 (d, J = 26.9 Hz, 4H), 3.00 (t,J = 6.6 Hz, 2H), 1.20 - 1.06 (m, 4H).

MS: Calculated mass (C24H26C1N03: 411.16, found mass: M+H=412 Example 56. l-((5'-(2-(trifluoromethyl)phenethoxy)-l',3'-dihydrospiro[az etidine- 3,2'-inden]-l-yl)methyl)cyclopropanecarboxylic acid

Ή NMR (600 MHz, DMSO-de) δ 7.74 - 7.69 (m, 1H), 7.67 - 7.60 (m, 2H), 7.48 - 7.43 (m, 1H), 7.08 (d, J= 8.2 Hz, 1H), 6.81 (d, J= 2.4 Hz, 1H), 6.70 (dd, J= 8.2, Hz, 1H), 4.15 (t, J= 6.9 Hz, 2H), 3.52 (s, 4H), 3.19 (t, J= 7.0 Hz, 2H), 3.06 (s, 2H), 3.02 (s, 2H), 2.81 (s, 2H), 0.92 (q, J= 3.7 Hz, 2H), 0.65 (q, J= 3.8 Hz, 2H).

MS: Calculated mass (C25H26F3N03): 445.19, found mass: M+H=446 Example 57. l-((5'-(3-chlorophenethoxy)-l',3'-dihydrospiro[azetidine-3,2 '-inden]-l- yl)methyl)cyclopropanecarboxylic acid

Ή NMR (600 MHz, DMSO-de) δ 7.41 (t, J = 1.9 Hz, 1H), 7.36 - 7.32 (m, 1H), 7.29 (dt, J = 7.0, 1.9 Hz, 2H), 7.10 (d, J= 8.3 Hz, 1H), 6.82 (d, J = 2.3 Hz, 1H), 6.71 (dd, J = 8.3, 2.5 Hz, 1H), 4.14 (t, J= 6.7 Hz, 2H), 4.09 (s, 4H), 3.16 (s, 2H), 3.11 (s, 2H), 3.02 (t, J= 6.7 Hz, 2H), 1.18 (q, J= 4.0 Hz, 2H), 1.04 (q, J= 4.1 Hz, 2H).

MS: Calculated mass (C24H26C1N03): 411.16, found mass: M+H=412/414

Example 58. l-((5'-(2-chlorophenethoxy)-l',3'-dihydrospiro[azetidine-3,2 '-inden]-l- yl)methyl)cyclopropanecarboxylic acid

Ή NMR (600 MHz, DMSO-de) δ 7.45 (dd, J = 7.6, 1.7 Hz, 2H), 7.33 - 7.26 (m, 2H), 7.08 (d, J = 8.2 Hz, 1H), 6.81 (d, J = 2.3 Hz, 1H), 6.70 (dd, J = 8.2, 2.5 Hz, 1H), 4.14 (t, J= 6.9 Hz, 2H), 3.51 - 3.43 (m, 4H), 3.14 (t, J = 6.9 Hz, 2H), 3.06 (s, 2H), 3.01 (s, 2H), 2.76 (s, 2H), 0.90 (q, J = 3.7 Hz, 2H), 0.62 (q, J = 3.7 Hz, 2H).

MS: Calculated mass (C24H26C1N03): 411.16, found mass: M+H=412/414

Example 59. l-((5'-(2,6-dichlorophenethoxy)-l',3'-dihydrospiro[azetidine -3,2'- inden] - 1 - yl) methyl) cycloprop anecarb oxylic acid

Ή NMR (600 MHz, DMSO-de) δ 7.50 (d, J= 8.1 Hz, 2H), 7.32 (t, J = 8.1 Hz, 1H), 7.09 (d, J = 8.3 Hz, 1H), 6.82 (d, J= 2.3 Hz, 1H), 6.71 (dd, J = 8.1, 2.5 Hz, 1H), 4.09 (t, J= 7.4 Hz, 2H), 3.73 (s, 4H), 3.33 (t, J= 7.3 Hz, 2H), 3.10 (s, 2H), 3.06 (s, 2H), 3.02 (s, 2H), 1.02 (q, J= 3.9 Hz, 2H), 0.80 (d, J= 4.2 Hz, 2H).

MS: Calculated mass (C24H25C12N03): 445.12, found mass: M+H=446/448/450

60. 2-(5'-phenethoxy-l',3'-dihydrospiro[azetidine-3,2'-inden]-l- yl)acetic

In a 100 mL round-bottomed l',3'-dihydrospiro[azetidine-3,2'-inden]-5'-ol (1 g, 5.71 mmol) was dissolved in DMF (40 mL) to give a colorless solution. DBU (2.5 mL, 16.59 mmol) and ethyl bromoacetate (800 μL, 7.21 mmol) were added.The reaction mixture was stirred at RT for 1 hour.

The reaction mixture was evaporated, the residue was dissolved in ethyl acetate and washed 2x with sat. NH4Cl-solution, the organic layer was dried with MgSC , filtrated and evaporated. The residue was purified using the Isco-Combiflash (40 g, 0-15% MeOH in CH2CI2, 30 mL/min).

Yield: 744 mg colorless oil.

Cs ⁺

In a 2 mL Microwave Tube ethyl 2-(5'-hydroxy-l',3'-dihydrospiro[azetidine-3,2'- inden]-l-yl)acetate (50 mg, 0.191 mmol) was dissolved in DMF (1 mL) to give a colorless solution. Cesium carbonate (145 mg, 0.445 mmol) and (2- bromoethyl)benzene (55 μϋι, 0.404 mmol) were added. The reaction mixture was stirred at 110°C for 15 minutes in the Biotage microwave.

The reaction mixture was evaporated. The residue was dissolved in CH2CI2 and water. After phase separation with a Chromabond PTS-cartridge, the organic layer was evaporated. The residue was purified using the Isco-Combiflash (4 g, 0-10% MeOH in CH2CI2, 18 mL/min).

Yield: 10 mg clear oil

In a 20 mL round-bottom-flask ethyl 2-(5'-phenethoxy-l',3'-dihydrospiro[azetidine- 3,2'-inden]-l-yl)acetate (10 mg, 0.027 mmol) was dissolved in MeOH (0.5 mL) and THF (0.5 mL)to give a colorless solution. 2M NaOH (0.068 mL, 0.137 mmol) was added. The reaction mixture was stirred at RT overnight.

The reaction mixture was evaporated. The residue was dissolved in water and neutralized with 2N HCl to pH 7-8. Approx. 100 mL CH2CI2 and a small amount of MeOH were added. After phase separation the organic layer was dried over MgS04, filtered and evaporated.

Yield: 7.8 mg white solid

Ή NMR (600 MHz, DMSO-d ₆ ) δ 7.37 - 7.18(m, 5H), 7.07 (d, J = 8.2 Hz, 1H), 6.80 (d, J =2.3 Hz, 1H), 6.69 (dd, J = 8.3, 2.4 Hz, 1H), 4.13(t, J = 6.9 Hz, 2H), 3.77 (s, 4H), 3.09 (d, J = 27.1 Hz, 4H), 3.00 (t, J = 6.8Hz, 2H),1.04 (d, J = 6.2 Hz, 3H).

MS: Calculated mass (C21H23N03): 337.17, found mass: M+H=338 Examples 61 - 63 were prepared analogous to example 60:

Example 61. 2-(5'-(2-chlorophenethoxy)-l',3'-dihydrospiro[azetidine-3,2' -inden]-l- yl) acetic acid Ή NMR (600 MHz, DMSO-de) δ 7.45 (dd, J = 7.5, 1.8 Hz, 2H), 7.34 - 7.25 (m, 2H), 7.08 (d, J = 8.2 Hz, 1H), 6.81 (d, J = 2.4 Hz, 1H), 6.70 (dd, J = 8.2, 2.5 Hz, 1H), 4.14 (t, J= 6.9 Hz, 2H), 3.77 (d, J= 1.5 Hz, 4H), 3.40 (s, 2H), 3.14 (d, J= 6.9 Hz, 2H), 3.11 (s, 2H), 3.06 (s, 2H).

MS: Calculated mass (C21H22C1N03): 371.13, found mass: M+H=372/374

Example 62. 2-(5'-(2-chlorophenethoxy)-l',3'-dihydrospiro[azetidine-3,2' -inden]-l- yl) acetic acid

Ή NMR (600 MHz, DMSO-de) δ 7.73 - 7.71 (m, 1H), 7.67 - 7.60 (m, 2H), 7.48 - 7.44 (m, 1H), 7.08 (d, J= 8.2 Hz, 1H), 6.81 (d, J= 2.5 Hz, 1H), 6.71 (dd, J= 8.3, 2.5 Hz, 1H), 4.15 (t, J= 6.9 Hz, 2H), 3.83 (s, 4H), 3.52 (s, 2H), 3.19 (t, J= 6.9 Hz, 2H), 3.12 (s, 2H), 3.08 (s, 2H).

MS: Calculated mass (C22H22F3N03): 405.16, found mass: M+H=406

Example 63. 2-(5'-(2,6-dichlorophenethoxy)-l',3'-dihydrospiro[azetidine- 3,2'- inden]-l-yl)acetic acid

Ή NMR (500 MHz, DMSO-de) δ 7.49 (d, J= 8.0 Hz, 2H), 7.35 - 7.30 (m, 1H), 7.10 (d, J = 8.2 Hz, 1H), 6.83 (d, J = 2.6 Hz, 1H), 6.72 (dd, J = 8.1, 2.4 Hz, 1H), 4.18 (s, 2H), 4.14 - 4.07 (m, 6H), 3.18 (s, 2H), 3.13 (s, 2H).

MS: Calculated mass (C21H21C12N03): 405.09, found mass:M+H=406/408/410 Example 64. 4-(5'-((2-chloro-6-ethylbenzyl)oxy)-l',3'-dihydrospiro[azeti dine-3,2'- inden] - 1 -yl) - 3 -methylbutanoic acid

In a 50 mL round-bottomed flask l',3'-dihydrospiro[azetidine-3,2'-inden]-5'-ol (100 mg, 0.571 mmol) was suspended in THF (5 mL) and MeOH (1 mL) to give a white suspension. Ethyl 3-methyl-4-oxobutanoate (329 mg, 2.283 mmol) was added (clear solution). After 30 min at RT Sodium triacetoxyborohydride (475 mg, 2.241 mmol) was added. The reaction mixture was stirred at RT overnight.

2mL water and CH2CI2 were added to the reaction mixture. The mixture was stirred for 10 min at RT. After phase separation with a Chromabond PTS cartridge the organic layer was evaporated. The residue was purified by using the Isco- Combiflash (4 g, 0-20% MeOH in CH2CI2, 18 mL/min)

Yield: 75 mg colorless oil

In a 100 mL round-bottomed flask ethyl 4-(5'-hydroxy-l',3'-dihydrospiro[azetidine- 3,2'-inden]-l-yl)-3-methylbutanoate (75 mg, 0.247 mmol) was dissolved in DMF (2 mL) to give a colorless solution. Cesium carbonate (89 mg, 0.272 mmol) and 2- (bromomethyl)-l-chloro-3-ethylbenzene (63.5 mg, 0.272 mmol) were added. The reaction mixture was stirred at RT.

The reaction mixture was evaporated. The residue was dissolved in CH2CI2 and water. After phase separation with a Chromabond PTS-cartridge the organic layer was evaporated. The residue was purified usingt the Isco-Combiflash (4 g, 0-10% MeOH in CH2CI2, 9 mL/min)

Yield: 58 mg colorless oil

In a 50 mL round-bottomed flask ethyl 4-(5'-((2-chloro-6-ethylbenzyl)oxy)-l',3'- dihydrospiro[azetidine-3,2'-inden]-l-yl)-3-methylbutanoate (58 mg, 0.127 mmol) was dissolved in MeOH (1 mL) and THF (1 mL) to give a colorless solution. 2M NaOH (0.318 mL, 0.636 mmol) was added. The reaction mixture was stirred overnight at RT.

The reaction mixture was evaporated and the residue was dissolved in water. The mixture was neutralized with 2n HC1 (300μυ> to pH value 6-7. CH2CI2 was added. After phase separation the organic layer was dried over MgS04, filtered and evaporated. The residue was dried under vacuum at 40°C.

Yield: 45 mg white foam

Ή NMR (600 MHz, DMSO-de) δ 7.38 - 7.34 (m, 2H), 7.28 (dd, J = 6.1, 2.9 Hz, 1H), 7.11 (d, J = 8.2 Hz, 1H), 6.93 (d, J= 2.4 Hz, 1H), 6.80 (dd, J = 8.1, 2.5 Hz, 1H), 5.09 (s, 2H), 3.30 - 3.17 (m, 4H), 3.04 (s, 2H), 2.99 (s, 2H), 2.71 (q, J = 7.6 Hz, 2H), 2.42 (d, J = 6.7 Hz, 2H), 2.31 (dd, J = 15.6, 6.9 Hz, 1H), 2.04 (dd, J= 15.6, 6.4 Hz, 1H), 1.81 (h, J= 6.7 Hz, 1H), 1.16 (t, J= 7.6 Hz, 3H), 0.86 (d, J = 6.8 Hz, 3H).

MS: Calculated mass (C25H30C1NO3): 427.19, found mass: M+H=428/430

Example 65 was prepared analogous to example 64: Example 65. 4-(5'-((2-ethyl-6-fluorobenzyl)oxy)-l',3'-dihydrospiro[azeti dine-3,2'- inden] - 1 -yl) - 3 -methylbutanoic acid

Ή NMR (600 MHz, DMSO-de) δ 7.38 (td, J= 8.0, 6.0 Hz, 1H), 7.15 - 7.06 (m, 3H), 6.91 (d, J = 2.4 Hz, 1H), 6.78 (dd, J = 8.2, 2.5 Hz, 1H), 5.02 (d, J = 1.8 Hz, 2H), 3.04 (s, 2H), 2.99 (s, 2H), 2.70 (q, J = 7.5 Hz, 2H), 2.31 (dd, J = 15.6, 6.9 Hz, 1H), 2.04 (dd, J= 15.6, 6.3 Hz, 1H), 1.81 (h, J= 6.8 Hz, 1H), 1.17 (t, J = 7.5 Hz, 3H), 0.86 (d, J = 6.8 Hz, 3H).

MS: Calculated mass (C25H30FNO3): 411.22, found mass: M+H=412

Example 66. 2-(5'-((2,3-dihydro-lH-inden-l-yl)oxy)-l',3'-dihydrospiro[az etidine- 3,2'-inden]-l-yl)acetic ac

In a 100 mL round-bottomed flask l',3'-dihydrospiro[azetidine-3,2'-inden]-5'-ol (1 g, 5.71 mmol) was dissolved in DMF (40 mL) to give a colorless solution. DBU (1.3 mL, 8.62 mmol) and ethyl bromoacetate (800 μL, 7.21 mmol) were added. The reaction mixture was stirred at RT overnight.

The reaction mixture was evaporated, the residue was dissolved in ethyl acetate and washed 2x with water, lx with saturated sodium chloride solution, the organic layer was dried with MgSC , filtered and evaporated. The residue was purified using the Isco-Combiflash (12 g, 0-20% MeOH in CH2CI2, 30 mL/min)

Yield: 990 mg yellow solid

To a 50mL round bottom flask containinig PS-Triphenylphosphin (160 mg, 0.296 mmol) was added to a solution of ethyl 2-(5'-hydroxy-l',3'-dihydrospiro[azetidine- 3,2'-inden]-l-yl)acetate (50 mg, 0.191 mmol) in THF (0,5 ml). The suspension was allowed to stand for 5 min and then a solution of di-tert-butyl azodicarboxylate (66.1 mg, 0.287 mmol) in THF (0.5 mL) was added. A further 0.5 mL THF was added and the solution agitated at RT for 30 min. A solution of 1-INDANOL (26 mg, 0.194 mmol) in THF (0.5 mL) was added and the reaction was stirred overnight.

The reaction mixture was diluted with CH2CI2 and water and stirred for 5 min at RT. After phase separation with a Chromabond PTS-cartridge the organic layer was evaporated. The residue was purified by using the Isco-Combiflash (4 g, 0-10% MeOH in CH2CI2, 18 mL/min)

Yield: 10 mg colorless oil

In a 50 mL round bottom flask ethyl 2-(5'-((2,3-dihydro-lH-inden-l-yl)oxy)-l',3'- dihydrospiro[azetidine-3,2'-inden]-l-yl)acetate (10 mg, 0.026 mmol) was dissolved in THF (0.5 mL) and MeOH (0.5 mL) to give a colorless solution. 2M NaOH (0.1 mL, 0.200 mmol) was added. The reaction was stirred at RT for 2 days.

The reaction mixture was evaporated. The residue was dissolved in water and neutralized with 100 μL 2n HC1. CH2CI2 was added. After phase separation the organic layer was dried over MgSC , filtered and evaporated. The residue was dried under vacuum at 40°C.

Yield: 5.6 mg white solid

Ή NMR (600 MHz, DMSO-de) δ 7.36 (d, J= 7.5 Hz, 1H), 7.33 - 7.28 (m, 2H), 7.22 (td, J = 7.1, 1.9 Hz, 1H), 7.12 (d, J= 8.1 Hz, 1H), 6.91 (d, J= 2.3 Hz, 1H), 6.80 (dd, J = 8.2, 2.5 Hz, 1H), 5.78 (dd, J = 6.7, 4.1 Hz, 1H), 3.80 (s, 4H), 3.43 (s, 2H), 3.15 (s, 2H), 3.09 (s, 2H), 3.02 (ddd, J= 15.9, 8.6, 5.6 Hz, 1H), 2.86 (ddd, J= 16.0, 8.6, 5.4 Hz, 1H), 2.04 - 1.95 (m, 1H).

MS: Calculated mass (C22H23N03): 349.17, found mass: M+H=350 Examples 67 - 69 were prepared analogous to example 66: Example 67. 2-(5'-((7-chloro-2,3-dihydro-lH-inden-l-yl)oxy)-l',3'- dihydrospiro[azetidine-3 '-inden]-l-yl)acetic acid

Ή NMR (600 MHz, DMSO-de) δ 7.37 (t, J= 7.7 Hz, 1H), 7.31 (dd, J = 7.5, 4.1 Hz, 2H), 7.12 (d, J = 8.2 Hz, 1H), 6.89 (d, J = 2.4 Hz, 1H), 6.77 (dd, J = 8.2, 2.5 Hz, 1H), 5.80 (dd, J = 6.6, 1.5 Hz, 1H), 3.82 - 3.74 (m, 4H), 3.15 (s, 2H), 3.09 (s, 2H), 2.94 (ddd, J = 16.7, 9.1, 2.5 Hz, 1H), 2.47 - 2.39 (m, 1H), 2.09 (ddt, J = 14.2, 8.0, 2.2 Hz, 1H).

MS: Calculated mass (C22H22C1N03): 383.13, found mass: M+H=384/386

Example 68. 2-(5'-((5-bromo-7-fluoro-2,3-dihydro-lH-inden-l-yl)oxy)-l',3 '- dihydrospiro[azetidine- '-inden]-l-yl)acetic acid

Ή NMR (600 MHz, DMSO-d ₆ ) δ 7.44 (d, J =1.4 Hz, 1H), 7.39 (dd, J = 8.7, 1.5 Hz, 1H), 7.12 (d, J = 8.2 Hz, 1H), 6.88 (d, J = 2.4 Hz, 1H),6.76 (dd, J = 8.2, 2.5 Hz, 1H), 5.91(dd, J = 6.5, 2.2 Hz, 1H), 3.83 - 3.73 (m, 4H), 3.17 - 3.06 (m, 5H),2.93 (ddd, J = 16.9, 9.1, 3.3 Hz, 1H), 2.14 - 2.04 (m, 1H).

MS: Calculated mass (C22H21BrFN03): 445.07, found mass: M+H=446/448 Example 69. 2-(5'-((5,7-dichloro-2,3-dihydro-lH-inden-l-yl)oxy)-l',3'- dihydrospiro[azetidine- '-inden]-l-yl)acetic acid

Ή NMR (600 MHz, DMSO-d ₆ ) δ 7.53 - 7.38 (m, 2H), 7.12 (d, J = 8.2 Hz, 1H), 6.88 (d, J = 2.4 Hz, 1H), 6.76 (dd, J = 8.2, 2.4Hz, 1H), 5.77 (dd, J = 6.9, 1.8 Hz, 1H), 3.77 (s, 4H), 3.18 - 3.05 (m, 6H), 2.95 (ddd, J = 16.9,9.1, 2.6 Hz, 2H), 2.10 (ddt, J = 14.1, 8.2, 2.3 Ηζ,ΙΗ), 1.44 - 1.33 (m, 1H), 1.25 (d, J = 21.2 Ηζ,ΙΗ). MS: Calculated mass (C22H21C12N03): 417.09, found mass: M+H=418/420/422

Example 70. 2-(5'-(2-phenoxyethoxy)-l',3'-dihydrospiro[azetidine-3,2'-in den]-l- yl) acetic acid

In a 100 mL round-bottomed flask l',3'-dihydrospiro[azetidine-3,2'-inden]-5'-ol (1 g, 5.71 mmol) was dissolved in DMF (40 mL) to give a colorless solution. DBU (1.3 mL, 8,62 mmol) and ethyl bromoacetate (800 μL, 7.21 mmol) were added. The reaction mixture was stirred at RT overnight.

The reaction mixture was evaporated, the residue was dissolved in ethyl acetate and washed 2x with water, lx with saturated sodium chloride solutoin, the organic layer was dried with MgSC , filtered and evaporated. The residue was purified using the Isco-Combiflash (12 g, 0-20% MeOH in CH2CI2, 30 mL/min)

Yield: 990 mg yellow solid

To a 50 mL round bottom flask containinig PS-Triphenylphosphin (155 mg, 0.287 mmol) was added a solution of ethyl 2-(5'-hydroxy-l',3'-dihydrospiro[azetidine-3,2'- inden]-l-yl)acetate (50 mg, 0.191 mmol) in THF (0.5 mL). The suspension was allowed to stand for 5 min and then a solution of di-tert-butyl azodicarboxylate (66.1 mg, 0.287 mmol) in THF (0.5 mL) was added. A further 0.5 mL THF was added and the solution agitated at RT for 30 min. A solution of 2-phenoxyethanol (0.025 mL, 0.201 mmol) in THF (0.5 mL) was added and the reaction was stirred overnight at RT. The reaction mixture was diluted with CH2CI2 and water and stirred for 5 min at RT. After phase separation with a Chromabond PTS-cartridge the organic layer was evaporated. The residue was purified by using the Isco-Combiflash (4 g, 0-10% MeOH in CH2CI2, 18 mL/min)

Yield: 14 mg colorless oil

In a 50 mL round bottom flask ethyl 2-(5'-(2-phenoxyethoxy)-l',3'- dihydrospiro[azetidine-3,2'-inden]-l-yl)acetate (14 mg, 0.037 mmol) was dissolved in THF (1 mL) and MeOH (lmL) to give a colorless solution. 2M NaOH (100 μΙ_, 0.2 mmol) was added. The reaction mixture was stirred overnight.

The reaction mixture was evaporated. The residue was dissolved in water and neutralized with 100 μϋι 2n HC1. The mixture was stirred at RT for 1 h, the precipitate was filtered, washed lx with 0.5 mL water and dried under vacuum at 40° C overnight.

Yield: 8.7 mg white solid

Ή NMR (600 MHz, DMSO-de) δ 7.32 - 7.28 (m, 2H), 7.11 (d, J = 8.2 Hz, 1H), 6.99 - 6.93 (m, 3H), 6.86 (d, J= 2.4 Hz, 1H), 6.75 (dd, J = 8.3, 2.5 Hz, 1H), 4.31 - 4.22 (m, 4H), 3.76 (s, 4H), 3.13 (s, 2H), 3.08 (s, 2H).

MS: Calculated mass (C21H23N04): 353.16, found mass: M+H=354

Example 71 was prepared analogous to example 70:

Example 71. 2-(5'-(2-(4-chlorophenoxy)ethoxy)-l',3'-dihydrospiro[azetidi ne-3,2'- inden]-l-yl)acetic acid

Ή NMR (600 MHz, DMSO-de) δ 7.36 - 7.31 (m, 2H), 7.11 (d, J = 8.3 Hz, 1H), 7.03 - 6.99 (m, 2H), 6.85 (d, J= 2.3 Hz, 1H), 6.74 (dd, J = 8.3, 2.5 Hz, 1H), 4.31 - 4.22 (m, 4H), 3.81 (s, 4H), 3.13 (s, 2H), 3.09 (s, 2H). MS: Calculated mass (C21H22C1N04): 387.12, found mass: M+H=388/390

Example 72. 2-(5'-((2,3-dihydrobenzofuran-7-yl)methoxy)-l',3'- dihy drospiro [azetidine- 3 , 2' -inden] - 1 -yl)acetic acid

In a 50 mL round-bottomed flask l',3'-dihydrospiro[azetidine-3,2'-inden]-5'-ol hydrochloride (100 mg, 0.472 mmol) was dissolved in acetonitrile (5 mL) to give a colorless solution. DBU (0.2 mL, 1.327 mmol) and ethyl bromoacetate (55 μL, 0.496 mmol) were added. The reaction mixture was stirred for 1 h at RT.

The reaction mixture was evaporated, the residue was dissolved in CH2CI2 and washed lx with sat. NH4CI- solution, the phases were separated with a

Chromabond PTS-Cartridge and the organic layer was evaporated. The residue was purified by flash chromatography (silica 4 g, 0-10% MeOH in CH2CI2)

Yield: 81 mg colorless oil

To a 50 mL round bottom flask containinig PS-Triphenylphosphine (a resin-bound triphenylphosphine, 183 mg, 0.344 mmol) was added a solution of ethyl 2-(5'- hydroxy-l',3'-dihydrospiro[azetidine-3,2'-inden]-l-yl)acetat e (60 mg, 0.230 mmol) in THF (0.5 mL). The suspension was allowed to stand for 5 min and then a solution of di-tert-butyl azodicarboxylate (79 mg, 0.344 mmol) in THF (0.5 mL) was added. A further 0.5 mL THF was added and the solution agitated at RT for 30 min. A solution of 2,3-dihydrobenzo[b]furan-7-methanol (35 mg, 0.233 mmol) in THF (0.5 niL) was added and the reaction was stirred overnight.

The reaction mixture was diluted with CH2CI2 and water and stirred for 5 min at RT. After phase separation with a Chromabond PTS-cartridge the organic layer was evaporated. The residue was purified by using the Isco-Combiflash (4 g, 0-10% MeOH in CH2CI2, 18 mL/min).

Yield: 15 mg yellow oil

In a 50 mL round bottom flask ethyl 2-(5'-((2,3-dihydrobenzofuran-7-yl)methoxy)- l',3'-dihydrospiro[azetidine-3,2'-inden]-l-yl)acetate (15 mg, 0.038 mmol) was dissolved in THF (0.5 mL) and MeOH (0.5 mL) to give a colorless solution. 2M NaOH (150 μL, 0.300 mmol) was added. The reaction mixture was stirred overnight.

The reaction mixture was evaporated. The residue was dissolved in water and neutralized with 150 μL 2n HCl. CH2CI2 was added. After phase separation the organic layer was dried over MgSC , filtered and evaporated. The residue was purified using the Isco-Combiflash (4 g, 0-40% MeOH in CH2CI2)

Yield: 10.1 mg white foam

Ή NMR (600 MHz, DMSO-d ⁶ ) 5 7.21 (dd, J =7.3, 1.3 Hz, 1H), 7.15 (dd, J = 7.6, 1.2 Hz, 1H), 7.09 (d, J = 8.3 Hz, 1H), 6.87 (d, J = 2.4 Ηζ,ΙΗ), 6.83 (t, J = 7.5 Hz, 1H), 6.75 (dd, J = 8.2, 2.5 Hz, 1H), 4.93 (s, 2H), 4.60 - 4.45 (m, 2H),3.76 (d, J = 1.6 Hz, 4H), 3.39 (s, 2H), 3.20 (t, J = 8.7 Hz, 3H), 3.07 (s, 4H).

23 protons

MS: Calculated mass (C22H23N04): 365.16, found mass: M+H=366

Examples 73 and 74 were prepared analogous to example 72: Example 73. 2-(5'-((2,3-dihydro-lH-inden-2-yl)oxy)-l',3'-dihydrospiro[az etidine- 3,2'-inden]-l-yl)acetic ac Ή NMR (600 MHz, DMSO-d ⁶ ) 5 7.21 (ddd, J= 52.7, 5.4, 3.2 Hz, 4H), 7.10 (d, J = 8.3 Hz, 1H), 6.81 (d, J = 2.3 Hz, 1H), 6.70 (dd, J = 8.2,2.5 Hz, 1H), 5.18 (td, J = 6.0, 2.9 Hz, 1H), 3.80(s, 2H), 3.41 (s, 4H), 3.32 (d, J = 6.0 Hz, 2H),3.11 (d, J = 29.2 Hz, 4H), 2.99 (dd, J = 16.9, 2.5Hz, 2H).

MS: Calculated mass (C22H23N03): 349.17, found mass: M+H=350

Example 74. 2-(5'-((2,3-dihydro-lH-inden-4-yl)methoxy)-l',3'- dihy drospiro [azetidine- ' -inden] - 1 -yl)acetic acid

Ή NMR (600 MHz, DMSO-d ⁶ ) 5 7.19 (t, J =7.6 Hz, 2H), 7.17 - 7.07 (m, 2H), 6.89 (d, J = 2.5 Hz, 1H), 6.77 (dd, J = 8.2, 2.5 Hz, 1H), 5.00(s, 2H), 3.77 (s, 4H), 3.10 (d, J = 30.2 Hz, 4H),2.88 (t, J = 7.5 Hz, 5H), 2.02 (p, J = 7.5 Hz,2H).

MS: Calculated mass (C23H25N03): 363.18, found mass: M+H=364

Example 75. 2-(5'-((6-isopropoxypyridin-3-yl)ethynyl)-l',3'-dihydrospiro [azetidine- 3,2'-inden]-l-yl)acetic acid

In a 50 mL 3 neck- flask ethyl 2-(5'-hydroxy-l\3'-dihydrospiro[azetidine-3,2'-inden]- l-yl)acetate (310 mg, 1.186 mmol, prepared as described for example 8) was dissolved in CH2CI2 (10 mL) to give a colorless solution. N,N-diisopropylethylamine (0.810 mL, 4.75 mmol) was added. The reaction mixture was cooled down to 0°C. Nonafluorobutanesulfonyl fluoride (0.533 mL, 2.97 mmol) was added slowly. The reaction mixture was stirred for 1 h at 0°C. LC/MS showed that the reaction was finished.

The reaction mixture was diluted with CH2CI2 and water was added. The mixture was stirred at RT for lOmin. A small amount of sat. NH4Cl-solution was added. After phase separation the organic layer was washed with saturated NaCl, dried over MgS04, filtered and evaporated. The residue was purified using the Isco- Combiflash (12 g, 0-10% MeOH in CH2CI2).

Yield: 302 mg colorless oil

In a 25 mL 3-neck round-bottom flask palladium(II) acetate (2.97 mg, 0.013 mmol), triphenylphosphine (11.58 mg, 0.044 mmol) and potassium phosphate tribasic (28.1 mg, 0.132 mmol) were suspended under stirring in an argon atmosphere for 30 min. In a second flask 5-ethynyl-2-isopropoxypyridine (26.7 mg, 0.166 mmol) and ethyl 2-(5'-(((perfluorobutyl)sulfonyl)oxy)-l',3'-dihydrospiro[aze tidine-3,2'-inden]-l- yl)acetate (60 mg, 0.110 mmol) was dissolved in dimethyl sulfoxide (DMSO) (2 mL) and dried under argon for 30 min. This solution was put into the 3-neck flask via syringe and heated to 80°C for 1 h.

The reaction mixture was diluted with CH2CI2 and water. The mixture was stirred at RT for lOmin. After phase separation with the organic layer was washed lx with water and lx with saturated NaCl, dried over MgS04, filtered and evaporated. The residue was purified using the Isco-Combiflash (4 g, 0-10% MeOH in CH2CI2, 18 mL/min)

Yield: 34 mg light brown oil

In a 50 mL round bottom flask ethyl 2-(5'-((6-isopropoxypyridin-3-yl)ethynyl)-l',3'- dihydrospiro[azetidine-3,2'-inden]-l-yl)acetate (34 mg, 0.084 mmol) was dissolved in THF (0.5 mL) and MeOH (0.5 mL) to give a colorless solution. 2M NaOH (250 μL, 0.5 mmol) was added. The reaction mixture was stirred overnight.

The reaction mixture was evaporated. The residue was dissolved in water and neutralized with 250μL 2n HC1. The mixture was stirred at RT for 2 h, the precipitate was filtered, washed lx with water and dried overnight at 40°C under vacuum. Yield: 30 mg brown solid (90% pure by HPLC)

Ή NMR (600 MHz, DMSO-d ⁶ ) 5 8.34 (d, J = 2.3 Hz, 1H), 7.81 (dd, J = 8.6, 2.4 Hz, 1H), 7.56 (ddd, J = 8.0, 7.39 (d, J = 1.4 Hz, 1H), 7.32 (dd, J = 7.7, 1.5 Hz, 1H), 7.26 (d, J = 7.9 Hz, 1H), 6.80 (d, J = 8.6 Hz, 1H), 5.26 (hept, J = 6.2 Hz, 1H), 3.77 (s, 4H), 3.19 (d, J = 5.4 Hz, 4H), 1.30 (d, J = 6.2 Hz, 6H).

MS: Calculated mass (C23H24N203): 376.18, found mass: M+H=377

Examples 76 - 82 were prepared analogous to example 75: Example 76. 2-(5'-((4-methylcyclohexyl)ethynyl)-l',3'-dihydrospiro[azeti dine-3,2'- inden]-l-yl)acetic acid

Ή NMR (600 MHz, DMSO-d ⁶ ) 5 7.26 - 7.09(m, 3H), 3.75 (d, J = 4.3 Hz, 4H), 3.19 3.09 (m, 4H), 2.92 (t, J = 4.1 Hz, 1H),1.98 - 0.91 (m, 10H), 0.88 (dd, J = 17.8, 6.5 Hz,3H).

MS: Calculated mass (C22H27N02): 337.20, found mass: M+H=338

Example 77. 2-(5'-((4-ethoxyphenyl)ethynyl)-l',3'-dihydrospiro[azetidine -3,2'- inden]-l-yl)acetic acid

Ή NMR (600 MHz, DMSO-d ⁶ ) 5 7.47 - 7.41 (m, 2H), 7.37 (s, 1H), 7.29 (dd, J = 7.7, 1.5 Hz, 1H), 7.24 (d, J = 7.8 Hz, 1H), 6.98 - 6.93 (m, 2H), 4.06 (q, J = 7.0 Hz, 2H), 3.77 (s, 4H), 3.18 (d, J = 4.7 Hz, 4H), 1.33 (t, J = 6.9 Hz, 3H).

MS: Calculated mass (C23H23N03): 361.17, found mass: M+H=362 Example 78. 2-(5'-((6-(cyclopentyloxy)pyridin-3-yl)ethynyl)-l',3'- dihy drospiro [azetidine- 3 , 2' -inden] - 1 -yl)acetic acid

Ή NMR (500 MHz, DMSO-d ⁶ ) 5 8.34 (d, J =2.4 Hz, 1H), 7.80 (dd, J = 8.6, 2.4 Hz, 1H), 7.39 (s, 1H), 7.32 (dd, J = 7.9, 1.5 Hz, 1H), 7.26 (d,J = 7.9 Hz, 1H), 6.80 (d, J = 8.6 Hz, 1H), 5.38 (tt, J = 6.0, 2.9 Hz, 1H), 3.74 (s, 4H), 3.18 (d, J = 4.3 Hz, 4H), 1.99 - 1.88 (m, 3H), 1.76 - 1.65 (m, 5H), 1.60 (tdq, J = 9.4, 6.6,3.2, 2.5 Hz, 2H).

MS: Calculated mass (C25H26N203): 402.19, found mass: M+H=403 Example 79. 2-(5'-((6-((l,l,l-trifluoropropan-2-yl)oxy)pyridin-3-yl)ethy nyl)-l',3'- dihy drospiro [azetidine- 3 , 2' -inden] - 1 -yl)acetic acid

Ή NMR (500 MHz, DMSO-d ⁶ ) 5 8.40 (d, J = 2.4 Hz, 1H), 7.94 (dd, J = 8.5, 2.4 Hz, 1H), 7.41 (s, 1H), 7.34 (dd, J = 7.9, 1.5 Hz, 1H), 7.27 (d, J = 7.9 Hz, 1H), 7.01 (d, J = 8.5 Hz, 1H), 5.91 (hept, J = 6.7 Hz, 1H), 3.74 (s, 4H), 3.19 (d, J = 4.5 Hz, 4H), 1.47 (d, J = 6.5 Hz, 3H).

MS: Calculated mass (C23H21F3N203): 430.15, found mass: M+H=431

Example 80. 2-(5'-((2-chlorophenyl)ethynyl)-l',3'-dihydrospiro[azetidine -3,2'- inden] -l-yl)acetic acid

Ή NMR (600 MHz, DMSO-d ⁶ ) 5 7.65 (td, J = 7.0, 6.6, 1.7 Hz, 1H), 7.61 - 7.57 (m, 1H), 7.46 - 7.34 (m, 4H), 7.30 (d, J = 7.7 Hz, 1H), 3.86 (s, 4H), 3.58 (s, 2H), 3.22 (d, J = 4.0 Hz, 4H).

MS: Calculated mass (C21H18C1N02): 351.10, found mass: M+H=352/354

Example 81. 2-(5'-((2-fluoro-4-methoxyphenyl)ethynyl)-l',3'- dihy drospiro [azetidin - 3 , 2' -inden] - 1 -yl)acetic acid

Ή NMR (600 MHz, DMSO-de) δ 7.50 (t, J = 8.6 Hz, 1H), 7.38 (s, 1H), 7.32 - 7.24 (m, 2H), 6.98 (dd, J = 11.7, 2.5 Hz, 1H), 6.84 (dd, J= 8.7, 2.5 Hz, 1H), 3.81 (s, 3H), 3.18 (d, J = 4.3 Hz, 4H).

MS: Calculated mass (C22H20FNO3): 365.14, found mass: M+H=366

Example 82. 2-(5'-(phenylethynyl)-l',3'-dihydrospiro[azetidine-3,2'-inde n]-l- yl)acetic acid

Ή NMR (600 MHz, Methanol-d ⁴ ) 5 7.51 - 7.44 (m, 2H), 7.40 - 7.31 (m, 5H), 7.24 (d, J = 7.7 Hz, 1H), 4.17 (s, 4H), 3.81 (s, 2H)

MS: Calculated mass (C21H19N02): 317.14, found mass: M+H=318

Example 83. 3-(5'-((2,3-dihydro-lH-inden-4-yl)methoxy)-l',3'

dihy drospiro [azetidine- 3, 2' -inden] -l-yl)cyclobutanecarboxylic

In a 100 mL 3-neck round-bottomed flask l',3'-dihydrospiro[azetidine-3,2'-inden]- 5'-ol (2 g, 11,41 mmol) was dissolved in THF (80 mL) to give a white suspension. Methyl 3-oxocyclobutanecarboxylate (2.92 g, 22.83 mmol) was added. The mixture was stirred for 60 min at RT. Sodium triacetoxyborohydride (4.84 g, 22.83 mmol) was added. The reaction mixture was stirred overnight at RT.

The reaction mixture was diluted with CH2CI2 and water and stirred for 30 min. CH2CI2 was added, the organic layer was washed 2x with NaHC03-solution, lx with saturated sodium chloride solution, dried over MgS04, filtered and evaporated.

Yield: 3.47 g light red solid

The product could either be used without further purification for the next or purified by flash chromatography: 2.5 g were absorbed on Celite XTR and purified using the Isco-Combiflash (12 g, 0-20% MeOH in CH2CI2, 35 mL/min).

Yield: 1 g colorless foam

To a 50 mL round bottom flask containinig PS-Triphenylphosphin (a resin-bound triphenylphosphine, 357 mg, 0.66 mmol) was added a solution of methyl 3-(5'- hydroxy-l',3'-dihydrospiro[azetidine-3,2'-inden]-l-yl)cyclob utanecarboxylate (50 mg, 0.174 mmol) in THF (4 mL). The suspension was allowed to stand for 5 min and then a solution of di-tert-butyl azodicarboxylate (60.1 mg, 0.261 mmol) was added. 2,3-DIHYDRO-lH-INDEN-4-YLMETHANOL (30.9 mg, 0.209 mmol) was added and the reaction was stirred for 2 days at RT. The reaction mixture was diluted with CH2CI2 and water and stirred for 5 min at RT. After phase separation with a Chromabond PTS-cartridge the organic layer was evaporated. The residue was purified by using the Isco-Combiflash (4 g, 0-10%

Yield: 7 mg colorless oil

In a 50 mL round bottom flask methyl 3-(5'-((2,3-dihydro-lH-inden-4-yl)methoxy)- l',3'-dihydrospiro[azetidine-3,2'-inden]-l-yl)cyclobutanecar boxylate (7 mg, 0.017 mmol) was dissolved in THF (0.5 mL) and MeOH (0.5 mL) to give a yellow solution. 2M NaOH (0.1 mL, 0.200 mmol) was added. The reaction mixture was stirred overnight at RT.

The reaction mixture was evaporated. The residue was dissolved in water and neutralized with 0.1 mL 2n HC1. CH2CI2 was added. After phase separation the organic layer was dried over MgSC , filtered and evaporated.

Yield: 3.2 mg colorless oil

Ή NMR (500 MHz, DMSO-d ⁶ ) 5 7.23 - 7.08 (m, 5H), 6.90 (d, J = 2.1 Hz, 1H), 6.79 (dd, J = 8.3, 2.4 Hz, 1H), 5.00 (s, 2H), 3.13 (s, 2H), 3.08 (s, 2H), 2.91 - 2.79 (m, 5H), 2.47 (s, 2H), 2.13 (s, 1H), 2.02 (p, J = 7.6 Hz, 2H), 1.37 (d, J = 16.2 Hz, 1H), 1.24 (s, 2H), 1.16 (d, J = 10.9 Hz, 2H).

MS: Calculated mass (C26H29N03): 403.21, found mass: M+H=404

Examples 84 - 86 were prepared analogous to example 83:

Example 84. 3-(5'-((4-(cyclopropylmethoxy)benzyl)oxy)-l',3'- dihydrospiro[azetidine-3,2'-inden]-l-yl)cyclobutanecarboxyli c

Ή NMR (600 MHz, DMSO-d ⁶ ) 5 7.34 - 7.30 (m, 2H), 7.07 (d, J = 8.3 Hz, 1H), 6.94 - 6.89 (m, 2H), 6.85 (d, J = 2.4 Hz, 1H), 6.79 - 6.71 (m, 1H), 4.94 (s, 2H), 3.80 (d, J = 7.0 Hz, 2H), 3.47 (s, 1H), 3.19 (d, J = 22.2 Hz, 5H), 3.01 (s, 2H), 2.97 (s, 2H), 2.71 (p, J = 8.5 Hz, 1H), 2.22 - 2.14 (m, 2H), 1.99 - 1.90 (m, 2H), 1.26 - 1.16 (m, 1H), 0.59 - 0.53 (m, 2H), 0.34 - 0.28 (m, 2H).

MS: Calculated mass (C27H31N04): 433.23, found mass: M+H=434

Example 85. 3-(5'-((4-ethoxy-2,6-difluorobenzyl)oxy)-l',3'-dihydrospiro[ azetidine- 3,2'-inden]-l-yl)cy lobutanecarboxylic acid

Ή NMR (500 MHz, DMSO-d ⁶ ) 5 7.10 (d, J = 8.2 Hz, 1H), 6.89 (d, J = 2.2 Hz, 1H), 6.77 (dq, J = 8.3, 2.9, 2.3 Hz, 3H), 4.95 (s, 2H), 4.07 (q, J = 7.0 Hz, 2H), 3.07 (s, 2H), 3.02 (s, 2H), 2.79 - 2.71 (m, 1H), 2.45 (d, J = 19.3 Hz, 4H), 2.24 (s, 3H), 2.01 (s, 2H), 1.32 (t, J = 7.0 Hz, 3H).

MS: Calculated mass (C25H27F2N04): 443.19, found mass: M+H=444

Example 86. 3-(5'-((4-ethoxy-2,3-difluorobenzyl)oxy)-l',3'-dihydrospiro[ azetidine- 3,2'-inden]-l-yl)cyclobutanecarboxylic acid

Ή NMR (600 MHz, Chloroform-d) 5 7.14 -7.06 (m, 2H), 6.81 (d, J = 2.3 Hz, 1H), 6.80 - 6.70 (m, 2H), 5.00 (s, 2H), 4.12 (q, J = 7.0 Hz, 2H), 3.92 (d, J = 56.9 Hz, 3H), 3.60 (p, J = 7.0 Hz, 1H), 3.39 - 3.10 (m, 4H), 2.99 (p, J = 8.2 Hz, 1H), 2.67 - 2.33 (m, 4H), 1.45 (t, J = 7.0 Hz, 3H).

MS: Calculated mass (C25H27F2N04): 443.19, found mass: M+H=444

Example 87. 3-(5'-((2-cyclopropyl-6-fluorobenzyl)oxy)-l',3'-dihydrospiro [azetidine- 3,2'-inden]-l-yl)cyclobutanecarboxylic acid

(2 -cyclopropyl-6-fluorophenyl) methanol was suspended in 48% aqueous HBr and stirred at RT overnight.

The reaction mixture was dilute with water (20 mL) and extracted with ethyl acetate. The extracts were washed successively with water, saturated NaHC03 and water. The organic phase was dried (MgSC ) and the solvent evaporated in vacuo. Yield: 550 mg light brown oil

In a 4 mL flask methyl 3-(5'-hydroxy-l',3'-dihydrospiro[azetidine-3,2'-inden]-l- yl)cyclobutanecarboxylate (50 mg, 0.174 mmol, prepared as described for example 83) was dissolved in DMF (3 mL) to give a colorless solution. Cesium carbonate (85 mg, 0.261 mmol) and 2-(bromomethyl)-l-cyclopropyl-3-fluorobenzene (45 mg, 0.196 mmol) were added. The reaction mixture was stirred at RT overnight.

The reaction mixture was evaporated. The residue was dissolved in water and CH2CI2. After phase separation the organic layer was washed lx with water and lx with saturated sodium chloride solution. The organic layer was dried over MgSC , filtered and evaporated. The residue was purified using the Isco-Combiflash (4 g, 0- 10% MeOH in CH2CI2, 18mL/min).

Yield: 35 mg colorless oil

In a 50 mL round bottom flask methyl 3-(5'-((2-cyclopropyl-6-fluorobenzyl)oxy)-l',3'- dihydrospiro[azetidine-3,2'-inden]-l-yl)cyclobutanecarboxyla te (35 mg, 0.080 mmol) was dissolved in THF (1 mL) and MeOH (1 mL) to give a colorless solution. 2M NaOH (0.4 mL, 0,800 mmol) was added. The reaction mixture was stirred overnight at RT.

The reaction mixture was evaporated. The residue was dissolved in water and neutralized with 0.4 mL 2n HC1. CH2CI2 and a small amount of MeOH were added. After phase separation the organic layer was dried over MgS04, filtered and evaporated.

The residue was purified using the Isco-Combiflash (4 g, 0-30% MeOH in CH2CI2, 18 mL/min).

Yield: 10 mg white foam

Ή NMR (600 MHz, DMSO-d ⁶ ) 5 7.33 (td, J =8.0, 6.0 Hz, 1H), 7.10 (dd, J = 8.3, 2.5 Hz, 1H), 7.06 (ddd, J = 9.5, 8.2, 1.1 Hz, 1H), 6.93 (s,lH), 6.85 (d, J = 7.8 Hz, 1H), 6.80 (dd, J = 8.1, 2.4 Hz, 1H), 5.16 (d, J = 1.8 Hz, 2H), 3.01 (d, J= 30.3 Hz, 4H), 2.70 (q, J = 8.5 Hz, 1H), 2.19 (d, J = 8.8 Hz, 2H), 2.06 (tt, J = 8.5, 5.3 Ηζ,ΙΗ), 1.94 (d, J = 9.9 Hz, 2H), 0.96 - 0.89 (m, 2H), 0.74 - 0.66 (m, 2H).

MS: Calculated mass (C26H28FN03): 421.21, found mass: M+H=422

Examples 88 - 94 (were prepared analogous to example 87:

Example 88. 3-(5'-((6-methoxy-2-methylpyridin-3-yl)methoxy)-l',3'- dihydrospiro[azetidine-3,2'-inden]-l-yl)cyclobutanecarboxyli c acid

Ή NMR (600 MHz, DMSO-d ⁶ ) 5 7.68 (d, J = 8.3 Hz, 1H), 7.11 (d, J = 8.2 Hz, 1H), 6.90 (d, J = 2.4 Hz, 1H), 6.79 (dd, J = 8.2, 2.4 Hz, 1H), 6.64 (d, J = 8.2 Hz, 1H), 4.98 (s, 2H), 3.83 (s, 2H), 3.08 (d, J = 6.8 Hz, 2H), 3.03 (d, J = 7.1 Hz, 2H), 2.75 (p, J = 8.7 Hz, 1H), 2.42 (s, 3H), 2.25 (dqd, J = 15.9, 8.5, 8.0, 2.5 Hz, 2H), 2.13 (s, 1H), 2.03 (qd, J = 8.9, 2.6 Hz, 2H).

MS: Calculated mass (C24H28N204): 408.20, found mass: M+H=409

Example 89. (lr,3r)-3-(5'-((2,5-dichlorobenzyl)oxy)-l',3'-dihydrospiro[a zetidine-3,2'- inden]-l-yl)cyclobutanecarboxylic acid

Ή NMR (500 MHz, Methanol-d ⁴ ) 5 7.54 (d, J= 2.5 Hz, 1H), 7.42 (d, J = 8.4 Hz, 1H), 7.33 (dd, J = 8.5, 2.5 Hz, 1H), 7.14 (d, J = 8.3 Ηζ,ΙΗ), 6.89 (d, J = 2.4 Hz, 1H), 6.82 (dd, J = 8.2, 2.5 Hz, 1H), 5.11 (s, 2H), 3.92 (s, 6H), 3.22 (s,2H), 3.18 (s, 2H), 2.98 (tt, J = 9.8, 4.8 Hz, 1H), 2.49 (dt, J = 13.1, 6.8 Hz, 2H), 2.22 (q, J =10.6, 10.1 Hz, 2H). MS: Calculated mass (C23H23C12N03): 431.11, found mass:M+H=432/434/436 Example 90. (ls,3s)-3-(5'-((2,5-dichlorobenzyl)oxy)-l',3'-dihydrospiro[a zetidine-3,2'- inden]-l-yl)cyclobutanecarboxylic acid

Ή NMR (500 MHz, Methanol-d ⁴ ) 5 7.54 (d, J= 2.6 Hz, 1H), 7.42 (d, J = 8.5 Hz, 1H), 7.32 (dd, J = 8.5, 2.6 Hz, 1H), 7.14 (d, J = 8.2 Ηζ,ΙΗ), 6.89 (d, J = 2.4 Hz, 1H), 6.82 (dd, J = 8.3, 2.4 Hz, 1H), 5.11 (s, 2H), 4.00 (s, 4H), 3.78 (p,J = 6.8 Hz, 1H), 3.24 (s, 2H), 3.19 (s, 2H), 2.84(p, J = 7.8 Hz, 1H), 2.60 - 2.51 (m, 2H), 2.22 -2.13 (m, 3H). MS: Calculated mass (C23H23C12N03): 431.11, found mass:M+H=432/434/436

Example 91. 3-(5'-((2-chloro-6-cyclopropylbenzyl)oxy)-l',3'-dihydrospiro [azetidine- 3,2'-inden]-l-yl)cyclobutanecarboxylic acid

Ή NMR (600 MHz, DMSO-d ⁶ ) 5 7.37 - 7.28(m, 2H), 7.11 (d, J = 8.2 Hz, 1H), 7.03 (dd, J = 7.4, 1.6 Hz, 1H), 6.94 (d, J = 2.5 Hz, 1H), 6.81(dd, J = 8.2, 2.5 Hz, 1H), 5.25 (s, 2H), 3.16 (s, 5H), 2.99 (s, 4H), 2.69 (q, J = 8.4 Hz, 1H), 2.17(d, J = 9.4 Hz, 2H), 2.10 - 2.02 (m, 1H), 1.97 -1.89 (m, 2H), 0.95 - 0.87 (m, 2H), 0.74 - 0.66(m, 2H). MS: Calculated mass (C26H28C1N03): 437.18, found mass. M+H=438/440

Example 92. 3-(5'-((2,6-dichlorobenzyl)oxy)-l',3'-dihydrospiro[azetidine -3,2'-inden]- l-yl)cyclobutanecarboxylic acid

Ή NMR (600 MHz, DMSO-d ⁶ ) 5 7.56 (d, J =8.1 Hz, 2H), 7.47 (dd, J = 8.7, 7.5 Hz, 1H), 7.11 (d, J = 8.2 Hz, 1H), 6.93 (d, J = 2.5 Hz, 1H),6.80 (dd, J = 8.2, 2.5 Hz, 1H), 5.16 (s, 2H), 3.20 (s, 4H), 3.17 (t, J = 7.4 Hz, 1H), 2.99 (s, 2H),2.71 (p, J = 8.4 Hz, 1H), 2.22 - 2.10 (m, 2H), 2.03 - 1.90 (m, 2H).

MS: Calculated mass (C23H23C12N03): 431.11, found mass: M+H=432/434/436

Example 93. 3-(5'-((2,5-dichlorobenzyl)oxy)-l',3'-dihydrospiro[azetidine -3,2'-inden]- l-yl)cyclobutanecarboxylic acid

Ή NMR (600 MHz, DMSO-d ⁶ ) 5 7.64 (d, J =2.7 Hz, 1H), 7.55 (dd, J = 8.6, 3.2 Hz, 1H), 7.47 (dt, J = 8.5, 2.8 Hz, 1H), 7.14 - 7.06 (m, 1H),6.93 - 6.87 (m, 1H), 6.79 (td, J = 7.8, 3.8 Hz, 1H), 5.08 (d, J = 4.8 Hz, 2H), 3.12 (s, 5H), 3.03(d, J = 2.9 Hz, 2H), 3.00 - 2.91 (m, 3H), 2.71 (dq, J = 16.8, 8.4, 7.8 Hz, 1H), 2.22 - 2.09 (m,2H), 2.00 - 1.88 (m, 2H).

MS: Calculated mass (C23H23C12N03): 431.11, found mass: M+H=432/434/436 Example 94. 3-(5'-((2-chloro-6-ethylbenzyl)oxy)-l',3'-dihydrospiro[azeti dine-3,2'- inden]-l-yl)cyclobutanecarboxylic acid

Ή NMR (600 MHz, DMSO-d ⁶ ) 5 7.40 - 7.32(m, 2H), 7.28 (dd, J = 6.0, 3.0 Hz, 1H), 7.12 (d, J = 8.2 Hz, 1H), 6.93 (d, J = 2.5 Hz, 1H), 6.80(dd, J = 8.2, 2.5 Hz, 1H), 5.09 (s, 2H), 3.23 (d, J = 21.9 Hz, 6H), 3.06 (s, 2H), 3.00 (s, 2H),2.71 (q, J = 7.6 Hz, 3H), 2.25 - 2.12 (m, 2H), 1.96 (qd, J = 8.5, 2.5 Hz, 2H), 1.16 (t, J = 7.5Hz, 3H).

MS: Calculated mass (C25H28C1N03): 425.18, found mass: M+H=426/428 Example 95. 3-(5'-((6-(cyclopentyloxy)pyridin-3-yl)ethynyl)-l',3'- dihydrospiro[azetidine-3,2'-inden]-l-yl)cyclobutanecarboxyli c acid

In a 100 mL 3 neck- flask methyl 3-(5'-hydroxy-l',3'-dihydrospiro[azetidine-3,2'- inden]-l-yl)cyclobutanecarboxylate (1 g, 3.48 mmol, prepared as described for example 83) was dissolved in CH2CI2 (30 mL) to give a colorless solution. N,N- diisopropylethylamine (2.377 mL, 13.92 mmol) was added. The reaction mixture was cooled down to 0°C. Nonafluorobutanesulfonyl fluoride (1.563 mL, 8.70 mmol) was added slowly. The reaction mixture was stirred for 1 h at 0°C.

The reaction mixture was diluted with CH2CI2 and water was added. The mixture was stirred at RT for lOmin. A small amount of sat. NH4Cl-solution was added. After phase separation the organic layer was washed with saturated NaCl, dried over MgS04, filtered and evaporated. The residue was purified using the Isco- Combiflash (12 g, 0-10% MeOH in CH2CI2). The crude product was purified using the Isco- Combiflash (24 g, 0-10% MeOH in CH2CI2, 35 mL/min). Yield: 980 mg yellow oil

A 25 mL 3-neck round-bottom flask was charged with palladium(II) acetate (3 mg, 0.013 mmol), triphenylphosphine (12 mg, 0.046 mmol) and potassium phosphate tribasic (30 mg, 0.141 mmol) in dimethylsulfoxide (2 mL) under argon atmosphere and the mixture stirred for 30 min. In a second flask 2-(cyclopentyloxy)-5- ethynylpyridine (30 mg, 0.160 mmol) and methyl 3-(5'- (((perfluorobutyl)sulfonyl)oxy)-l',3'-dihydrospiro[azetidine -3,2'-inden]-l- yl)cyclobutanecarboxylate (60 mg, 0.105 mmol) were dissolved in dimethyl sulfoxide (DMSO) (2 mL) and dried under argon for 30 min. This solution was put into the 3-neck flask via syringe and heated to 80°C for 60min.

The reaction mixture was diluted with CH2CI2 and water. The mixture was stirred at RT for 10 min. After phase separation with the organic layer was washed successively with water and saturated sodium chloride solution. The organic phase was dried over MgS04, filtered and evaporated. The residue was purified using the Isco-Combiflash (4 g, 0-10% MeOH in CH2CI2, 18 mL/min)

Yi ld: 26 mg brown oil

In a 50 mL round bottom flask methyl 3-(5'-((6-(cyclopentyloxy)pyridin-3- yl)ethynyl)-l',3'-dihydrospiro[azetidine-3,2'-inden]-l-yl)cy clobutanecarboxylate (26 mg, 0.057 mmol) was dissolved in THF (0.5 mL) and MeOH (0.5 mL) to give a yellow solution. 2M NaOH (0.2 niL, 0.400 mmol) was added. The reaction mixture was stirred overnight at RT.

The reaction mixture was evaporated. The residue was dissolved in water and neutralized with 0.2 mL 2n HC1. CH2CI2 was added. After phase separation with a Chromabond PTS-cartridge the organic layer was evaporated. The residue was purified using the Isco-Combiflash (4 g, 0-30% MeOH in CH2CI2, 18 mL/min) Yield: 5 mg yellow foam

Ή NMR (600 MHz, DMSO-d ⁶ ) 5 8.34 (d, J = 2.3 Hz, 1H), 7.80 (dd, J = 8.6, 2.4 Hz, 1H), 7.37 (s, 1H), 7.31 (dd, J = 7.7, 1.5 Hz, 1H), 7.25 (d, J = 7.8 Hz, 1H), 6.80 (d, J = 8.6 Hz, 1H), 5.38 (tt, J = 6.0, 2.8 Hz, 1H), 3.16 (s, 4H), 3.12 (q, J = 7.3 Hz, 1H), 2.70 (p, J = 8.5 Hz, 1H), 2.16 (dtd, J = 9.6, 7.4, 2.5 Hz, 2H), 2.00 - 1.89 (m, 4H), 1.70 (qdd, J = 7.2, 6.0, 5.0, 2.7 Hz, 4H), 1.60 (tdd, J = 9.5, 5.1, 2.9 Hz, 2H).

MS: Calculated mass (C28H30N2O3): 442.23, found mass: M+H=443 Examples 96 - 103 were prepared analogous to example 95:

Example 96. 3-(5'-((6-isopropoxypyridin-3-yl)ethynyl)-l',3'-dihydrospiro [azetidine- 3,2'-inden]-l-yl)cyclobutanecarboxylic acid

Ή NMR (600 MHz, DMSO-d ⁶ ) 5 8.34 (d, J = 2.3 Hz, 1H), 7.81 (dd, J = 8.5, 2.4 Hz, 1H), 7.37 (s, 1H), 7.31 (dd, J = 7.7, 1.6 Hz, 1H), 7.25 (d, J = 7.8 Hz, 1H), 6.79 (d, J = 8.6 Hz, 1H), 5.26 (hept, J = 6.2 Hz, 1H), 3.15 (q, J = 7.5 Hz, 1H), 3.08 (d, J = 4.2 Hz, 4H), 2.70 (p, J = 8.5 Hz, 1H), 2.48 (s, 1H), 2.21 - 2.10 (m, 2H), 1.94 (qd, J = 8.6, 2.5 Hz, 2H), 1.30 (d, J = 6.2 Hz, 6H), 1.26 (dt, J = 15.1, 7.1 Hz, 1H).

MS: Calculated mass (C26H28N203): 416.21, found mass: M+H=417

Example 97. 3-(5'-((4-isopropoxyphenyl)ethynyl)-l',3'-dihydrospiro[azeti dine-3,2'- inden]-l-yl)cyclobutanecarboxylic acid

Ή NMR (600 MHz, DMSO-d ⁶ ) 5 7.43 (d, J = 8.6 Hz, 2H), 7.35 (s, 1H), 7.28 (d, J = 7.8 Hz, 1H), 7.23 (d, J = 7.8 Hz, 1H), 6.94 (d, J = 8.4 Hz, 2H), 4.66 (hept, J = 6.1 Hz, 1H), 3.21 (s, 4H), 3.16 (d, J = 8.8 Hz, 1H), 3.08 (d, J = 3.4 Hz, 4H), 2.71 (p, J = 8.5 Hz, 1H), 2.22 - 2.11 (m, 2H), 1.99 - 1.90 (m, 2H), 1.27 (d, J = 6.0 Hz, 6H), 1.23 (s, 1H).

MS: Calculated mass (C27H29N03): 415.21, found mass: M+H=416

Example 98. 3-(5'-((4-ethoxyphenyl)ethynyl)-l',3'-dihydrospiro[azetidine -3,2'- inden]-l-yl)cyclobutanecarboxylic acid

Ή NMR (600 MHz, DMSO-d ⁶ ) 5 7.47 - 7.42 (m, 2H), 7.35 (s, 1H), 7.28 (dd, J = 7.7, 1.5 Hz, 1H), 7.23 (d, J = 7.8 Hz, 1H), 6.98 - 6.93 (m, 2H), 4.06 (q, J = 7.0 Hz, 2H), 3.22 (d, J = 23.7 Hz, 5H), 3.09 (d, J = 3.8 Hz, 4H), 2.71 (p, J = 8.6 Hz, 1H), 2.18 (dtd, J = 15.0, 12.4, 11.1, 6.6 Hz, 2H), 2.05 - 1.92 (m, 2H), 1.33 (t, J = 7.0 Hz, 3H) MS: Calculated mass (C26H27N03): 401.20, found mass: M+H=402

Example 99. 3-(5'-((6-(cyclopropylmethoxy)pyridin-3-yl)ethynyl)-l',3'- dihydrospiro[azetidine-3,2'-inden]-l-yl)cyclobutanecarboxyli c acid

Ή NMR (600 MHz, Methanol-d ⁴ ) 5 8.24 (d, J= 2.3 Hz, 1H), 7.74 (dd, J = 8.6, 2.4 Hz, 1H), 7.37 (d, J = 3.5 Hz, 1H), 7.32 (dt, J = 7.9, 2.0Hz, 1H), 7.23 (d, J = 7.9 Hz, 1H), 6.78 (d, J = 8.6 Hz, 1H), 4.13 (d, J = 7.1 Hz, 2H), 4.06 (s,4H), 3.82 (p, J = 7.1 Hz, 1H), 3.29 (d, J = 4.5 Hz, 4H), 2.86 (p, J = 8.2Hz, 1H), 2.56 (dddd, J = 19.0, 13.2, 7.7, 3.6 Hz,2H), 2.34 - 2.20 (m, 2H), 1.27 (tt, J = 7.6, 4.7Hz, 1H), 0.64 - 0.55 (m, 2H), 0.34 (dt, J = 6.2,4.4 Hz, 2H).

MS: Calculated mass (C27H28N203): 428.21, found mass: M+H=429

Example 100. 3-(5'-((4-ethoxy-3-fluorophenyl)ethynyl)-l',3'-dihydrospiro[ azetidine- 3,2'-inden]-l-yl)cyclobutanecarboxylic acid

Ή NMR (600 MHz, Methanol-d ⁴ ) 5 7.36 (d, J = 1.4 Hz, 1H), 7.31 (dd, J = 7.7, 1.4 Hz, 1H), 7.26 - 7.18 (m, 3H), 7.06 (t, J = 8.6 Hz, 1H), 4.13 (q, J = 7.0 Hz, 2H), 4.05 (s, 4H), 3.86 - 3.78 (m, 1H), 3.29 (d, J = 4.5 Hz, 4H), 2.90 - 2.82 (m, 1H), 2.58 (dddd, J = 11.6, 8.6, 5.0, 2.1 Hz, 2H), 2.19 - 2.11 (m, 2H), 1.42 (t, J = 7.0 Hz, 3H). 25 protons

MS: Calculated mass (C26H26FN03): 419.19, found mass: M+H=420

Example 101. 3-(5'-((4-methoxy-2-methylphenyl)ethynyl)-l',3'- dihydrospiro[azetidine-3,2'-inden]-l-yl)cyclobutanecarboxyli c acid

Ή NMR (500 MHz, DMSO-d ⁶ ) 5 7.42 - 7.33 (m, 2H), 7.28 (dd, J = 7.7, 1.5 Hz, 1H), 7.23 (d, J = 7.7 Hz, 1H), 6.90 (d, J = 2.7 Hz, 1H), 6.79 (dd, J = 8.5, 2.7 Hz, 1H), 3.77 (s, 3H), 3.10 (d, J = 32.4 Hz, 8H), 2.69 (p, J = 8.4 Hz, 1H), 2.47 (p, J = 1.8 Hz, 1H), 2.42 (s, 3H), 2.21 - 2.11 (m, 2H), 1.92 (qd, J = 8.3, 2.5 Hz, 2H).

26 protons

MS: Calculated mass (C26H27N03): 401.20, found mass: M+H=402

Example 102. 3-(5'-((4-methylcyclohexyl)ethynyl)-l',3'-dihydrospiro[azeti dine-3,2'- inden]-l-yl)cyclobutanecarboxylic acid

Ή NMR (600 MHz, DMSO-d ⁶ ) 5 7.40 - 7.00(m, 3H), 3.10 (s, 6H), 3.01 (s, 1H), 2.92 (t, J = 4.0 Hz, 1H), 2.68 (qd, J = 8.4, 1.5 Hz, 1H), 2.15(dddd, J = 11.9, 9.3, 7.1, 2.2 Hz, 2H), 1.91 (dddd, J = 17.3, 14.1, 10.2, 3.0 Hz, 3H), 1.73(dd, J = 13.3, 3.7 Hz, 1H), 1.69 - 1.63 (m, 1H), 1.54 (ddq, J = 16.8, 12.5, 3.8 Hz, 3H), 1.36(dtd, J = 24.6, 11.7, 10.5, 3.3 Hz, 3H), 0.95 (td, J = 12.5, 11.7, 3.4 Hz, 1H), 0.88 (dd, J = 18.1,6.5 Hz, 3H).

29 protons

MS: Calculated mass (C25H31N02): 377.24, found mass: M+H=378

Example 103. 3-(5'-((6-((l,l,l-trifluoropropan-2-yl)oxy)pyridin-3-yl)ethy nyl)-l',3'- dihydrospiro[azetidine-3,2'-inden]-l-yl)cyclobutanecarboxyli c acid

Ή NMR (600 MHz, DMSO-d ⁶ ) 5 8.40 (d, J = 2.5 Hz, 1H), 7.94 (dd, J = 8.6, 2.3 Hz, 1H), 7.40 (s, 1H), 7.33 (dd, J = 7.6, 1.6 Hz, 1H), 7.26 (d, J = 7.9 Hz, 1H), 7.01 (d, J = 8.6 Hz, 1H), 5.91 (h, J = 6.7 Hz, 1H), 3.17 (s, 5H), 3.08 (d, J = 3.8 Hz, 4H), 2.70 (p, J = 8.5 Hz, 1H), 2.56 - 2.52 (m, 1H), 2.17 (q, J = 9.5 Hz, 2H), 1.97 - 1.89 (m, 2H), 1.47 (d, J = 6.5 Hz, 3H).

25 protons

MS: Calculated mass (C26H25F3N203): 470.18, found mass: M+H=471

Example 104. 3-(5'-((2,3-dihydro-lH-inden-l-yl)oxy)-l',3'-dihydrospiro[az etidine- 3,2'-inden]-l-yl)cyclobutanecarboxylic acid

In a 100 mL round-bottomed flask l',3'-dihydrospiro[azetidine-3,2'-inden]-5'-ol hydrobromide (1 g, 3.90 mmol) was suspended in THF (40 mL). Methyl 3- oxocyclobutanecarboxylate (1.0 g, 7.81 mmol) was added. The mixture was stirred for 60 min at RT. Sodium triacetoxyborohydride (1.655 g, 7.81 mmol) was added. The reaction mixture was stirred overnight at RT.

The reaction mixture was poured in an Erlenmeyer flask containing 100 mL CH2CI2 and 10 mL water. The mixture was stirred for 30 min. The organic layer was diluted with CH2CI2 and washed twice with NaH CO 3- solution, lx with saturated NaCl, dried over MgSC , filtered and evaporated.

Yield: 1.04 g orange oil

In a microwave flask methyl 3-(5'-hydroxy-l',3'-dihydrospiro[azetidine-3,2'-inden]- l-yl)cyclobutanecarboxylate (50 mg, 0.174 mmol) and 1-INDANOL (60 mg, 0.447 mmol) were dissolved in toluene (PI1CH3) (3 ml).

Cyanomethylenetributylphosphorane (0.5 mL, 0.5 mmol) was added. The mixture was stirred for 8 h at 80°C in the Biotage microwave.

The reaction mixture was evaporated. The residue was dissolved in CH2CI2 and washed once with water. After phase separation with a Chromabond PTS cartridge the organic layer was evaporated. The residue was purified using the Isco- Combiflash (4 g, 0-10% MeOH in CH2CI2, 18 mL/min).

Yield: 73 mg light brown solid

In a 50 mL round bottom flask methyl 3-(5'-((2,3-dihydro-lH-inden-l-yl)oxy)-l',3'- dihydrospiro[azetidine-3,2'-inden]-l-yl)cyclobutanecarboxyla te (73 mg, 0.090 mmol) was dissolved in THF (0.5 mL) and MeOH (0.5 mL) to give a yellow solution. 2M NaOH (0.25 mL, 0.500 mmol) was added. The reaction mixture was stirred at RT overnight.

The reaction mixture was evaporated. The residue was dissolved in water and neutralized with 0.25 mL 2n NaOH. CH2CI2 was added, the mixture was stirred at RT for 1 h. After phase separation with a Chromabond PTS cartridge the organic layer was evaporated. The residue was purified using the Isco-Combiflash (4 g, 0- 30% MeOH in CH2CI2, 18 mL/min).

Yield: 10 mg white foam

Ή NMR (600 MHz, Methanol-d ⁴ ) 5 7.36 -7.32 (m, 1H), 7.31 - 7.24 (m, 2H), 7.22 - 7.16 (m, 1H), 7.14 (d, J = 8.2 Hz, 1H), 6.91 (d, J =2.4 Hz, 1H), 6.83 (dd, J = 8.2, 2.4 Hz, 1H), 5.76 (dd, J = 6.7, 4.2 Hz, 1H), 4.04 (s, 4H), 3.84 -3.78 (m, 1H), 3.23 (d, J = 24.0 Hz, 4H), 3.08 (ddd, J = 15.7, 8.5, 5.6 Hz, 1H), 2.94 - 2.81 (m,2H), 2.62 - 2.49 (m, 3H), 2.17 - 2.06 (m, 3H).

26 protons

MS: Calculated mass (C25H27N03): 389.20, found mass: M+H=390

Examples 105 - 107 were prepared analogously to example 104:

Example 105. 3-(5'-(2-(trifluoromethyl)phenethoxy)-l',3'-dihydrospiro[aze tidine- 3,2'-inden]-l-yl)cyclobutanecarboxylic acid

Ή NMR (600 MHz, Methanol-^) δ 7.67 (d, J = 7.9 Hz, 1H), 7.58 - 7.53 (m, 2H), 7.40 (td, J = 7.0, 6.0, 2.3 Hz, 1H), 7.09 (d, J = 8.2 Hz, 1H), 6.79 (d, J = 2.4 Hz, 1H), 6.72 (dd, J= 8.3, 2.5 Hz, 1H), 4.15 (t, J = 6.9 Hz, 2H), 4.01 (s, 4H), 3.79 (p, J Hz, 1H), 3.24 (td, J = 7.0, 1.3 Hz, 2H), 3.21 (s, 2H), 3.17 (s, 2H), 2.84 (p, J= ί 1H), 2.62 - 2.49 (m, 2H), 2.25 - 2.17 (m, 2H).

MS: Calculated mass (C25H26F3N03): 445.19, found mass: M+H=446

Example 106. 3-(5'-((7-chloro-2,3-dihydro-lH-inden-l-yl)oxy)-l',3'- dihydrospiro[azetidin -3,2'-inden]-l-yl)cyclobutanecarboxylic acid

Ή NMR (600 MHz, Methanol-^) δ 7.30 (t, J= 7.7 Hz, 1H), 7.27 - 7.21 (m, 2H), 7.14 (d, J = 8.2 Hz, 1H), 6.89 (d, J= 2.3 Hz, 1H), 6.81 (dd, J = 8.2, 2.4 Hz, 1H), 5.79 (dd, J = 6.4, 1.5 Hz, 1H), 4.05 (s, 4H), 3.82 (p, J= 7.3 Hz, 1H), 3.25 (s, 2H), 3.21 (s, 2H), 3.20 - 3.15 (m, 1H), 2.96 (ddd, J = 16.4, 9.0, 2.4 Hz, 1H), 2.86 (p, J = 8.0 Hz, 1H), 2.62 - 2.53 (m, 2H), 2.46 - 2.36 (m, 1H), 2.27 - 2.18 (m, 3H).

MS: Calculated mass (C25H26C1N03): 423.16, found mass: M+H=424/426

Example 107. 3-(5'-((4-ethoxy-3,5-difluorobenzyl)oxy)-l',3'-dihydrospiro[ azetidine- 3,2'-inden]-l-yl)cyclobutanecarboxylic acid

Ή NMR (600 MHz, Chloroform-d) 5 7.10 (d, J = 8.2 Hz, 1H), 7.00 - 6.93 (m, 2H), 6.79 (d, J = 2.4 Hz, 1H), 6.76 (dd, J = 8.2, 2.5 Hz, 1H), 4.94 (s, 2H), 4.20 (q, J = 7.1 Hz, 2H), 3.29 (ddq, J = 6.2, 4.1, 1.9 Hz, 1H), 3.20 - 3.07 (m, 5H), 2.53 (dddd, J = 13.1, 8.4, 5.8, 2.6 Hz, 2H), 2.02 (d, J = 12.7 Hz, 2H), 1.39 (t, J = 7.0 Hz, 3H).

MS: Calculated mass (C25H27F2N04): 443.19, found mass: M+H=444 Example 108. l-((5'-(4-((4-chlorobenzyl)oxy)phenyl)-l',3'-dihydrospiro[az etidine- 3,2'-inden]-l-yl)methyl)cyclopropanecarboxylic acid

In a Schlenck flask methyl l-((5'-hydroxy-l',3'-dihydrospiro[azetidine-3,2'-inden]-l- yl)methyl)cyclopropanecarboxylate (104 mg, 0.362 mmol, prepared as described for example 28) was dissolved in CH2CI2 (3 mL) to give a light yellow solution. Pyridine (0.07 mL, 0.865 mmol) was added. The mixture was cooled to 0°C and at this temperature trifluoromethanesulfonic anhydride (0.4 mL, 0.400 mmol) was added dropwise. The color of the solution turned to yellow. The reaction mixture was diluted with CHiC and washed twice with sat. NH4Cl-solution and once with saturated sodium chloride solution. The organic layer was dried over MgS04, filtered and evaporated. The residue was purified by flash chromatography (4 g, 0-

Yield: 75 mg (49%), yellow oil.

methyl l-((5'-(((trifluoromethyl)sulfonyl)oxy)-l',3'-dihydrospiro[a zetidine-3,2'- inden]-l-yl)methyl)cyclopropanecarboxylate (90 mg, 0.215 mmol) was dissolved in dry DMF (3 mL) and 4-(4'-chlorobenzyloxy)phenylboronic acid (67.7 mg, 0.258 mmol) and 10% sodium carbonate solution (517 μϋι, 0.537 mmol) followed by Tetrakis(triphenylphosphine)palladium(0) (9.9 mg, 8.6 μιηοΐ) were added. The reaction mixture was heated under stirring in the microwave to 120°C for 30 min. The organic solvent was removed in vacuo, the residue was treated with CH2CI2 and water. The organic phase was washed with water and dried (MgSC ). The solvent was evaporated in vacuo and the crude product purified by flash

chromatography (silica, n-heptane, ethyl acetate).

Yield: 38.6 mg, yellow oil (36.9%)

methyl l-((5'-(4-((4-chlorobenzyl)oxy)phenyl)-l',3'-dihydrospiro[az etidine-3,2'- inden]-l-yl)methyl)cyclopropanecarboxylate (38 mg, 0.078 mmol) was dissolved in THF (1 mL) and MeOH (1 mL). IN NaOH (800 μΙ_, 0.8 mmol) was added under stirring at RT. Stirring was continued at RT for 20 h. IN HCL (800 μΙ_, 0.8 mmol) was added followed by water (1 mL). The organic phase was evaporated in vacuo. The product precipitated as colorless solid. l-((5'-(4-((4-chlorobenzyl)oxy)phenyl)- l',3'-dihydrospiro[azetidine-3,2'-inden]-l-yl)methyl)cyclopr opanecarboxylic acid was obtained by filtration and dried over phosphorus pentoxide in vacuo at 50°C. The product was purified by flash chromatography (silica, C^C MeOH 95/5).

Yield: 8.5 mg, colorless solid (23%). 1H NMR (600 MHz, DMSO-d6) 5 7.58 - 7.53 (m, 2H), 7.52 - 7.43 (m, 6H), 7.39 (dd, J = 7.9, 1.7 Hz, 1H), 7.27 (d, J = 8.0 Hz, 1H), 7.10 - 7.04 (m, 2H), 5.15 (s, 2H), 4.02 (s, 5H), 3.23 (d, J = 17.1 Hz, 5H), 1.14 (t, J = 4.0 Hz, 2H), 0.98 (s, 2H).

28 Protons

Calculated mass (C29H28C1N03): 473.991, found mass: M+H ⁺ =474/476

Example 109. 2-(5'-((2,6-dichlorobenzyl)oxy)-l',3'-dihydrospiro[azetidine -3,2'- inden]-l-yl)acetic acid

Ethyl 2-(5'-hydroxy-l',3'-dihydrospiro[azetidine-3,2'-inden]-l-yl) acetate (52 mg, 0.199 mmol, prepared as described for example 8) was dissolved in dry DMF (3 mL). Cs ₂ C0 ₃ (78 mg, 0.239 mmol) and 2,6-dichlorobenzyl bromide (52.5 mg, 0.219 mmol) were added under stirring. The reaction mixture was stirred at RT for 2 h. The organic solvent was removed in vacuo and the residue treated with CH2CI2 and water. The organic phase was washed with water and dried (MgSO i). The crude product was purified by flash chromatography (silica, CH2CI2, MeOH).

Yield: 44 mg (52.6%), pale yellow oil.

ethyl 2-(5'-((2,6-dichlorobenzyl)oxy)-l',3'-dihydrospiro[azetidine -3,2'-inden]-l- yl)acetate (44 mg, 0.105 mmol) was dissolved in THF (2 mL) and MeOH (2 mL). 1M NaOH (1 niL, 1.0 mmol) was added under stirring. The reaction mixtures was stirred under RT for 20 h. IN HC1 (1 mL) was added. The organic solvent was evaporated in vacuo. The crude product was extracted with CH2CI2, dried (MgSO i) and concentrated in vacuo.

Yield: 34 mg, colorless solid (83%).

Ή NMR (600 MHz, DMSO-de) δ 7.56 (d, J = 8.1 Hz, 2H), 7.47 (dd, J = 8.7, 7.5 Hz, 1H), 7.13 (d, J = 8.2 Hz, 1H), 6.95 (d, J = 2.3 Hz, 1H), 6.81 (dd, J = 8.2, 2.5 Hz, 1H), 5.17 (s, 2H), 3.81 - 3.76 (m, 4H), 3.42 (s, 2H), 3.13 (d, J = 31.3 Hz, 4H).

18 Protons

Calculated mass (C20H19C12NO3): 392.276, found mass: M+ H ⁺ =392

Examples 110 and 111 were prepared analogous to example 109:

Example 110. 2-(5'-((2-cyclopropyl-6-fluorobenzyl)oxy)-l',3'-dihydrospiro [azetidine- 3,2'-inden]-l-yl)acetic ac

Ή NMR (600 MHz, DMSO-d ₆ ) δ 7.33 (td, J = 8.1, 6.1 Hz, 1H), 7.12 (d, J = 8.3 Hz, 1H), 7.06 (ddd, J = 9.6, 8.2, 1.1 Hz, 1H), 6.95 (d, J = 2.4 Hz, 1H), 6.90 - 6.79 (m, 2H), 5.16 (d, J = 1.8 Hz, 2H), 3.85 - 3.78 (m, 4H), 3.46 (s, 2H), 3.12 (d, J = 31.9 Hz, 4H), 2.05 (tt, J = 8.4, 5.3 Hz, 1H), 0.99 - 0.88 (m, 2H), 0.74 - 0.66 (m, 2H).

23 Protons

Calculated mass (C23H24FN03): 381.440, found mass: M+ H ⁺ =382

Example 111. 2-(5'-((2-cyclopropylbenzyl)oxy)-l',3'-dihydrospiro[azetidin e-3,2'- inden]-l-yl)acetic acid

Ή NMR (600 MHz, DMSO-d ₆ ) δ 7.38 (dd, J = 7.5, 1.4 Hz, 1H), 7.25 (td, J = 7.5, 1.4 Hz, 1H), 7.18 (td, J = 7.4, 1.3 Hz, 1H), 7.11 (d, J = 8.3 Hz, 1H), 7.01 (dd, J = 7.7, 1.2 Hz, 1H), 6.93 (d, J = 2.3 Hz, 1H), 6.80 (dd, J = 8.2, 2.5 Hz, 1H), 5.18 (s, 2H), 3.78 (s, 4H), 3.41 (s, 2H), 3.14 (s, 2H), 3.08 (s, 2H), 2.02 (tt, J = 8.6, 5.4 Hz, 2H), 0.95 - 0.86 (m, 2H), 0.70 - 0.61 (m, 2H).

25 Protons

Calculated mass (C23H25N03): 363.450, found mass: M+ H ⁺ =364

Example 112. l-((5'-((4-ethoxyphenyl)ethynyl)-l',3'-dihydrospiro[azetidin e-3,2'- inden]-l-yl)methyl)cyclopropanecarboxylic acid

Methyl l-((5'-hydroxy-l',3'-dihydrospiro[azetidine-3,2'-inden]-l- yl)methyl)cyclopropanecarboxylate (1.64 g, 5.71 mmol, prepared as described for example 28) was dissolved in CH2CI2 (40 mL) under an atmosphere of argon. N,N- diisopropylethylamine (3.9 mL, 22.83 mmol) was added and thre reaction mixture cooled to 0°C. At that temperature Nonafluorobutanesulfonyl fluoride (2.56 mL, 14.27 mmol) was added under stirring. After stirring at 0°C for 2 h the reaction mixture was allowed to warm to RT. Stirring was continued for 3 h. The reaction mixture was diluted with CH2CI2 (50 mL) and washed with water (twice), dried (MgS04) and concentrated in vacuo. The crude product was purified by flash chromatography (silica, CH2CI2, MeOH).

Yield: 3.1 g (95 %), yellow oil.

Methyl l-((5'-(((perfluorobutyl)sulfonyl)oxy)-l',3'-dihydrospiro[az etidine-3,2'-inden]- l-yl)methyl)cyclopropanecarboxylate (100 mg, 0.176 mmol) was dissolved in dry DMSO (2 niL) and 4-ethoxyphenylacetylene (38.5 mg, 0.263 mmol) was added under an atmosphere of argon. The reaction mixture was degased with argon for 5 min. Potassium phosphate tribasic (44.7 mg, 0.211 mmo), palladium(II) acetate (4.73 mg, 0.021 mmol) and triphenylphosphine (18.4 mg, 0.07 mmol) were added. The reaction mixture was heated under stirring and an argon atmosphere to 80°C for 1 h. The reaction mixture was diluted with CH2CI2, successively washed with water (twice) and saturated sodium bicarbonate solution. The organic phase was dried (MgSO i) and concentrated in vacuo. The crued product was purified by flash chromatography (silica, CH2CI2, MeOH).

Yield: 65 mg (89%), yellow oil.

methyl l-((5'-((4-ethoxyphenyl)ethynyl)-l',3'-dihydrospiro[azetidin e-3,2'-inden]-l- yl)methyl)cyclopropanecarboxylate (65 mg, 0.156 mmol) was dissolved in THF (3 mL) and MeOH (3 mL). 1 M NaOH (1.6 mL, 1.6 mmol) was added and the reaction mixture heated to 50° under stirring for 2 h. Stirring was continued at RT overnight. IN HC1 (1.6 ml, 1.6 mmol) was added and the reaction mixture diluted with water (5 niL). The organic solvents were removed in vacuo. The product precipitate and was obtained by filtration. l-((5'-((4-ethoxyphenyl)ethynyl)- l',3'- dihydrospiro[azetidine-3,2'-inden]-l-yl)methyl)cyclopropanec arboxylic acid was dried in vacuo over phosphorus pentoxide at 40°C.

Yield: 59 mg (94%), pale yellow solid.

Ή NMR (600 MHz, DMSO-de) δ 7.48 - 7.42 (m, 2H), 7.37 (d, J = 1.4 Hz, 1H), 7.29 (dd, J = 7.7, 1.5 Hz, 1H), 7.24 (d, J = 7.8 Hz, 1H), 6.99 - 6.93 (m, 2H), 4.06 (q, J = 7.0 Hz, 2H), 3.48 (s, 4H), 3.13 (d, J = 1.8 Hz, 4H), 2.77 (s, 2H), 1.33 (t, J = 7.0 Hz, 3H), 0.92 (q, J = 3.7 Hz, 2H), 0.64 (q, J = 3.8 Hz, 2H).

26 Protons

Calculated mass (C26H27N03): 401.497, found mass: M+ H ⁺ =402

Examples 113 - 118 were prepared analogous to example 112:

Example 113. l-((5'-((4-isopropoxyphenyl)ethynyl)-l',3'-dihydrospiro[azet idine- 3,2'-inden]-l-yl)methyl)cyclopropanecarboxylic acid

Ή NMR (500 MHz, DMSO-d ₆ ) δ 7.46 - 7.40 (m, 2H), 7.37 (s, 1H), 7.33 - 7.27 (m, 1H), 7.25 (d, J = 7.7 Hz, 1H), 6.97 - 6.91 (m, 2H), 4.66 (p, J = 6.0 Hz, 1H), 3.78 (s, 4H), 3.18 (s, 4H), 3.05 (s, 2H), 1.27 (d, J = 6.0 Hz, 6H), 1.05 (q, J = 3.9 Hz, 2H), 0.84 (q, J = 4.1 Hz, 2H).

28 Protons

Calculated mass (C27H29N03): 415.524, found mass: M+ H ⁺ =416 Example 114. l-((5'-((6-isopropoxypyridin-3-yl)ethynyl)-l',3'- dihydrospiro[azetidine-3,2'-inden]-l-yl)methyl)cyclopropanec arboxylic acid

Ή NMR (500 MHz, DMSO-d ₆ ) δ 8.34 (d, J = 2.4 Hz, 1H), 7.81 (dd, J = 8.6, 2.4 Hz, 1H), 7.39 (d, J = 1.5 Hz, 1H), 7.32 (dd, J = 7.7, 1.5 Hz, 1H), 7.26 (d, J = 7.7 Hz, 1H), 6.79 (d, J = 8.5 Hz, 1H), 5.27 (dq, J = 12.4, 6.1 Hz, 1H), 3.50 (s, 4H), 3.14 (s, 2H), 2.79 (s, 2H), 1.30 (d, J = 6.2 Hz, 6H), 0.94 (q, J = 3.8 Hz, 2H), 0.67 (q, J = 3.8 Hz, 2H).

25 Protons

Calculated mass (C26H28N203): 416.512, found mass: M+ H ⁺ =417

Example 115. 1 - ((5'- ((4- methylcyclohexyl)ethynyl) - , 3'- dihy drospiro [azetidine- 3,2'-inden]-l-yl)methyl)cyclopropanecarboxylic acid

Ή NMR (600 MHz, DMSO-d ₆ ) δ 7.32 - 7.07 (m, 3H), 3.82 (s, 4H), 3.15 (t, J = 5.3 Hz, 4H), 3.10 (s, 2H), 2.92 (t, J = 4.0 Hz, 1H), 1.93 (dt, J = 14.0, 4.5 Hz, 1H), 1.77 - 1.63 (m, 2H), 1.54 (ddq, J = 20.6, 10.4, 3.8 Hz, 3H), 1.44 - 1.27 (m, 3H), 1.06 (q, J = 3.3, 2.8 Hz, 2H), 0.95 (qd, J = 13.1, 3.5 Hz, 1H), 0.88 (dd, J = 17.1, 6.4 Hz, 5H). 31 Protons

Calculated mass (C25H31N02): 377.519, found mass: M+ H ⁺ =378 cis/trans mixture

Example 116. l-((5'-((6-(cyclopentyloxy)pyridin-3-yl)ethynyl)-l',3'- dihydrospiro[azetidine-3,2'-inden]-l-yl)methyl)cyclopropanec arboxylic acid

Ή NMR (600 MHz, DMSO-d ₆ ) δ 8.35 (d, J = 2.4 Hz, 1H), 7.81 (dd, J = 8.6, 2.4 Hz, 1H), 7.39 (d, J = 1.5 Hz, 1H), 7.32 (dd, J = 7.6, 1.5 Hz, 1H), 7.26 (d, J = 7.8 Hz, 1H), 6.81 (d, J = 8.5 Hz, 1H), 5.38 (td, J = 6.0, 3.0 Hz, 1H), 3.49 (s, 5H), 3.14 (t, J = 1.6 Hz, 5H), 2.77 (s, 2H), 1.99 - 1.89 (m, 2H), 1.75 - 1.66 (m, 4H), 1.60 (dddd, J = 11.7, 9.5, 5.1, 2.1 Hz, 2H), 0.92 (q, J = 3.7 Hz, 2H), 0.65 (q, J = 3.8 Hz, 2H).

31 Protons

Calculated mass (C28H30N2O3): 442.549, found mass: M+ H ⁺ =443 Example 117. l-((5'-((6-((l,l,l-trifluoropropan-2-yl)oxy)pyridin-3-yl)eth ynyl)-l',3'- dihydrospiro[azetidine-3,2'-inden]-l-yl)methyl)cyclopropanec arboxylic acid

Ή NMR (600 MHz, DMSO-d ₆ ) δ 8.40 (d, J = 2.3 Hz, 1H), 7.94 (dd, J = 8.6, 2.4 Hz, 1H), 7.41 (d, J = 1.4 Hz, 1H), 7.34 (dd, J = 7.7, 1.4 Hz, 1H), 7.28 (d, J = 7.8 Hz, 1H), 7.01 (d, J = 8.5 Hz, 1H), 5.91 (p, J = 6.7 Hz, 1H), 3.49 (s, 5H), 3.14 (d, J = 2.3 Hz, 4H), 2.77 (s, 2H), 1.47 (d, J = 6.5 Hz, 4H), 0.92 (q, J = 3.7 Hz, 2H), 0.64 (q, J = 3.8 Hz, 2H).

26 Protons

Calculated mass (C26H25F3N203): 470.484, found mass: M+ H ⁺ =471

Example 118. l-((5'-((4-methoxy-2-methylphenyl)ethynyl)-l',3'- dihydrospiro[azetidine-3,2'-inden]-l-yl)methyl)cyclopropanec arboxylic acid

Ή NMR (600 MHz, Methanol-d ₄ ) δ 7.37 (d, J = 8.6 Hz, 2H), 7.32 (dd, J = 7.8, 1.4 Hz, 1H), 7.22 (d, J = 7.8 Hz, 1H), 6.80 (d, J = 2.6 Hz, 1H), 6.73 (dd, J = 8.5, 2.6 Hz, 1H), 4.20 - 4.16 (m, 4H), 3.81 (s, 3H), 3.30 (s, 4H), 3.27 (s, 2H), 2.47 (s, 3H), 1.20 (q, J = 4.1 Hz, 2H), 0.75 (q, J = 4.1 Hz, 2H).

26 Protons

Calculated mass (C26H27N03): 401.497, found mass: M+ H ⁺ =402

Example 119. l-((5'-(2-(6-isopropoxypyridin-3-yl)ethyl)-l',3'- dihydrospiro[azetidine-3,2'-inden]-l-yl)methyl)cyclopropanec arboxylic acid

Methyl l-((5'-(((perfluorobutyl)sulfonyl)oxy)-l',3'-dihydrospiro[az etidine-3,2'-inden]- l-yl)methyl)cyclopropanecarboxylate (100 mg, 0.176 mmol, prepared as described for example 112) was dissolved in dry DMSO (3 mL) under an atmosphere of argon. 5-ethynyl-2-(propan-2-yloxy)pyridine (42.5 mg, 0.263 mmol) was added. The reaction mixture was degased with argon for 5 min. Potassium phosphate (44.7 mg, 0.211 mmol), palladium acetate (4.7 mg, 0.021 mmol) and triphenylphosphine (18.4 mg, 0.07 mmol) were added. The reaction mixture was stirred at 80°C for 1 h. The reaction mixture was cooled to RT, diluted with CH2CI2, successively washed with water (twice, 20 mL), saturated sodium bicarbonate (20 mL), water (20 mL) and dried (MgSO i). The organic solvent was removed in vacuo and the crude product was purified by flash chromatography (silica, Cl Cb/MeOH 95/5).

Yield: 62 mg (82 %, pale yellow oil).

Methyl l-((5'-((6-isopropoxypyridin-3-yl)ethynyl)-l',3'-dihydrospir o[azetidine-3,2'- inden]-l-yl)methyl)cyclopropanecarboxylate (62 mg, 0.044 mmol) was dissolved in THF (3 mL) and MeOH (3 mL). 1M NaOH (1.5 mL, 1.5 mmol) was added and the reaction mixture stirred at 50°C for 3 h. The reaction m mixture was cooled to RT and IN HC1 (1.5 mL, 1.5 mmol) was added. The reaction mixture was diluted with water (5 mL) and the organic solvents were removed in vacuo. The aqueous phase was extracted with CH2CI2 and the combined extracts were dried (MgSC ). The crude product was used for the next step without purification.

Yield: 60 mg (quantitative, light brown foam).

l-((5'-((6-isopropoxypyridin-3-yl)ethynyl)-l',3'-dihydros piro[azetidine-3,2'-inden]-l- yl)methyl)cyclopropanecarboxylic acid (35 mg, 0.084 mmol) was dissolved in Ethanol (4 mL), degassed with argon and 10% Pd-C (20 mg, 0.188 mmol) was added. The reaction mixture was stirred under an atmosphere of hydrogen for 2 h. The catalyst was removed by filtration and the solvent was evaporated in vacuo. The crude product was purified by flash chromatography (silica, CH2CI2, MeOH). Yield: 20 mg (56.6%, pale yellow solid).

Ή NMR (600 MHz, DMSO-d ₆ ) δ 7.94 (d, J = 2.4 Hz, 1H), 7.54 (dd, J = 8.5, 2.5 Hz, 1H), 7.13 - 7.06 (m, 2H), 6.98 (dd, J = 7.6, 1.6 Hz, 1H), 6.67 - 6.62 (m, 1H), 5.18 (p, J = 6.2 Hz, 1H), 3.51 (s, 4H), 3.07 (d, J = 4.8 Hz, 4H), 2.82 - 2.72 (m, 6H), 1.25 (d, J = 6.2 Hz, 6H), 0.92 (q, J = 3.7 Hz, 2H), 0.65 (q, J = 3.8 Hz, 2H).

31 Protons

Calculated mass (C26H32N203): 420.544, found mass: M+ H ⁺ =421

Example 120. l-((5'-((4-ethoxy-3,5-difluorobenzyl)oxy)-l',3'-dihydrospiro [azetidine- 3,2'-inden]-l-yl)methyl)cyclopropanecarboxylic acid

Methyl l-((5'-hydroxy-l',3'-dihydrospiro[azetidine-3,2'-inden]-l- yl)methyl)cyclopropanecarboxylate (60 mg, 0.209 mmol, prepared as described for example 28) was dissolved in dry THF (2 mL) and polystryrene bound

triphenylphosphine (167 mg, 1.88 mmol/g, 0.313 mmol) was added. After 5 min 4- ethoxy-3,5-difluorobenzyl alcohol (47.1 mg, 0.251 mmo) and di-tert-butyl azodicarboxylate (72.1 mg, 0.313 mmo) were added. The reaction mixture was stirred at RT for 20 h. The polymer was removed by filtration and the filtrate concentrated in vacuo. The crude product was purified by flash chromatog

(silica, CH ₂ Cl ₂ /MeOH 95/5).

Yield: 66 mg (69.1 %, colorless oil).

Methyl l-((5'-((4-ethoxy-3,5-difluorobenzyl)oxy)-l',3'-dihydrospiro [azetidine-3,2'- inden]-l-yl)methyl)cyclopropanecarboxylate (65 mg, 0.142 mmol) was dissolved in THF (3 mL) and MeOH (3 mL) and 1M NaOH (1.5 mL, 1.5 mmol) was added. The reaction mixture was stirred at 50°C for 2 h and then overnight at RT. IN HC1 (1.5 mL, 1.5 mmol) was added and the reaction mixture diluted with water (3 mL). The organic solvents were removed in vacuo. The aqueous phase was extracted with CH2CI2 (three times, 20 mL) and the combined extracts were dried (MgSC ). The solvent was evaporated in vacuo and the crude product was purified by flash chromatography (silica, CH2CI2, MeOH) and then crystallized from n-pentane. Yield: 45 mg (71.4 %, colorless solid).

Ή NMR (600 MHz, DMSO-d ₆ ) δ 7.25 - 7.17 (m, 2H), 7.11 (d, J = 8.3 Hz, 1H), 6.88 (d, J = 2.4 Hz, 1H), 6.77 (dd, J = 8.2, 2.4 Hz, 1H), 5.00 (s, 2H), 4.14 (q, J = 7.0 Hz, 2H), 3.49 (s, 4H), 3.05 (d, J = 29.2 Hz, 4H), 2.78 (s, 2H), 1.29 (t, J = 7.0 Hz, 3H), 0.91 (q, J = 3.7 Hz, 2H), 0.63 (q, J = 3.7 Hz, 2H).

26 Protons

Calculated mass (C25H27F2N04): 443.483, found mass: M+ H ⁺ =444

Examples 121 - 130 were prepared analogous to example 120:

Example 121. l-((5'-((6-methoxy-2-methylpyridin-3-yl)methoxy)-l',3'- dihydrospiro[azetidine-3,2'-inden]-l-yl)methyl)cyclopropanec arboxylic acid

Ή NMR (600 MHz, DMSO-d ₆ ) δ 7.68 (d, J = 8.3 Hz, 1H), 7.11 (d, J = 8.3 Hz, 1H), 6.90 (d, J = 2.4 Hz, 1H), 6.79 (dd, J = 8.2, 2.5 Hz, 1H), 6.64 (d, J = 8.3 Hz, 1H), 4.98 (s, 2H), 3.83 (s, 3H), 3.50 (s, 4H), 3.06 (d, J = 28.6 Hz, 4H), 2.79 (s, 2H), 2.56 - 2.51 (m, 1H), 2.42 (s, 3H), 0.91 (q, J = 3.6 Hz, 2H), 0.64 (q, J = 3.7 Hz, 2H).

28 Protons

Calculated mass (C24H28N204): 408.490, found mass: M+ H ⁺ =409

Example 122. l-((5'-((4-ethoxy-2,6-difluorobenzyl)oxy)-l',3'-dihydrospiro [azetidine- 3,2'-inden]-l-yl)methyl)cyclopropanecarboxylic acid

Ή NMR (600 MHz, DMSO-d ₆ ) δ 7.11 (d, J = 8.2 Hz, 1H), 6.89 (d, J = 2.2 Hz, 1H), 6.82 - 6.74 (m, 3H), 4.94 (s, 2H), 4.07 (q, J = 7.0 Hz, 2H), 3.49 (s, 4H), 3.05 (d, J = 27.7 Hz, 4H), 2.78 (s, 2H), 1.32 (t, J = 7.0 Hz, 3H), 0.91 (q, J = 3.7 Hz, 2H), 0.63 (q, J = 3.7 Hz, 2H).

26 Protons

Calculated mass (C25H27F2N04): 443.483, found mass: M+ H ⁺ =444

Example 123. l-((5'-((4-ethoxy-2,3-difluorobenzyl)oxy)-l',3'-dihydrospiro [azetidine- 3,2'-inden]-l-yl)methyl)cyclopropanecarboxylic acid

Ή NMR (600 MHz, DMSO-d ₆ ) δ 7.27 (td, J = 8.4, 2.1 Hz, 1H), 7.11 (d, J = 8.2 Hz, 1H), 7.03 (td, J = 8.3, 7.7, 1.7 Hz, 1H), 6.90 (d, J = 2.3 Hz, 1H), 6.77 (dd, J = 8.2, 2.5 Hz, 1H), 5.03 (s, 2H), 4.15 (q, J = 7.0 Hz, 2H), 3.48 (s, 4H), 3.05 (d, J = 28.3 Hz, 4H), 2.77 (s, 2H), 1.36 (t, J = 7.0 Hz, 3H), 0.91 (q, J = 3.7 Hz, 2H), 0.63 (q, J = 3.8 Hz, 2H).

26 Protons

Calculated mass (C25H27F2N04): 443.483, found mass: M+ H ⁺ =444

Example 124. l-((5'-((2,5-dichloropyridin-3-yl)methoxy)-l',3'- dihydrospiro[azetidin -3,2'-inden]-l-yl)methyl)cyclopropanecarboxylic acid

Ή NMR (600 MHz, DMSO-d ₆ ) δ 8.52 (d, J = 2.7 Hz, 1H), 8.15 (d, J = 2.6 Hz, 1H), 7.14 (d, J = 8.3 Hz, 1H), 6.96 (d, J = 2.3 Hz, 1H), 6.84 (dd, J = 8.2, 2.5 Hz, 1H), 5.10 (s, 2H), 3.52 (s, 4H), 3.08 (d, J = 30.4 Hz, 7H), 2.80 (s, 2H), 0.92 (q, J = 3.7 Hz, 2H), 0.65 (q, J = 3.7 Hz, 2H).

24 Protons

Calculated mass (C22H22C12N203): 433.328, found mass: M+ H ⁺ =433/435

Example 125. l-((5'-((2,3-dihydro-lH-inden-4-yl)methoxy)-l',3'- dihydrospiro[azetidin -3,2'-inden]-l-yl)methyl)cyclopropanecarboxylic acid

Ή NMR (600 MHz, DMSO-d ₆ ) δ 7.19 (t, J = 7.0 Hz, 2H), 7.16 - 7.07 (m, 2H), 6.89 (d, J = 2.4 Hz, 1H), 6.77 (dd, J = 8.2, 2.5 Hz, 1H), 5.00 (s, 2H), 3.49 (s, 4H), 3.05 (d, J = 28.1 Hz, 4H), 2.88 (t, J = 7.4 Hz, 4H), 2.78 (s, 2H), 2.02 (p, J = 7.5 Hz, 2H), 0.91 (q, J = 3.7 Hz, 2H), 0.63 (q, J = 3.7 Hz, 2H).

28 Protons

Calculated mass (C26H29N03): 403.513, found mass: M+ H ⁺ =404

Example 126. l-((5'-(cyclohexylmethoxy)-l',3'-dihydrospiro[azetidine-3,2' -inden]-l- yl)methyl)cyclopropanecarboxylic acid

Ή NMR (600 MHz, DMSO-d6) 5 7.08 (d, J = 8.2 Hz, 1H), 6.79 (d, J = 2.3 Hz, 1H), 6.68 (dd, J = 8.3, 2.4 Hz, 1H), 3.71 (d, J = 6.3 Hz, 2H), 3.64 (s, 4H), 3.07 (d, J = 27.8 Hz, 5H), 2.93 (s, 2H), 1.79 (dd, J = 12.9, 3.7 Hz, 2H), 1.68 (ddt, J = 33.1, 12.3, 3.9 Hz, 5H), 1.30 - 1.09 (m, 4H), 1.07 - 0.92 (m, 4H), 0.73 (q, J = 4.0 Hz, 2H).

33 Protons

Calculated mass (C23H31N03): 369.497, found mass: M+ H ⁺ =370

Example 127. l-((5'-((2,3-dihydro-lH-inden-2-yl)oxy)-l',3'-dihydrospiro[a zetidine- 3,2'-inden]-l-yl)methyl)cyclopropanecarboxylic acid

Ή NMR (600 MHz, DMSO-d ₆ ) δ 7.25 (dd, J = 5.4, 3.3 Hz, 2H), 7.21 - 7.12 (m, 2H), 7.10 (d, J = 8.2 Hz, 1H), 6.81 (d, J = 2.3 Hz, 1H), 6.69 (dd, J = 8.2, 2.4 Hz, 1H), 5.17 (td, J = 5.9, 2.9 Hz, 1H), 3.49 (s, 4H), 3.33 (dd, J = 16.8, 6.1 Hz, 3H), 3.10 - 2.95 (m, 5H), 2.78 (s, 2H), 0.91 (q, J = 3.7 Hz, 2H), 0.63 (q, J = 3.7 Hz, 2H).

26 Protons

Calculated mass (C25H27N03): 389.487, found mass: M+ H ⁺ =390

Example 128. l-((5'-((4-(cyclopropylmethoxy)benzyl)oxy)-l',3'- dihydrospiro[azetidine-3,2'-inden]-l-yl)methyl)cyclopropanec arboxylic acid

Ή NMR (600 MHz, DMSO-d ₆ ) δ 7.35 - 7.29 (m, 2H), 7.08 (d, J = 8.2 Hz, 1H), 6.94 - 6.88 (m, 2H), 6.86 (d, J = 2.3 Hz, 1H), 6.75 (dd, J = 8.2, 2.5 Hz, 1H), 4.94 (s, 2H), 3.80 (d, J = 7.0 Hz, 2H), 3.49 (s, 4H), 3.04 (d, J = 27.2 Hz, 4H), 2.78 (s, 2H), 1.21 (ddt, J = 9.3, 7.5, 3.9 Hz, 1H), 0.90 (q, J = 3.7 Hz, 2H), 0.62 (q, J = 3.7 Hz, 2H), 0.59 - 0.51 (m, 2H), 0.36 - 0.26 (m, 2H).

30 Protons

Calculated mass (C27H31N04): 433.539, found mass: M+ H ⁺ =434

Example 129. l-((5'-((7-chloro-2,3-dihydro-lH-inden-l-yl)oxy)-l',3'- dihydrospiro[azetidine- '-inden]-l-yl)methyl)cyclopropanecarboxylic acid

Ή NMR (600 MHz, DMSO-d ₆ ) δ 7.41 - 7.28 (m, 3H),

7.12 (d, J = 8.3 Hz, 1H), 6.89 (d, J = 2.3 Hz, 1H), 6.77 (dd, J = 8.2, 2.4 Hz, 1H), 5.79 (dd, J = 6.5, 1.5 Hz, 1H), 3.54 - 3.52 (m, 4H), 3.07 (d, J = 29.7 Hz, 7H), 2.94 (ddt, J = 19.3, 10.3, 5.2 Hz, 1H), 2.80 (s, 2H), 2.47 - 2.40 (m, 1H), 2.10 (ddt, J = 14.1, 8.2, 2.1 Hz, 1H), 0.91 (q, J = 3.7 Hz, 2H), 0.64 (q, J = 3.7 Hz, 2H).

27 Protons

Calculated mass (C25H26C1N03): 423.932, found mass: M+ H ⁺ =424/426

Example 130. l-((5'-((2,3-dihydro-lH-inden-l-yl)oxy)-l',3'-dihydrospiro[a zetidine- 3,2'-inden]-l-yl)methyl)cyclopropanecarboxylic acid

Ή NMR (600 MHz, DMSO-d ₆ ) δ 7.36 (d, J = 7.5 Hz, 1H), 7.35 - 7.27 (m, 2H), 7.22 (td, J = 7.2, 1.8 Hz, 1H), 7.12 (d, J = 8.3 Hz, 1H), 6.91 (d, J = 2.5 Hz, 1H), 6.80 (dd, J = 8.2, 2.5 Hz, 1H), 5.79 (s, 1H), 3.49 (d, J = 1.6 Hz, 4H), 3.09 - 2.99 (m, 5H), 2.86 (ddd, J = 16.0, 8.6, 5.4 Hz, 1H), 2.78 (s, 2H), 2.57 - 2.50 (m, 1H), 1.99 (dddd, J = 13.9, 8.6, 5.4, 4.1 Hz, 1H), 0.91 (q, J = 3.7 Hz, 2H), 0.63 (q, J = 3.7 Hz, 2H).

26 Protons

Calculated mass (C25H27N03): 389.487, found mass: M+ H ⁺ =390 Example 131. l-((5'-((2-cyclopropyl-6-fluorobenzyl)oxy)- l',3'- dihydrospiro[azetidine- '-inden]-l-yl)methyl)cyclopropanecarboxylic acid

(2-cyclopropyl-6-fluorophenyl)methanol (400 mg, 2.407 mmol) was suspended in 48% hydrogen bromide (5 mL) and the reaction mixture was stirred at RT overnight. The reaction mixture was diluted with water (20 mL) and extracted with ethyl acetate (20 mL). The organic phase was successively washed with saturated sodium bicarbonate (twice) and water and dried (MgSO i). The solvent was removed in vacuo. The crude 2-(bromomethyl)-l-cyclopropyl-3-fluorobenzene was used without further purification for the next step.

Yield: 550 mg (quantitative, light brown oil).

Methyl l-((5'-hydroxy- l',3'-dihydrospiro[azetidine-3,2'-inden]-l- yl)methyl)cyclopropanecarboxylate (100 mg, 0.348 mmol, prepared as described for example 28) was dissolved in dry DMF (4 mL). Cesium carbonate (227 mg, 0.696 mmol) and 2-(bromomethyl)- l-cyclopropyl-3-fluorobenzene (120 mg, 0.522 mmol) were added and the reaction mixture stirred at RT for 2 h. The DMF was removed in vacuo, the residue was treated with CH2CI2 and water. The organic phase was washed with water (twice) and dried (MgSO i). The crude product was purified by flash chromatography (silica, CF C /MeOH 95/5).

Yield: 47 mg (31 %, pale yellow oil).

Methyl l-((5'-((2-cyclopropyl-6-fluorobenzyl)oxy)-l',3'-dihydrospir o[azetidine-3,2'- inden]-l-yl)methyl)cyclopropanecarboxylate (47 mg, 0.108 mmol) was dissolved in THF (2 niL) and MeOH (2 niL). 1M NaOH (1.1 mL, 1.1 mmol) was added and the reaction mixture was stirred at 50°C for 2 h. The reaction mixture was cooled to RT and IN HC1 (1.1 mL, 1.1 mmol) and water (5 mL) were added. The organic solvents were removed in vacuo and the aqueous phase was extracted with CH2CI2 (twice). The solvent was removed in vacuo and the crude product was purified by flash chromatography (silica, CH2CI2, MeOH) and crystallized from n-pentane.

Yield: 31 mg (68.2 %, colorless solid).

Ή NMR (600 MHz, DMSO-d ₆ ) δ 7.33 (td, J = 8.1, 6.0 Hz, 1H), 7.12 (d, J = 8.2 Hz, 1H), 7.06 (ddd, J = 9.5, 8.2, 1.0 Hz, 1H), 6.95 (d, J = 2.3 Hz, 1H), 6.85 (d, J = 7.7 Hz, 1H), 6.82 (dd, J = 8.2, 2.5 Hz, 1H), 5.16 (d, J = 1.7 Hz, 2H), 3.52 (s, 4H), 3.07 (d, J = 29.8 Hz, 4H), 2.80 (s, 2H), 2.05 (tt, J = 8.4, 5.2 Hz, 1H), 0.96 - 0.89 (m, 4H), 0.73 - 0.67 (m, 2H), 0.64 (q, J = 3.7 Hz, 2H).

27 Protons

Calculated mass (C26H28FN03): 421.504, found mass: M+ H ⁺ =422 Example 132. l-((5'-(2-cyclohexylethoxy)-l',3'-dihydrospiro[azetidine-3,2 '-inden]-l- yl) methyl)cyclopr op anecarb oxylic acid

A 4mL scintillation vial was charged with a stir bar, 500μ]1ι of a solution of methyl l-((5'-hydroxy-l',3'-dihydrospiro[azetidine-3,2'-inden]-l- yl)methyl)cyclopropanecarboxylate (prepared as described for example 28) in toluene anhydrous (30.0mg, 0.104mmol), 350μ]1ι of a 0.6mmol preweighed vial containing a solution of cyclopentylmethanol dissolved in toluene anhydrous (20.9 mg, 0.21 mmol, 2 eq), and Cyanomethylenetributylphospharane (CMBP)(63.0 mg, 0.26mmol, 2.5 eq). The vial was capped and placed to heat at 80°C for 16 hours. Upon completion the solvent is removed under a N2 blower and the crude material is redissolved in δθθμϋι of THF. To this 1500μ]1ι of a 1M aqueous solution of LiOH in 75% MeOH is added, the vial capped once more and placed to heat at 60°C for 1 hour. The crude material is then passed through a cartridge containing 300mg of celite and washed with Acetonitrile 2 x ΙΟΟΟμΚ The recovered crude solution is then dried under N2 and dissolved once again with 1500μ]1ι of DMSO/MeOH (1: 1 v/v), and sent to APS for reverse phase HPLC purification using the ammonium acetate method, to recover l-((5'-(2-cyclohexylethoxy)-l',3'-dihydrospiro[azetidine- 3,2'-inden]-l-yl)methyl)cyclopropanecarboxylic acid. (8.4mg, 28.7%).

Ή NMR (400 MHz, DMSO-de) δ 7.07 (d, J = 8.2 Hz, 1H), 6.77 (d, J = 2.4 Hz, 1H), 6.68 (dd, J = 8.1, 2.4 Hz, 1H), 3.95 (t, J = 6.6 Hz, 2H), 3.66 (s, 4H), 3.11 (s, 2H), 3.06 (s, 2H), 2.90 (s, 2H), 1.74 - 1.64 (m, 3H), 1.59 (q, J = 6.6 Hz, 3H), 1.46 (dtt, J = 14.0, 6.9, 3.6 Hz, 1H), 1.28 - 1.12 (m, 3H), 1.00 (dd, J = 12.4, 3.0 Hz, 1H), 0.96 (q, J = 3.7 Hz, 3H), 0.94 - 0.85 (m, 1H), 0.62 (q, J = 3.7 Hz, 2H). MS (APCI+) m/z 384.3 (M+H ⁺ ).

Examples 133 - 148 were prepared analogous to example 132:

Example 133. l-((5'-((4-methylbenzyl)oxy)-l',3'-dihydrospiro[azetidine-3, 2'-inden]- l-yl)methyl)cyclopropanecarboxylic acid

(3.2mg, 32.7%). Ή NMR (400 MHz, DMSO-de) δ 7.30 (d, J = 7.8 Hz, 2H), 7.18 (d, J = 7.8 Hz, 2H), 7.08 (d, J = 8.2 Hz, 1H), 6.86 (d, J = 2.3 Hz, 1H), 6.75 (dd, J = 8.3, 2.4 Hz, 1H), 4.99 (s, 2H), 3.46 (s, 4H), 3.06 (s, 2H), 3.01 (s, 2H), 2.76 (s, 2H), 2.30 (s, 3H), 0.90 (q, J = 3.7 Hz, 2H), 0.61 (q, J = 3.8 Hz, 2H). MS (APCI+) m/z 378.2 (M+H ⁺ ). Example 134. l-((5'-(2-methylphenethoxy)-l 3'-dihydrospiro[azetidine-3,2'-inden]- 1 - yl) methyl)cycloprop anecarb oxylic acid

(21.1mg, 72.2%). Ή NMR (400 MHz, DMSO-de) δ 7.23 - 7.20 (m, 1H), 7.18 - 7.05 (m, 4H), 6.77 (d, J = 2.4 Hz, 1H), 6.69 (dd, J = 8.2, 2.5 Hz, 1H), 4.14 (t, J = 6.8 Hz, 2H), 3.65 (s, 4H), 3.10 (s, 2H), 3.06 (s, 2H), 3.00 (t, J = 6.8 Hz, 2H), 2.89 (s, 2H), 2.31 (s, 3H), 0.96 (q, J = 3.7 Hz, 2H), 0.62 (q, J = 3.7 Hz, 2H). MS (APCI+) m/z 392.3 (M+H ⁺ ). Example 135. l-((5'-(4-methoxyphenethoxy)- l',3'-dihydrospiro[azetidine-3,2'- inden]-l-yl)methyl)cyclopropanecarboxylic acid

(19.0 mg, 64.9%). Ή NMR (400 MHz, DMSO-de) δ 7.22 - 7.17 (m, 2H), 7.07 (d, J = 8.2 Hz, 1H), 6.88 - 6.83 (m, 2H), 6.77 (d, J = 2.3 Hz, 1H), 6.68 (dd, J = 8.2, 2.5 Hz, 1H), 4.12 (t, J = 6.7 Hz, 2H), 3.73 (s, 2H), 3.63 (s, 4H), 3.10 (s, 2H), 3.06 (s, 2H), 2.93 (t, J = 6.7 Hz, 2H), 2.88 (s, 2H), 0.95 (q, J = 3.7 Hz, 2H), 0.61 (q, J = 3.7 Hz, 2H). MS (APCI+) m/z 408.5 (M+H ⁺ ).

Example 136. l-((5'-(2-fluorophenethoxy)- l',3'-dihydrospiro[azetidine-3,2'-inden]- l-yl)methyl)cyclopropanecarboxylic acid

(21.8 mg, 74.5%). Ή NMR (400 MHz, DMSO-de) δ 7.36 (t, J = 7.6 Hz, 1H), 7.30 - 7.24 (m, 1H), 7.16 - 7.05 (m, 3H), 6.78 - 6.73 (m, 1H), 6.67 (dd, J = 8.0, 2.2 Hz, 1H), 4.17 (t, J = 6.7 Hz, 2H), 3.57 (s, 4H), 3.08 (s, 2H), 3.06 - 3.02 (m, 4H), 2.86 (s, 2H), 0.93 (q, J = 3.7 Hz, 2H), 0.58 (q, J = 3.5 Hz, 2H). MS (APCI+) m/z 396.2 (M+H ⁺ ).

Example 137. l-((5'-(4-fluorophenethoxy)-l',3'-dihydrospiro[azetidine-3,2 '-inden]- l-yl)methyl)cyclopropanecarboxylic acid

(23.7mg, 81%) Ή NMR (400 MHz, DMSO-de) δ 7.31 (dd, J = 8.4, 5.6 Hz, 2H), 7.10 - 7.03 (m, 3H), 6.77 (s, 1H), 6.71 - 6.66 (m, 1H), 4.15 (t, J = 6.5 Hz, 2H), 3.84 - 3.37 (m, 4H), 3.08 (d, J = 17.1 Hz, 4H), 2.99 (t, J = 6.5 Hz, 3H), 0.96 (s, 2H), 0.63 (s, 2H). MS (APCI+) m/z 396.3 (M+H ⁺ ).

Example 138. l-((5'-((2-methylbenzyl)oxy)-l',3'-dihydrospiro[azetidine-3, 2'-inden]- l-yl)methyl)cyclopropanecarboxylic acid

(12.4mg, 42.4%). Ή NMR (400 MHz, DMSO-de) δ 7.38 (t, J = 8.8 Hz, 1H), 7.28 - 7.11 (m, 4H), 7.13 - 7.04 (m, 1H), 6.89 (d, J = 9.2 Hz, 1H), 6.81 (d, J = 8.3 Hz, 1H), 5.03 (s, 2H), 3.68 (s, 5H), 3.11 (d, J = 8.5 Hz, 3H), 2.90 (s, 2H), 2.32 (s, 2H), 0.97 - 0.91 (m, 2H), 0.64 - 0.56 (m, 2H). MS (APCI+) m/z 378.2 (M+H ⁺ ).

Example 139. l-((5'-((4-methoxybenzyl)oxy)-l',3'-dihydrospiro[azetidine-3 ,2'- in den] - 1 - yl) methyl) cycloprop anecarb oxylic acid

(22.6 mg, 77.2%). Ή NMR (400 MHz, DMSO-de) δ 7.35 - 7.31 (m, 2H), 7.08 (d, J = 8.2 Hz, 1H), 6.95 - 6.90 (m, 2H), 6.85 (d, J = 2.4 Hz, 1H), 6.76 (dd, J = 8.2, 2.5 Hz, 1H), 4.96 (s, 2H), 3.76 (s, 3H), 3.66 (s, 4H), 3.11 (s, 2H), 3.07 (s, 2H), 2.90 (s, 2H), 0.96 (q, J = 3.7 Hz, 2H), 0.62 (q, J = 3.7 Hz, 2H). MS (APCI+) m/z 394.1 (M+H ⁺ ).

Example 140. l-((5'-((2-fluorobenzyl)oxy)-l',3'-dihydrospiro[azetidine-3, 2'-inden]- l- yl)methyl)cyclopropanecarboxylic acid

(20.4 mg, 69.8%). Ή NMR (400 MHz, DMSO-de) δ 7.50 (td, J = 7.6, 1.7 Hz, 1H), 7.39 (tdd, J = 7.6, 5.3, 1.7 Hz, 1H), 7.24 - 7.15 (m, 2H), 7.11 (d, J = 8.2 Hz, 1H), 6.88 (d, J = 2.3 Hz, 1H), 6.79 (dd, J = 8.2, 2.4 Hz, 1H), 5.08 (s, 2H), 3.67 (s, 4H), 3.13 (s, 2H), 3.08 (s, 2H), 2.90 (s, 2H), 0.97 (q, J = 3.8 Hz, 2H), 0.63 (q, J = 3.8 Hz, 2H). MS (APCI+) m/z 382.1 (M+H ⁺ ).

Example 141. l-((5'-((2-chlorobenzyl)oxy)-l',3'-dihydrospiro[azetidine-3, 2'-inden]- l-yl)methyl)cyclopropanecarboxylic acid

(22.3 mg, 76.2%). Ή NMR (400 MHz, DMSO-de) δ 7.55 (dd, J = 5.6, 3.8 Hz, 1H), 7.49 - 7.44 (m, 1H), 7.39 - 7.33 (m, 2H), 7.11 (d, J = 8.2 Hz, 1H), 6.89 (d, J = 2.3 Hz, 1H), 6.79 (dd, J = 8.2, 2.4 Hz, 1H), 5.11 (s, 2H), 3.66 (s, 4H), 3.13 (s, 2H), 3.08 (s, 2H), 2.90 (s, 2H), 0.97 (q, J = 3.7 Hz, 2H), 0.63 (q, J = 3.7 Hz, 2H). MS (APCI+) m/z 398.2 (M+H ⁺ ).

Example 142. l-((5'-((4-cyanobenzyl)oxy)- l',3'-dihydrospiro[azetidine-3,2'-inden]-l- yl)methyl)cyclopropanecarboxylic acid

(9.1mg, 31.1%). Ή NMR (400 MHz, DMSO-de) δ 7.78 (d, J = 8.3 Hz, 2H), 7.61 (d, J = 8.1 Hz, 2H), 7.09 (d, J = 8.2 Hz, 1H), 6.88 - 6.86 (m, 1H), 6.79 - 6.76 (m, 1H), 5.14 (s, 2H), 3.52 (s, 4H), 3.08 (s, 2H), 3.04 (s, 2H), 2.84 (s, 2H), 0.94 - 0.87 (m, 2H), 0.59 - 0.52 (m, 2H). MS (APCI+) m/z 389.2 (M+H ⁺ ).

Example 143. l-((5'-(benzo[d] [l,3]dioxol-5-ylmethoxy)-l',3'-dihydrospiro[azetidine- 3,2'-inden]-l-yl)methyl)cyclopropanecarboxylic acid

(18.1mg, 61.8%). Ή NMR (400 MHz, DMSO-de) δ 7.08 (d, J = 8.2 Hz, 1H), 6.94 - 6.82 (m, 4H), 6.76 (dd, J = 8.2, 2.3 Hz, 1H), 5.96 (d, J = 1.1 Hz, 2H), 4.94 (s, 2H), 3.66 (s, 4H), 3.11 (s, 2H), 3.07 (s, 2H), 2.90 (s, 2H), 0.96 (q, J = 3.7 Hz, 2H), 0.62 (q, J = 3.8 Hz, 2H). MS (APCI+) m/z 408.3 (M+H ⁺ ). Example 144. l-((5'-(2-(lH-indol-3-yl)ethoxy)- l',3'-dihydrospiro[azetidine-3,2'- in den] - 1 - yl) methyl) cycloprop anecarb oxylic acid

(3.1 mg, 10.8%)Ή NMR (400 MHz, DMSO-de) δ 7.56 (dt, J = 7.8, 1.1 Hz, 1H), 7.36 (dt, J = 8.1, 1.0 Hz, 1H), 7.17 (s, 1H), 7.10 - 7.05 (m, 2H), 6.99 (ddd, J = 8.0, 7.0, 1.1 Hz, 1H), 6.79 (d, J = 2.4 Hz, 1H), 6.71 (dd, J = 8.2, 2.5 Hz, 1H), 4.20 (t, J = 6.8 Hz, 2H), 3.63 (s, 4H), 3.13 (dd, J = 6.8, 0.9 Hz, 1H), 3.10 (s, 2H), 3.06 (s, 2H), 2.88 (s, 2H), 0.95 (q, J = 3.7 Hz, 2H), 0.60 (q, J = 3.7 Hz, 2H). MS (APCI+) m/z 417.2 (M+H ⁺ ).

Example 145. l-((5'-(2-(2-chlorophenoxy)ethoxy)- l',3'-dihydrospiro[azetidine-3,2'- in den] - 1 - yl) methyl) cycloprop anecarb oxylic acid

(20.2mg, 68.8%). Ή NMR (400 MHz, DMSO-de) δ 7.39 (dd, J = 7.9, 1.6 Hz, 1H), 7.29 (ddd, J = 8.9, 7.4, 1.6 Hz, 1H), 7.18 (dd, J = 8.2, 1.4 Hz, 1H), 7.10 (d, J = 8.2 Hz, 1H), 6.97 (td, J = 7.6, 1.4 Hz, 1H), 6.85 (s, 1H), 6.75 (dd, J = 8.2, 2.5 Hz, 1H), 4.37 (dd, J = 5.5, 3.1 Hz, 2H), 4.30 (dd, J = 5.9, 3.0 Hz, 2H), 3.64 (s, 4H), 3.11 (s, 2H), 3.07 (s, 2H), 2.89 (s, 2H), 0.96 (q, J = 3.7 Hz, 2H), 0.61 (q, J = 3.7 Hz, 2H). MS (APCI+) m/z 428.4 (M+H ⁺ ). Example 146. l-((5'-(3-(6-methylpyridin-2-yl)propoxy)- l',3'-dihydrospiro[azetidine- 3,2'-inden]-l-yl)methyl)cyclopropanecarboxylic acid

(1.2 mg,4.1%). Ή NMR (400 MHz, DMSO-de) δ 7.55 (t, J = 7.7 Hz, 1H), 7.09 - 7.02 (m, 3H), 6.76 (s, 1H), 6.68 (d, J = 8.0 Hz, 1H), 3.97 (t, J = 6.5 Hz, 3H), 2.86 - 2.79 (m, 2H), 2.43 (s, 3H), 2.12 - 2.04 (m, 2H), 1.52 - 1.28 (m, 2H), 0.99 - 0.93 (m, 1H), 0.89 (t, J = 7.2 Hz, 2H), 0.67 - 0.57 (m, 2H). MS (APCI+) m/z 407.2 (M+H ⁺ ).

Example 147. l-((5'-((3-cyanobenzyl)oxy)- l',3'-dihydrospiro[azetidine-3,2'-inden]-l- yl)methyl)cyclopropanecarboxylic acid

(18.3mg, 62.6%). Ή NMR (400 MHz, DMSO-de) δ 7.81 (s, 1H), 7.78 - 7.71 (m, 2H), 7.59 (t, J = 7.8 Hz, 1H), 7.11 (d, J = 8.3 Hz, 1H), 6.89 (d, J = 2.3 Hz, 1H), 6.80 (dd, J = 8.3, 2.5 Hz, 1H), 5.12 (s, 2H), 3.66 (s, 4H), 3.12 (s, 2H), 3.08 (s, 2H), 2.90 (s, 2H), 0.97 (q, J = 3.8 Hz, 2H), 0.63 (q, J = 3.8 Hz, 2H). MS (APCI+) m/z 390.1 (M+H ⁺ ). Example 148. l-((5'-(3-fluorophenethoxy)-l',3'-dihydrospiro[azetidine-3,2 '-inden]- l-yl)methyl)cyclopropanecarboxylic acid

(17.8 mg, 60.8%) Ή NMR (400 MHz, DMSO-de) δ 7.32 (td, J = 7.9, 6.2 Hz, 1H), 7.14 - 7.06 (m, 3H), 6.99 (td, J = 8.7, 2.6 Hz, 1H), 6.77 (d, J = 2.3 Hz, 1H), 6.69 (dd, J = 8.2, 2.4 Hz, 1H), 4.18 (t, J = 6.5 Hz, 2H), 3.64 (s, 4H), 3.10 (s, 2H), 3.06 (s, 2H), 3.02 (t, J = 6.5 Hz, 2H), 2.88 (s, 2H), 0.95 (q, J = 3.7 Hz, 2H), 0.61 (q, J = 3.7 Hz, 2H). MS (APCI+) m/z 396.6 (M+H ⁺ ). Example 149. 2-(6'-((4-chlorophenyl)ethynyl)-3'H-spiro[azetidine-3,2'-ben zofuran]- 1-yl) acetic acid

3'H-spiro[azetidine-3,2'-benzofuran]-6'-ol (242 mg, 1.366 mmol) was dissolved in dry DMF (20 mL) and l,8-diazabicyclo[5.4.0]undec-7-ene (0.244 mL, 2.049 mmol) and ethyl bromoacetate (0.197 mL, 1.775 mmol) were added at RT. The reaction mixture was stirred at RT for 2 h. The solvent was removed in vacuo and the residue treated with CH2CI2 (40 mL) and water (20 mL). The organic phase was washed with saturated sodium chloride solution and dried (MgSC ). The crude product was purified by flash chromatography (silica n-heptane, ethyl acetate). Yield: 158 mg (43.9 %), pale yellow solid.

Ethyl 2-(6'-hydroxy-3'H-spiro[azetidine-3,2'-benzofuran]-l-yl)acet ate (247 mg, 0.938 mmol) was dissolved in CH2CI2 (5 mL) and N,N-diisopropylethylamine (0.64 mL, 3.75 mmol) were added. The reaction mixture was cooled to 0°C and

Nonafluorobutanesulfonyl fluoride (0.42 mL, 2.35 mmol) were added. After 2 h stirring at 0°C the reaction mixture was allowed to come to RT and stirring was continued for additional 2 h. The reaction mixture was diluted with CH2CI2 (20 mL) and washed with water (twice). The organic solution was dried (MgSC ) and concentrated in vacuo. The crude product was purified by flash chromatography (silica, n-heptane, ethyl acetate).

Yield: 400 mg (78 %), colorless oil.

Ethyl 2-(6'-(((perfluorobutyl)sulfonyl)oxy)-3'H-spiro[azetidine-3, 2'-benzofuran]-l- yl)acetate (100 mg, 0.183 mmol) was dissolved in dry DMSO (2 mL) under an argon atmosphere, l-chloro-4-ethynylbenzene (37.6 mg, 0.275 mmol) was added. The reaction mixture was degased with argon for 5 min. Potassium phosphate (46.7 mg, 0.220 mmol), palladium acetate (4.94 mg, 0.022 mmol) and triphenyl phosphine (19.24 mg, 0.073 mmol) were added. The reaction mixture was heated to 80°C under stirring for 1 h. The reaction mixture was diluted with CH2CI2 and successively washed with water (twice), saturated sodium bicarbonate solution and water. The organic phase was dried (MgSO i) and concentrated in vacuo. The crude product was purified by flash chromatography (silica, CH2CI2, MeOH).

Yield: 63 mg (90 %), pale yellow solid.

Ethyl 2-(6'-((4-chlorophenyl)ethynyl)-3'H-spiro[azetidine-3,2'-ben zofuran]-l- yl)acetate (61 mg, 0.160 mmol) was dissolved in THF (3 mL) and MeOH (3 mL). 1M NaOH (1 mL, 1.0 mmol) was added and the reaction mixture was stirred at RT for 1 h. IN HC1 (1.0 mL) was added. The organic solvents were removed in vacuo. 2-(6'- ((4-chlorophenyl)ethynyl) - 3Ή - spiro [azetidine- 3, 2' -benzofuran] - 1 -yl)acetic acid precipitated and was obtained by filtration and washed with water. The product was dried in vacuo at 40°C.

Yield: 50 mg (88%), pale yellow solid.

Ή NMR (600 MHz, DMSO-de) δ 7.58 - 7.55 (m, 2H), 7.51 - 7.47 (m, 2H), 7.28 (d, J = 7.6 Hz, 1H), 7.08 (dd, J = 7.6, 1.4 Hz, 1H), 6.97 (d, J= 1.3 Hz, 1H), 3.72 - 3.68 (m, 2H), 3.62 - 3.58 (m, 2H), 3.49 (s, 2H), 3.33 (s, 2H).

MS: Calculated for (C20H16C1NO3): 353.08, found mass: M+H ⁺ = 354

Examples 150 - 155 were prepared analogously to example 149: Example 150. 2-(6'-(cyclohexylethynyl)-3'H-spiro[azetidine-3,2'-benzofura n]-l- yl) acetic acid

Ή NMR (600 MHz, DMSO-de) δ 7.17 (d, J= 7.7 Hz, 1H), 6.87 (dd, J= 7.6, 1.4 Hz, 1H), 6.75 (s, 1H), 3.72 - 3.66 (m, 2H), 3.59 (d, J = 9.2 Hz, 2H), 1.84 - 1.78 (m, 2H), 1.67 (dq, J= 9.1, 2.7 Hz, 2H), 1.55 - 1.39 (m, 3H), 1.38 - 1.25 (m, 3H).

MS: Calculated for (C20H23NO3): 325.17, found mass: M+H ⁺ = 326

Example 151. 2-(6'-(phenylethynyl)-3'H-spiro[azetidine-3,2'-benzofuran]-l - yl) acetic acid

Ή NMR (600 MHz, DMSO-de) δ 7.53 (td, J= 5.5, 4.9, 3.0 Hz, 2H), 7.42 (dd, J = 5.0, 2.0 Hz, 3H), 7.26 (d, J= 7.6 Hz, 1H), 7.07 (dd, J= 7.6, 1.4 Hz, 1H), 6.95 (d, J= 1.3 Hz, 1H), 3.68 (d, J = 8.7 Hz, 2H), 3.58 (d, J = 8.7 Hz, 2H), 3.49 (s, 2H), 3.32 (s, 2H). MS: Calculated for (C20H17NO3): 319.12, found mass: M+H ⁺ = 320 Example 152. 2-(6'-((3-chlorophenyl)ethynyl)-3'H-spiro[azetidine-3,2'-ben zofuran]- 1-yl) acetic acid

Ή NMR (600 MHz, DMSO-de) δ 7.62 (t, J = 1.9 Hz, 1H), 7.53 - 7.48 (m, 2H), 7.47 7.43 (m, 1H), 7.28 (d, J= 7.6 Hz, 1H), 7.09 (dd, J = 7.6, 1.4 Hz, 1H), 6.97 (d, J = 1. Hz, 1H), 3.70 - 3.65 (m, 2H), 3.60 - 3.56 (m, 2H), 3.49 (s, 2H), 3.32 (s, 2H).

MS: Calculated for (C20H16C1NO3): 353.08, found mass: M+H ⁺ = 354 Example 153. 2-(6'-((2-chlorophenyl)ethynyl)-3'H-spiro[azetidine-3,2'-ben zofuran]- 1-yl) acetic acid

Ή NMR (600 MHz, DMSO-de) δ 7.66 (ddd, J= 6.7, 4.8, 1.8 Hz, 1H), 7.59 (dt, J = 8.0, 1.7 Hz, 1H), 7.41 (dtt, J= 24.8, 7.5, 2.2 Hz, 2H), 7.31 (dd, J = 24.2, 7.6 Hz, 1H), 7.09 (d, J = 7.6 Hz, 1H), 6.95 (s, 1H), 4.25 (s, 1H), 4.12 (q, J = 5.3 Hz, 1H), 3.17 (d, J = 3.4 Hz, 4H).

MS: Calculated for (C20H16C1NO3): 353.08, found mass: M+H ⁺ = 354 Example 154. 2-(6'-((4-ethoxyphenyl)ethynyl)-3'H-spiro[azetidine-3,2'-ben zofuran]- 1-yl) acetic acid

10684304-0991

Ή NMR (600 MHz, DMSO-de) δ 7.47 - 7.43 (m, 2H), 7.24 (d, J = 7.6 Hz, 1H), 7.02 (dd, J= 7.5, 1.4 Hz, 1H), 6.97 - 6.93 (m, 2H), 6.91 (d, J= 1.3 Hz, 1H), 4.06 (q, J = 7.0 Hz, 2H), 3.69 - 3.63 (m, 2H), 3.59 - 3.54 (m, 2H), 3.47 (s, 2H), 3.31 (s, 2H), 1.33 (t, J= 7.0 Hz, 3H).

MS: Calculated for (C22H21N04): 363.15, found mass: M+H ⁺ =364 Example 155. 2-(6'-((4-methylcyclohexyl)ethynyl)-3'H-spiro[azetidine-3,2' - benzofuran]-l-yl)acetic acid

10684304-0992

Ή NMR (600 MHz, DMSO-de) δ 7.16 (dd, J = 9.4, 7.7 Hz, 1H), 6.87 (ddd, J = 19.4, 7.5, 1.4 Hz, 1H), 6.74 (dd, J= 16.2, 1.3 Hz, 1H), 3.65 (dd, J = 9.5, 3.5 Hz, 2H), 3.58 - 3.52 (m, 2H), 3.43 (d, J = 3.6 Hz, 2H), 3.30 (d, J = 2.7 Hz, 2H), 1.96 - 1.89 (m, 1H), 1.77 - 1.69 (m, 1H), 1.66 (dd, J = 13.8, 3.5 Hz, 1H), 1.53 (ddd, J = 12.7, 10.1, 6.2 Hz, 2H), 1.42 - 1.27 (m, 3H), 0.94 (dd, J= 11.8, 3.3 Hz, 1H), 0.87 (dd, J = 19.6, 6.5 Hz, 3H).

MS: Calculated for (C21H25N03): 339.18, found mass: M+H ⁺ =340

Example 156. l-((6'-((2-chloro-6-ethylbenzyl)oxy)-3'H-spiro[azetidine-3,2 '- benzofuran]-l-yl)methyl)cyclopropanecarboxylic acid

In a 50 mL round-bottomed flask 3'H-spiro[azetidine-3,2'-benzofuran]-6'-ol (50 mg, 0.282 mmol) was dissolved in DMF (2 mL) to give a colorless solution. DBU (0.064 mL, 0.423 mmol) and methyl l-(bromomethyl)cyclopropane-carboxylate (70.8 mg, 0.367 mmol) were added. Stirred at RT overnight.

The residue was evaportated. The mixture was extracted with ethyl acetate and water. The organic layer was washed with sodium chloride soloution. The residue dried over MgS04 and evaporated. The residue was purified by flash

chromatography (silica 4 g, 0-10% MeOH in CH2CI2, 18 mL/min)

Yield: 25.4mg (0.088 mmol, 31 %, colorless oil).

In a 50 mL round-bottomed flask methyl l-((6'-hydroxy-3'H-spiro[azetidine-3,2'- benzofuran]-l-yl)methyl)cyclopropanecarboxylate (25.4 mg, 0.088 mmol) was dissolved in DMF (2 mL) to give a colorless solution. Cesium carbonate (40 mg, 0.123 mmol) and 2-(bromomethyl)-l-chloro-3-ethylbenzene (25 mg, 0.107 mmol) were added. Stirred at RT for 2 days. The residue was evaportated. The mixture was extracted with CH2CI2 and water. After phase separation with a Chromabond PTS-cartridge the organic layer was evaporated. The residue was purified by flash chromatography (silica 4 g, 0-10% MeOH in CH2CI2, 18 mL/min)

Yield: 25 mg (0,057 mmol, 64 %, colorless oil).

In a 50 mL round-bottomed flask methyl l-((6'-((2-chloro-6-ethylbenzyl)oxy)-3'H- spiro[azetidine-3,2'-benzofuran]-l-yl)methyl)cyclopropanecar boxylate (25 mg, 0.057 mmol) was dissolved in THF (0.5 mL) and MeOH (0.5 mL) to give a colorless solution. IN NaOH (250 0.500 mmol) were added. Stirred at RT. The reaction mixture was evaporated, the residue was dissolved in water and neutralized with 250 μL. CH2CI2 was added. After phase separation the organic layer was dried with MgSC , filtered and evaporated. Crude product: 22 mg white foam. The foam was purified by flash chromatography (silica 4 g, 0-50% MeOH in CH2CI2, 18mL/min) Yield: 19 mg (0.044 mmol, 78 %, white foam).

Ή NMR (600 MHz, DMSO-de) δ 7.38 - 7.34 (m, 2H), 7.27 (dd, J = 6.0, 3.0 Hz, 1H), 7.10 (dd, J= 8.0, 1.3 Hz, 1H), 6.56 - 6.52 (m, 2H), 5.08 (s, 2H), 3.63 - 3.55 (m, 2H), 3.53 - 3.46 (m, 2H), 2.73 (s, 2H), 2.70 (q, J= 7.6 Hz, 2H), 1.15 (t, J= 7.5 Hz, 3H), 0.97 (q, J = 3.8 Hz, 2H), 0.74 (q, J = 3.9 Hz, 2H).

MS: Calculated mass (C24H26C1N04): 427.16, found mass: M+H=438/430 Example 157. 4-(6'-((2-chloro-6-ethylbenzyl)oxy)-3'H-spiro[azetidine-3,2' - benzofuran] - 1 -yl) - 3- methylbutanoic acid

In a 250 mL round-bottomed flask 3'H-spiro[azetidine-3,2'-benzofuran]-6'-ol (50 mg, 0.282 mmol) was dissolved in THF (5 mL) with Ethyl 3-methyl-4-oxobutanoate (50 mg, 0.347 mmol) to give a yellow solution. Stirred for 30 min at RT. Sodium triacetoxyborohydride (90 mg, 0.423 mmol) was added. Stirred for 30 min at RT. The mixture was extracted with 10 mL G C and 2 mL water. Stirred for 10 min at RT. After phase separation with a Chromabond PTS-cartridge the organic layer was evaporated. The residue was purified by flash chromatography (silica 4 g, 0- 10% MeOH in CH2CI2, 12 mL/min)

Yield: 59 mg (0.193 mmol, 68.5 %, clear oil).

In a 50 mL round-bottomed flask ethyl 4-(6'-hydroxy-3'H-spiro[azetidine-3,2'- benzofuran]-l-yl)-3-methylbutanoate (59 mg, 0.193 mmol) was dissolved in DMF (4 mL) to give a colorless solution. Cesium carbonate (70 mg, 0.215 mmol) and 2- (bromomethyl)-l-chloro-3-ethylbenzene (50 mg, 0.214 mmol) were added. Stirred at RT over the night. The residue was evaportated. The mixture was extracted with CH2CI2 and water. After phase separation with a Chromabond PTS-cartridge the organic layer was evaporated. The residue was purified by flash chromatography (silica 4 g, 0-10% MeOH in CH2CI2, 18 mL/min) Yield: 48 mg (0.105 mmol, 54 %, colorless oil).

In a 50mL round-bottom flask ethyl 4-(6'-((2-chloro-6-ethylbenzyl)oxy)-3'H- spiro[azetidine-3,2'-benzofuran]-l-yl)-3-methylbutanoate (48 mg, 0.105 mmol) was dissolved in THF (0.5 mL) and MeOH (0.5 mL) to give a colorless solution. 1M NaOH (0.5 ml, 1.000 mmol) was added. The reaction mixture was evaporated. The residue was dissolved in water and neutralized to pH 7 with ~0.5mL 2N HC1.

CH2CI2 was added. After phase separation the organic layer was dried over MgS04, filtered and evaporated.

Yield: 44 mg (0.102 mmol, 98 %, colorless foam).

Ή NMR (600 MHz, DMSO-de) δ 7.38 - 7.35 (m, 2H), 7.27 (dd, J = 5.9, 3.1 Hz, 1H), 7.11 (d, J = 7.9 Hz, 1H), 6.54 (d, J= 7.9 Hz, 2H), 5.09 (s, 2H), 2.70 (q, J= 7.5 Hz, 2H), 2.35 (dd, J= 15.6, 5.7 Hz, 1H), 2.01 (dd, J= 15.6, 7.9 Hz, 1H), 1.86 (s, 1H), 1.15 (t, J= 7.6 Hz, 3H), 0.90 (d, J= 6.7 Hz, 3H).

MS: Calculated mass (C24H28C1N04): 429.17, found mass: M+H=430/432

Example 158. 2-(6'-((2-chloro-6-ethylbenzyl)oxy)-3'H-spiro[azetidine-3,2' - benzofuran]-l-yl)acetic acid

A solution of (2-chloro-6-ethylphenyl)methanol (6 g, 35.2 mmol) in aqueous 40% HBr (20 mL) was stirred for 12 hr at 50 °C. Ethyl acetate was added, the organic layer was separated and washed with saturated sodium bicarbonate solution, dried with anhydrous NaiSC . The solvent was removed to give 2-(bromomethyl)-l- chloro-3-ethylbenzene.

Yield: 7.215 g (27.2 mmol, 77 % yield, oil).

In a 50 mL round-bottomed flask 3'H-spiro[azetidine-3,2'-benzofuran]-6'-ol (50 mg, 0.282 mmol) was dissolved in DMF (2 mL) to give a colorless solution. DBU (64 μϋι, 0.425 mmol) and ethyl bromoacetate (42 μϋι, 0.379 mmol) were added. Stirred at RT overnight. The reaction mixture was evaporated. The residue was extracted with CH2CI2 and water. After phase separation with a Chromabond PTS cartridge the organic layer was evaporated. The residue was purified by flash

chromatography (silica 4 g, 0-10% MeOH in CH2CI2, 18 mL/min).

Yield: 55 mg (colorless oil).

In a 50 mL round-bottomed flask ethyl 2-(6'-hydroxy-3'H-spiro[azetidine-3,2'- benzofuran]-l-yl)acetate (55 mg, 0.209 mmol) was dissolved in DMF (2 mL) to give a colorless solution. Cesium carbonate (90 mg, 0.276 mmol) and 2-(bromomethyl)-l- chloro-3-ethylbenzene (60 mg, 0.257 mmol) were added. Stirred at RT for 30 min. The reaction mixture was evaporated. The residue was extracted with CH2CI2 and water. After phase separation with a Chromabond PTS-cartridge the organic layer was evaporated. The residue was purified by flash chromatography (silica 4 g, 0- 10% MeOH in CH2CI2, 18 mL/min).

Yield: 21 mg (yellow oil).

In a 10 mL flask ethyl 2-(6'-((2-chloro-6-ethylbenzyl)oxy)-3'H-spiro[azetidine-3,2' - benzofuran]-l-yl)acetate (21 mg, 0.050 mmol) was dissolved in THF (0.5 mL) and MeOH (0.5 mL) to give a colorless solution. NaOH (0.2 mL, 0.400 mmol) was added. Stirred at RT overnight. The reaction mixture was evaporated. The residue was dissolved in water and neutralized with 2N HC1 (0.2 mL). CH2CI2 was added. After phase separation the organic layer was dried over MgS04, filtered and evaporated. Yield: 17 mg (87 %, 0.044 mmol, colorless solid).

Ή NMR (600 MHz, DMSO-de) δ 7.38 - 7.34 (m, 2H), 7.27 (dd, J = 5.9, 3.1 Hz, 1H), 7.11 (d, J = 8.0 Hz, 1H), 6.57 - 6.52 (m, 2H), 5.09 (s, 2H), 3.67 (d, J = 8.7 Hz, 2H), 3.57 (d, J = 8.7 Hz, 2H), 2.70 (q, J = 7.5 Hz, 2H), 1.15 (t, J = 7.6 Hz, 3H).

MS: Calculated mass (C21H22C1N04): 387.12, found mass: M+H=388/390

Example 159. 2-(5-((2-ethyl-6-fluorobenzyl)oxy)-l,3-dihydrospiro[indene-2 ,4'- piperidin]-l'-yl)acetic acid hydrochloride

HCI

1 ,3-dihydrospiro[indene-2, 4 '-piperidinj- 5-ol

To a solution of commercially availablel'-benzyl-l,3-dihydrospiro[indene-2,4'- piperidin]-5-ol (1.3 g, 4.43 mmol) in 10ml methanol) was added Pd C(10%, 1.415 g) at 20 °C. After stirring at 20 °C for 2h under hydrogen the catalyst was filtered off. The filtrate was concentrated to give l,3-dihydrospiro[indene-2,4'-piperidin]-5-ol (710.1 mg) as a white solid. Ethyl 2-( 5-hydroxy-l, 3-dihydrospiro[indene-2, 4 '-piperidinj- 1 '-yl)acetate

To a solution of l,3-dihydrospiro[indene-2,4'-piperidin]-5-ol (268 mg, 1.3 mmol) in 12ml DMF was added DBU (301 mg; 2 mmol) and ethyl 2-bromoacetate (242 mg, 1.4 mmol). After stirring at RT for 75 minutes sat NH4C1 solution was added. The reaction mixture was extracted with ethyl acetate and the combined organic layers discarded. The aqueous layer was reduced to dryness and the residue was stirred consecutively first with 500 ml ethyl acetate and then with 500 ml DCM. The organic layers were reduced to dryness affording 418 mg and 147 mg of product still containing inorganic impurities. This material was subsequently used without further purification.

Ethyl 2-(5-((2-ethyl-6-fluorobenzyl)oxy)- l,3-dihydrospiro[indene-2,4'-piperidinJ- 1 '- yl)acetate

To a solution of ethyl 2-(5-hydroxy-l,3-dihydrospiro[indene-2,4'-piperidin]-l'- yl)acetate (78 mg, 0.27 mmol) in DMF was added potassium carbonate (56 mg, 0.4 mmol) and 2-(bromomethyl)-l-ethyl-3-fluorobenzene (65 mg, 0.3 mmol). After stirring at RT overnight water was added and the reaction mixture was extracted 3x with ethyl acetate. Combined organic layers were washed with sat NH4CI solution, dried over Na2S04 and the solved evaporated. The residue was purified by chromatography affording 36 mg of desired product. 2-(5-((2-ethyl-6-fluorobenzyl)oxy)-l,3-dihydrospiro[indene-2 ,4'-piperidinJ-l '-yl)acetic acid hydrochloride

To a solution of ethyl 2-(5-((2-ethyl-6-fluorobenzyl)oxy)-l,3-dihydrospiro[indene- 2,4'-piperidin]-l'-yl)acetate (36 mg, 0.08 mmol) in THF was added sodium hydroxide (2M in water, 0.25 ml, 0.5 mmol). After stirring at RT overnight the solvent was evaporated, then water was added and the mixture adjusted to pHl with 2N HCl. The precipitate was filtered of and dried affording 29 mg of desired product as a white solid.

Ή-NMR: (600 MHz, DMSO-d6) 5 14.05 (s, 1H), 9.83 (s, 1H), 7.38 (td, J = 8.0, 6.0 Hz, 1H), 7.17 - 7.05 (m, 4H), 6.90 (d, J = 2.4 Hz, 1H), 6.81 (dd, J = 8.2, 2.5 Hz, 1H), 5.03 (d, J = 1.7 Hz, 2H), 4.14 (s, 2H), 2.81 - 2.76 (m, 2H), 2.70 (q, J = 7.6 Hz, 2H), 1.82 (s, 4H), 1.17 (t, J = 7.6 Hz, 3H).

MS: 398 (M+H ⁺ )

Examples 160 and 161 were prepared analogous to example 159

Example 160. 2-(5-((2,6-dichlorobenzyl)oxy)-l,3-dihydrospiro[indene-2,4'- piperidin]-l'-yl)acetic acid

HCl

Example 160 was prepared as described for example 159 using 2-(bromom

1,3-dichlorobenzene instead of 2-(bromomethyl)-l-ethyl-3-fluorobenzene

MS: 420 (M+H+), isotope pattern for two chlorines 1H NMR (600 MHz, DMSO-d6; some signals may be covered by solvent) δ 7.56 (d, J = 8.1 Hz, 2H), 7.50 - 7.44 (m, 1H), 7.11 (d, J = 8.2 Hz, 1H), 6.90 (d, J = 2.3 Hz, 1H), 6.80 (dd, J = 8.2, 2.5 Hz, 1H), 5.17 (s, 2H), 3.03 (br, s, 4H), 2.78 (m, 2H), 2.73 (m, 2H), 1.73 (t, J = 5.6 Hz, 4H).

Example 161. 2-(5-((2-chloro-6-ethylbenzyl)oxy)-l,3-dihydrospiro[indene-2 ,4'- piperidin]-l'-yl)acetic acid hydrochloride

HCI

Example 161 was prepared as described for example 159 using 2-(bromomethyl)-l- chloro-3-ethylbenzene instead of 2-(bromomethyl)-l-ethyl-3-fluorobenzene

MS: 414 (M+H+), isotope pattern for one chlorine

1H NMR (600 MHz, DMSO-d6; some signals may be covered by solvent) δ 14.06 (br, s, 1H), 9.8 (br, s, 1H), 7.39 - 7.33 (m, 2H), 7.28 (dd, J = 5.8, 3.1 Hz, 1H), 7.12 (d, J = 8.2 Hz, 1H), 6.91 (d, J = 2.3 Hz, 1H), 6.82 (dd, J = 8.2, 2.5 Hz, 1H), 5.10 (s, 2H), 4.12 (s, 2H), 2.83 - 2.80 (m, 2H), 2.78 - 2,75 (m, 2H), 2.72 (q, J = 7.5 Hz, 2H), 1.82 (m, 4H), 1.17 (t, J = 7.5 Hz, 3H).

4. Assessment of agonist potency

Agonistic activity was measured as described below. The results are shown in table 1.

Genetically engineered cells

Cell clone CHO-A21-Edgl #17 carries the transgenes human EDGl (SlPRl) receptor (Accession number NP_001391.2), mitochondrially targeted Aequorin (active part corresponds to accession number 1SL8_A) and chimaeric Gaqi5 = Gaq modified with the 5 C-terminal amino-acids replaced with those of the Gai protein (DCGLF). CHO-A2-S1P3 Mix is a cell pool ectopically expressing human EDG3 (S1PR3) receptor (Accession number NP_005217.2) mitochondrially targeted Aequorin (active part has a sequence similar to accession number AY601106.1) and GNA16 (Accession number NP_002059.3). Cell clone CHO-A21-EDG8 #12 carries the transgenes human EDG8 (S1PR5) receptor (Acession number NP_110387.1), mitochondrially expressed Aequorin (active part corresponds to accession number 1SL8_A) and chimaeric Gaqi5 (Gaq modified to present the 5 last amino-acids of the Gai protein "DCGLF"; see above). Cells are grown to mid-log phase in culture medium (HAM's F12, 10% FBS, 100 IU/mL penicillin, 100 μg/mL streptomycin, 250 μg/mL Zeocin, 400 μg/mL G418). 18 hours prior to frozen cells preparation, the medium is changed to remove the antibiotics.

Aequorin assay

18 hours prior to the test, vials of frozen cells are quickly thawed in a 37°C water bath, cells are recovered by centrifugation and resuspended in assay buffer

(DMEM/HAM's F12 with HEPES, without phenol red + 0.1% fatty acid-free BSA). Cells are gently agitated in suspension overnight at RT in presence of 5 μΜ of Coelenterazine h (Molecular Probes). On the day of the test, cells are diluted to their final working concentrations in assay buffer and agitated in suspension for lh at RT. Cells are then placed in the luminescence reader (Hamamatsu Functional Drug Screening System 6000, FDSS6000). During cells incubation, compounds are prepared in 100% DMSO, and subsequently diluted in assay buffer. Compounds are then dispensed in the assay plate (black, clear-bottom, 384-well plate). After binding of agonists to the human SIP receptor the intracellular calcium

concentration increases and binding of calcium to the Aequorin/Coelenterazine complex leads to an oxidation reaction of coelenterazine, which results in the production of Aequorin, coelenteramide, C02 and light (Dmax 469nm). The luminescent response is dependent on the agonist concentration. For agonist testing, 30 μΐι of cell suspension are injected on 30 μ∑ι of test compound or reference agonist in the assay plate. The resulting emission of light is recorded for 90 seconds using the FDSS6000. Dose response curves with the reference compounds are performed before testing the compounds. SIP is the reference agonist and JTE-013 the reference antagonist for S1P2.

Following an incubation of 3 min after the first injection, 30 μϋι of the reference agonist for a final concentration corresponding to its EC80 is injected on the 60 μϋι 5 of cell suspension and test compound mixture, for antagonist testing. The resulting emission of light is recorded for 90 seconds using the FDSS6000.

Luminescence data are integrated over the reading interval for agonist and antagonist modes. To standardize the emission of recorded light (determination of the "100% signal") across plates and across different experiments, some of the wells0 contain ΙΟΟμΜ digitonin or a saturating concentration of ATP (20μΜ). Plates also contain the reference agonist at a concentration equivalent to the EC80 obtained during the test validation and the EC 100. Dose-response data from test compounds were analyzed with XLfit (IDBS) software using nonlinear regression applied to a sigmoidal dose-response model and the following equation:

5 XL Fit fit Model 203: 4 Parameter Logistic Model

A : Bottom

B : TOP

C : LogEC50

D : Hill

0 fit = (A+((B-A)/(l+(((10 ^A C)/x) ^A D))))

inv = ((10-C)/((((B-A)/(y-A))-l)-(l/D)))

res = (y-fit)

Table 1.

Ex. Name S1P5 SlPl S1P3 S1P4

EC50 EC50 EC50 EC50 range

#

1 1 - ((5'- ((4-ethoxyphenyl)ethynyl) - V ,3' - D > 1 μΜ > 1 μΜ dihydrospiro[azetidine-3,2'-inden]-l- yl)methyl)cyclopropanecarboxylic acid

2 l-((5'-((2-methoxy-4-propylbenzyl)oxy)-l',3'- D > 1 μΜ < 1 μΜ dihydrospiro[azetidine-3,2'-inden]-l- yl)methyl)cyclopropanecarboxylic acid

3 2-(5'-((4-butyl-2-chlorobenzyl)oxy)-l ^, ,3'- D > 1 μΜ < 1 μΜ dihydrospiro[azetidine-3,2'-inden]-l-yl)acetic acid

4 2-(5'-((2-chloro-4-ethylbenzyl)oxy)-l ^, ,3'- C > 1 μΜ < 1 μΜ dihydrospiro[azetidine-3,2'-inden]-l-yl)acetic acid Ex. Name S1P5 SlPl S1P3 S1P4

EC50 EC50 EC50 EC50 range

#

5 3-(5'-((tetrahydro-2H-pyran-3-yl)methoxy)-l',3'- D > 1 μΜ > 1 μΜ dihydrospiro[azetidine-3,2'-inden]-l- yl)cyclobutanecarboxylic acid

6 3-(5'-(benzyloxy)-l',3'-dihydrospiro[azetidine-3,2'- D > 1 μΜ > 1 μΜ < 1 μΜ inden]-l-yl)propanoic acid

7 3-(5 (2-chloro-6-ethylbenzyl)oxy)-l',3'- A > 1 μΜ > 1 μΜ < 1 μΜ dihydrospiro[azetidine-3,2'-inden]-l-yl)propanoic

acid

8 2-(5'-(benzyloxy)-l',3'-dihydrospiro[azetidine-3,2'- C > 1 μΜ > 1 μΜ < 1 μΜ inden]-l-yl)acetic acid

9 2-(5'-((2-chloro-6-methoxybenzyl)oxy)-l',3'- C > 1 μΜ > 1 μΜ dihydrospiro[azetidine-3,2'-inden]-l-yl)acetic acid

10 2-(5'-((2-£luoro-6-methoxybenzyl)oxy)-l',3'- C > 1 μΜ < 1 μΜ dihydrospiro[azetidine-3,2'-inden]-l-yl)acetic acid

11 -(5 (4-chlorobenzyl)oxy)-l',3'- D > 1 μΜ > 1 μΜ < 1 μΜ dihydrospiro[azetidine-3,2'-inden]-l-yl)acetic acid

12 2-(5'-((2-(trifluoromethyl)benzyl)oxy)-l ^, ,3'- B > 1 μΜ < 1 μΜ dihydrospiro[azetidine-3,2'-inden]-l-yl)acetic acid

13 2-(5 ^, -((2,6-difluorobenzyl)oxy)-l ^, ,3'- B > 1 μΜ < 1 μΜ dihydrospiro[azetidine-3,2'-inden]-l-yl)acetic acid

14 2-(5'-((3,5-difluorobenzyl)oxy)-l',3'- B > 1 μΜ > 1 μΜ < 1 μΜ dihydrospiro[azetidine-3,2'-inden]-l-yl)acetic acid

15 2-(5'-((2-chloro-6-cyclopropylbenzyl)oxy)-l',3'- A > 1 μΜ > 1 μΜ < 1 μΜ dihydrospiro[azetidine-3,2'-inden]-l-yl)acetic acid

16 2-(5'-((3-chlorobenzyl)oxy)-l ^, ,3'- A > 1 μΜ > 1 μΜ < 1 μΜ dihydrospiro[azetidine-3,2'-inden]-l-yl)acetic acid

compound with acetic acid

17 2-(5'-((2-fluoro-6-methylbenzyl)oxy)-l ^, ,3'- A > 1 μΜ < 1 μΜ dihydrospiro[azetidine-3,2'-inden]-l-yl)acetic acid

18 2-(5 ^, -((2-chloro-6-fluorobenzyl)oxy)-l ^, ,3'- A > 1 μΜ < 1 μΜ dihydrospiro[azetidine-3,2'-inden]-l-yl)acetic acid

19 2-(5'-((2-fluoro-6-(trifluoromethyl)benzyl)oxy)- A > 1 μΜ < 1 μΜ l',3'-dihydrospiro[azetidine-3,2'-inden]-l-yl)acetic

acid

20 2-(5'-((2-chloro-6-(tri£luoromethyl)benzyl)oxy)- A > 1 μΜ < 1 μΜ l',3'-dihydrospiro[azetidine-3,2'-inden]-l-yl)acetic

acid

21 2-(5 ^, -((2-ethyl-6-fluorobenzyl)oxy)-l ^, ,3'- A > 1 μΜ < 1 μΜ dihydrospiro[azetidine-3,2'-inden]-l-yl)acetic acid

22 2-(5'-((4-bromo-2-chlorobenzyl)oxy)-l',3'- B > 1 μΜ < 1 μΜ dihydrospiro[azetidine-3,2'-inden]-l-yl)acetic acid

23 2-(5'-((2,5-dichlorobenzyl)oxy)-l ^, ,3'- A > 1 μΜ > 1 μΜ < 1 μΜ dihydrospiro[azetidine-3,2'-inden]-l-yl)acetic acid

24 2-(5'-((2-chloro-6-ethylbenzyl)oxy)-l ^, ,3'- A > 1 μΜ > 1 μΜ < 1 μΜ dihydrospiro[azetidine-3,2'-inden]-l-yl)acetic acid

25 2-(5'-((3,4-dichlorobenzyl)oxy)-l ^, ,3'- B > 1 μΜ > 1 μΜ < 1 μΜ dihydrospiro[azetidine-3,2'-inden]-l-yl)acetic acid

26 2-(5'-((2,6-dimethylbenzyl)oxy)-l ^, ,3'- dihydrospiro[azetidine-3,2'-inden]-l-yl)acetic acid Ex. Name S1P5 SlPl S1P3 S1P4

EC50 EC50 EC50 EC50 range

#

27 2-(5'-((5-£luoro-2-(tri£luoromethyl)benzyl)oxy)- A > 1 μΜ < 1 μΜ l',3'-dihydrospiro[azetidine-3,2'-inden]-l-yl)acetic

acid

28 l-((5 (2-chloro-6-ethylbenzyl)oxy)-l',3'- A > 1 μΜ > 1 μΜ < 1 μΜ dihydrospiro[azetidine-3,2'-inden]-l- yl)methyl)cyclopropanecarboxylic acid

29 l-((5'-(benzyloxy)-l',3'-dihydrospiro[azetidine- D > 1 μΜ > 1 μΜ > 1 μΜ

3,2'-inden]-l-yl)methyl)cyclopropanecarboxylic

acid

30 l-((5'-((2-£luoro-6-methoxybenzyl)oxy)-l',3'- D > 1 μΜ > 1 μΜ dihydrospiro[azetidine-3,2'-inden]-l- yl)methyl)cyclopropanecarboxylic acid

31 l-((5'-((2-chloro-6-methoxybenzyl)oxy)-l',3'- C > 1 μΜ < 1 μΜ dihydrospiro[azetidine-3,2'-inden]-l- yl)methyl)cyclopropanecarboxylic acid

32 l-((5'-((2-chloro-4-ethoxybenzyl)oxy)-l',3'- D > 1 μΜ < 1 μΜ dihydrospiro[azetidine-3,2'-inden]-l- yl)methyl)cyclopropanecarboxylic acid

33 1 - ((5'- ((4-chlorobenzyl)oxy) - V, 3'- D > 1 μΜ < 1 μΜ dihydrospiro[azetidine-3,2'-inden]-l- yl)methyl)cyclopropanecarboxylic acid

34 l-CCB'-^-chloro-e-fluorobenzy^oxy)-!'^'- D > 1 μΜ < 1 μΜ dihydrospiro[azetidine-3,2'-inden]-l- yl)methyl)cyclopropanecarboxylic acid

35 l-((5 (4-ethoxybenzyl)oxy)-l',3'- D > 1 μΜ < 1 μΜ dihydrospiro[azetidine-3,2'-inden]-l- yl)methyl)cyclopropanecarboxylic acid

36 l-((5 (2,5-dichlorobenzyl)oxy)-l',3'- D > 1 μΜ < 1 μΜ dihydrospiro[azetidine-3,2'-inden]-l- yl)methyl)cyclopropanecarboxylic acid

37 l-CCB'-^^-difluorobenzy^oxy)-!'^'- D > 1 μΜ < 1 μΜ dihydrospiro[azetidine-3,2'-inden]-l- yl)methyl)cyclopropanecarboxylic acid

38 l-CCB'-C^-dichlorobenzy^oxy)-!'^'- D > 1 μΜ < 1 μΜ dihydrospiro[azetidine-3,2'-inden]-l- yl)methyl)cyclopropanecarboxylic acid

39 l-CCB'-^^-dimethylbenzy^oxy)-!'^'- A > 1 μΜ > 1 μΜ < 1 μΜ dihydrospiro[azetidine-3,2'-inden]-l- yl)methyl)cyclopropanecarboxylic acid

40 l-((5'-((2-chloro-4-methoxybenzyl)oxy)-l',3'- D > 1 μΜ < 1 μΜ dihydrospiro[azetidine-3,2'-inden]-l- yl)methyl)cyclopropanecarboxylic acid

41 l-((5'-((2-(trifluoromethyl)benzyl)oxy)-l ^, ,3'- D > 1 μΜ < 1 μΜ dihydrospiro[azetidine-3,2'-inden]-l- yl)methyl)cyclopropanecarboxylic acid

42 l-CCB'-^-fluoro-e-methylbenzy^oxy)-!'^'- C > 1 μΜ < 1 μΜ dihydrospiro[azetidine-3,2'-inden]-l- yl)methyl)cyclopropanecarboxylic acid

43 l-((5'-((5-fluoro-2-(trifluoromethyl)benzyl)oxy)- D > 1 μΜ < 1 μΜ Ex. Name S1P5 SlPl S1P3 S1P4

EC50 EC50 EC50 EC50 range

#

l',3'-dihydrospiro[azetidine-3,2'-inden]-l- yl)methyl)cyclopropanecarboxylic acid

44 l-((5'-((2-chloro-6-cyclopropylbenzyl)oxy)-l',3'- A > 1 μΜ > 1 μΜ < 1 μΜ dihydrospiro[azetidine-3,2'-inden]-l- yl)methyl)cyclopropanecarboxylic acid

45 l-((5 (3-chlorobenzyl)oxy)-l',3'- B > 1 μΜ > 1 μΜ < 1 μΜ dihydrospiro[azetidine-3,2'-inden]-l- yl)methyl)cyclopropanecarboxylic acid

46 l-((5 (2,6-(u<Morobenzyl)oxy)- r,3'- A > 1 μΜ > 1 μΜ < 1 μΜ dihydrospiro[azetidine-3,2'-inden]-l- yl)methyl)cyclopropanecarboxylic acid

47 l-((5'-((2-chloro-6-(tri£luoromethyl)benzyl)oxy)- A > 1 μΜ < 1 μΜ l',3'-dihydrospiro[azetidine-3,2'-inden]-l- yl)methyl)cyclopropanecarboxylic acid

48 l-((5 (2-ethyl-6-fluorobenzyl)oxy)-l',3'- A > 1 μΜ < 1 μΜ dihydrospiro[azetidine-3,2'-inden]-l- yl)methyl)cyclopropanecarboxylic acid

49 l-((5'-((2-£luoro-6-(tri£luoromethyl)benzyl)oxy)- A > 1 μΜ < 1 μΜ l',3'-dihydrospiro[azetidine-3,2'-inden]-l- yl)methyl)cyclopropanecarboxylic acid

50 l-((5 ^, -(4-((3-fluorobenzyl)oxy)phenyl)-l ^, ,3'- A > 1 μΜ > 1 μΜ < 1 μΜ dihydrospiro[azetidine-3,2'-inden]-l- yl)methyl)cyclopropanecarboxylic acid

51 1 - ((5'- (4- (cyclohexylmethoxy)phenyl) - , 3'- B > 1 μΜ > 1 μΜ > 1 μΜ dihydrospiro[azetidine-3,2'-inden]-l- yl)methyl)cyclopropanecarboxylic acid

52 l-((5'-(4-((3-chlorobenzyl)oxy)phenyl)-l',3'- B > 1 μΜ > 1 μΜ < 1 μΜ dihydrospiro[azetidine-3,2'-inden]-l- yl)methyl)cyclopropanecarboxylic acid

53 l-((5'-(4-(benzyloxy)phenyl)-l',3'- C > 1 μΜ < 1 μΜ dihydrospiro[azetidine-3,2'-inden]-l- yl)methyl)cyclopropanecarboxylic acid

54 l-((5'-phenethoxy-l',3'-dihydrospiro[azetidine- D > 1 μΜ < 1 μΜ

3,2'-inden]-l-yl)methyl)cyclopropanecarboxylic

acid

55 1 - ((5'- (4-chlorophenethoxy) - ,3' - D > 1 μΜ < 1 μΜ dihydrospiro[azetidine-3,2'-inden]-l- yl)methyl)cyclopropanecarboxylic acid

56 1 - ((5'- (2- (trifluoromethyl)phenethoxy) - 1' ,3' - B > 1 μΜ < 1 μΜ dihydrospiro[azetidine-3,2'-inden]-l- yl)methyl)cyclopropanecarboxylic acid

57 1 - ((5' - (3 - chlorophenethoxy) - 1 ' , 3' - C < 1 μΜ < 1 μΜ dihydrospiro[azetidine-3,2'-inden]-l- yl)methyl)cyclopropanecarboxylic acid

58 1 - ((5' - (2 - chlorophenethoxy) - 1 ', 3' - C > 1 μΜ < 1 μΜ dihydrospiro[azetidine-3,2'-inden]-l- yl)methyl)cyclopropanecarboxylic acid

59 l-((5'-(2,6-dichlorophenethoxy)-l',3'- A > 1 μΜ > 1 μΜ < 1 μΜ dihydrospiro[azetidine-3,2'-inden]-l- Ex. Name S1P5 SlPl S1P3 S1P4

EC50 EC50 EC50 EC50 range

#

yl)methyl)cyclopropanecarboxylic acid

60 2-(5'-phenethoxy-l',3'-dihydrospiro[azetidine-3,2'- D > 1 μΜ > 1 μΜ inden]-l-yl)acetic acid

61 2-(5'-(2-chlorophenethoxy)-l',3'- B > 1 μΜ < 1 μΜ dihydrospiro[azetidine-3,2'-inden]-l-yl)acetic acid

62 2-(5'-(2-chlorophenethoxy)-l',3'- A > 1 μΜ > 1 μΜ < 1 μΜ dihydrospiro[azetidine-3,2'-inden]-l-yl)acetic acid

63 2-(5'-(2,6-dichlorophenethoxy)-l',3'- A > 1 μΜ > 1 μΜ < 1 μΜ dihydrospiro[azetidine-3,2'-inden]-l-yl)acetic acid

64 4-(5'-((2-chloro-6-ethylbenzyl)oxy)-l ^, ,3'- A > 1 μΜ < 1 μΜ dihydrospiro[azetidine-3,2'-inden]-l-yl)-3- methylbutanoic acid

65 4-(5'-((2-ethyl-6-fluorobenzyl)oxy)-l ^, ,3'- B > 1 μΜ < 1 μΜ dihydrospiro[azetidine-3,2'-inden]-l-yl)-3- methylbutanoic acid

66 2-(5'-((2,3-dihydro-lH-inden-l-yl)oxy)-l ^, ,3'- A > 1 μΜ < 1 μΜ dihydrospiro[azetidine-3,2'-inden]-l-yl)acetic acid

67 2-(5'-((7-chloro-2,3-dihydro-lH-inden-l-yl)oxy)- A > 1 μΜ < 1 μΜ l',3'-dihydrospiro[azetidine-3,2'-inden]-l-yl)acetic

acid

68 2-(5'-((5-bromo-7-fluoro-2,3-dihydro-lH-inden-l- A > 1 μΜ < 1 μΜ yl)oxy)-l',3'-dihydrospiro[azetidine-3,2'-inden]-l- yl)acetic acid

69 2-(5'-((5,7-dichloro-2,3-dihydro-lH-inden-l- A > 1 μΜ < 1 μΜ yl)oxy)-l',3'-dihydrospiro[azetidine-3,2'-inden]-l- yl)acetic acid

70 2-(5'-(2-phenoxyethoxy)-l',3'- C > 1 μΜ < 1 μΜ dihydrospiro[azetidine-3,2'-inden]-l-yl)acetic acid

71 2-(5'-(2-(4-chlorophenoxy)ethoxy)-l',3'- D > 1 μΜ > 1 μΜ dihydrospiro[azetidine-3,2'-inden]-l-yl)acetic acid

72 2-(5'-((2,3-dihydrobenzofuran-7-yl)methoxy)-l',3'- C > 1 μΜ < 1 μΜ dihydrospiro[azetidine-3,2'-inden]-l-yl)acetic acid

73 2-(5'-((2,3-dihydro-lH-inden-2-yl)oxy)-l ^, ,3'- C > 1 μΜ < 1 μΜ dihydrospiro[azetidine-3,2'-inden]-l-yl)acetic acid

74 2-(5 ^, -((2,3-dihydro-lH-inden-4-yl)methoxy)-l ^, ,3'- A > 1 μΜ < 1 μΜ dihydrospiro[azetidine-3,2'-inden]-l-yl)acetic acid

75 2-(5'-((6-isopropoxypyridin-3-yl)ethynyl)-l',3'- A < 1 μΜ > 1 μΜ dihydrospiro[azetidine-3,2'-inden]-l-yl)acetic acid

76 2-(5'-((4-methylcyclohexyl)ethynyl)-l ^, ,3'- A > 1 μΜ < 1 μΜ dihydrospiro[azetidine-3,2'-inden]-l-yl)acetic acid

77 2-(5'-((4-ethoxyphenyl)ethynyl)-l',3'- A < 1 μΜ < 1 μΜ dihydrospiro[azetidine-3,2'-inden]-l-yl)acetic acid

78 2- (5'- ((6- (cyclopentyloxy)pyridin- 3-yl)ethynyl) - A < 1 μΜ < 1 μΜ l',3'-dihydrospiro[azetidine-3,2'-inden]-l-yl)acetic

acid

79 2- (5'-((6-((l,l,l-trifl.uoropropan-2-yl)oxy)pyridin- A < 1 μΜ < 1 μΜ

3- yl)ethynyl)-l',3'-dihydrospiro[azetidine-3,2'- inden]-l-yl)acetic acid

80 2-(5'-((2-chlorophenyl)ethynyl)-l',3'- A > 1 μΜ < 1 μΜ Ex. Name S1P5 SlPl S1P3 S1P4

EC50 EC50 EC50 EC50 range

#

dihydrospiro[azetidine-3,2'-inden]-l-yl)acetic acid

81 2-(5'-((2-fluoro-4-methoxyphenyl)ethynyl)-l',3'- dihydrospiro[azetidine-3,2'-inden ^" |-l-yl)acetic acid

82 2-(5'-(phenylethynyl)-l',3'-dihydrospiro[azetidine- B > 1 μΜ < 1 μΜ 3,2'-inden]-l-yl)acetic acid

83 3-(5 ^, -((2,3-dihydro-lH-inden-4-yl)methoxy)-l ^, ,3'- B > 1 μΜ < 1 μΜ dihydrospiro[azetidine-3,2'-inden]-l- yl)cyclobutanecarboxylic acid

84 3-(5'-((4-(cyclopropylmethoxy)benzyl)oxy)-l',3'- D > 1 μΜ > 1 μΜ dihydrospiro[azetidine-3,2'-inden]-l- yl)cyclobutanecarboxylic acid

85 3-(5 (4-ethoxy-2,6-difluorobenzyl)oxy)-l',3'- D > 1 μΜ < 1 μΜ dihydrospiro[azetidine-3,2'-inden]-l- yl)cyclobutanecarboxylic acid

86 3-(5 (4-ethoxy-2,3-difluorobenzyl)oxy)-l',3'- D > 1 μΜ < 1 μΜ dihydrospiro[azetidine-3,2'-inden]-l- yl)cyclobutanecarboxylic acid

87 3-(5'-((2-cyclopropyl-6-£luorobenzyl)oxy)-l',3'- A > 1 μΜ < 1 μΜ dihydrospiro[azetidine-3,2'-inden]-l- yl)cyclobutanecarboxylic acid

88 3-(5'-((6-methoxy-2-methylpyridin-3-yl)methoxy)- D > 1 μΜ < 1 μΜ l',3'-dihydrospiro[azetidine-3,2'-inden]-l- yl)cyclobutanecarboxylic acid

89 (lr,3r)-3-(5 ^, -((2,5-dichlorobenzyl)oxy)-l ^, ,3'- B > 1 μΜ < 1 μΜ dihydrospiro[azetidine-3,2'-inden]-l- yl)cyclobutanecarboxylic acid

90 (ls,3s)-3-(5 ^, -((2,5-dichlorobenzyl)oxy)-l ^, ,3'- C > 1 μΜ < 1 μΜ dihydrospiro[azetidine-3,2'-inden]-l- yl)cyclobutanecarboxylic acid

91 3-(5'-((2-chloro-6-cyclopropylbenzyl)oxy)-l',3'- A < 1 μΜ < 1 μΜ dihydrospiro[azetidine-3,2'-inden]-l- yl)cyclobutanecarboxylic acid

92 S-CB'-^^-dichlorobenzy^oxy)-!'^'- A > 1 μΜ < 1 μΜ dihydrospiro[azetidine-3,2'-inden]-l- yl)cyclobutanecarboxylic acid

93 S-CB'-^^-dichlorobenzy^oxy)-!'^'- B > 1 μΜ < 1 μΜ dihydrospiro[azetidine-3,2'-inden]-l- yl)cyclobutanecarboxylic acid

94 S-CB'-^-chloro-e-ethylbenzy^oxy)-!'^'- A < 1 μΜ < 1 μΜ dihydrospiro[azetidine-3,2'-inden]-l- yl)cyclobutanecarboxylic acid

95 3- (5'- ((6- (cyclopentyloxy)pyridin- 3-yl)ethynyl) - A < 1 μΜ < 1 μΜ l',3'-dihydrospiro[azetidine-3,2'-inden]-l- yl)cyclobutanecarboxylic acid

96 3-(5'-((6-isopropoxypyridin-3-yl)ethynyl)-l',3'- B < 1 μΜ > 1 μΜ dihydrospiro[azetidine-3,2'-inden]-l- yl)cyclobutanecarboxylic acid

97 3-(5'-((4-isopropoxyphenyl)ethynyl)-l',3'- A < 1 μΜ > 1 μΜ dihydrospiro[azetidine-3,2'-inden]-l- Ex. Name S1P5 SlPl S1P3 S1P4

EC50 EC50 EC50 EC50 range

#

yl)cyclobutanecarboxylic acid

98 3-(5'-((4-ethoxyphenyl)ethynyl)-l',3'- B < 1 μΜ > 1 μΜ dihydrospiro[azetidine-3,2'-inden]-l- yl)cyclobutanecarboxylic acid

99 3-(5'-((6-(cyclopropylmethoxy)pyridin-3- C < 1 μΜ > 1 μΜ yl)ethynyl)-l',3'-dihydrospiro[azetidine-3,2'- inden] - l-yl)cyclobutanecarboxylic acid

100 S-CB'-^-ethoxy-S-fluoropheny^ethynyl)-!'^'- A < 1 μΜ > 1 μΜ dihydrospiro[azetidine-3,2'-inden]-l- yl)cyclobutanecarboxylic acid

101 3-(5'-((4-methoxy-2-methylphenyl)ethynyl)-l',3'- D > 1 μΜ < 1 μΜ dihydrospiro[azetidine-3,2'-inden]-l- yl)cyclobutanecarboxylic acid

102 3-(5'-((4-methylcyclohexyl)ethynyl)-l',3'- A > 1 μΜ < 1 μΜ dihydrospiro[azetidine-3,2'-inden]-l- yl)cyclobutanecarboxylic acid

103 3-(5'-((6-((l,l,l-trifluoropropan-2-yl)oxy)pyridin- A < 1 μΜ < 1 μΜ 3-yl)ethynyl)-l',3'-dihydrospiro[azetidine-3,2'- inden] - l-yl)cyclobutanecarboxylic acid

104 3-(5 (2,3-dihydro-lH nden-l-yl)oxy)-l',3'- A > 1 μΜ < 1 μΜ dihydrospiro[azetidine-3,2'-inden]-l- yl)cyclobutanecarboxylic acid

105 3-(5'-(2-(trifluoromethyl)phenethoxy)-l',3'- D > 1 μΜ < 1 μΜ dihydrospiro[azetidine-3,2'-inden]-l- yl)cyclobutanecarboxylic acid

106 3-(5'-((7-chloro-2,3-dihydro-lH-inden-l-yl)oxy)- A < 1 μΜ < 1 μΜ l',3'-dihydrospiro[azetidine-3,2'-inden]-l- yl)cyclobutanecarboxylic acid

107 3-(5 (4-ethoxy-3,5-difluorobenzyl)oxy)-l',3'- dihydrospiro[azetidine-3,2'-inden]-l- yl)cyclobutanecarboxylic acid

108 1 - ((5'- (4- ((4-chlorobenzyl)oxy)phenyl) - , 3'- B > 1 μΜ > 1 μΜ > 1 μΜ dihydrospiro[azetidine-3,2'-inden]-l- yl)methyl)cyclopropanecarboxylic acid

109 2-(5'-((2,6-dichlorobenzyl)oxy)-l ^, ,3'- A > 1 μΜ > 1 μΜ < 1 μΜ dihydrospiro[azetidine-3,2'-inden]-l-yl)acetic acid

110 2-(5'-((2-cyclopropyl-6-£luorobenzyl)oxy)-l',3'- A > 1 μΜ > 1 μΜ < 1 μΜ dihydrospiro[azetidine-3,2'-inden]-l-yl)acetic acid

111 2-(5'-((2-cyclopropylbenzyl)oxy)-l',3'- A > 1 μΜ > 1 μΜ < 1 μΜ dihydrospiro[azetidine-3,2'-inden]-l-yl)acetic acid

112 1 - ((5'- ((4-ethoxyphenyl)ethynyl) - V ,3' - C > 1 μΜ > 1 μΜ dihydrospiro[azetidine-3,2'-inden]-l- yl)methyl)cyclopropanecarboxylic acid

113 l-((5'-((4-isopropoxyphenyl)ethynyl)-l',3'- A < 1 μΜ > 1 μΜ dihydrospiro[azetidine-3,2'-inden]-l- yl)methyl)cyclopropanecarboxylic acid

114 l-((5'-((6-isopropoxypyridin-3-yl)ethynyl)-l',3'- C > 1 μΜ > 1 μΜ dihydrospiro[azetidine-3,2'-inden]-l- yl)methyl)cyclopropanecarboxylic acid Ex. Name S1P5 SlPl S1P3 S1P4

EC50 EC50 EC50 EC50 range

#

115 l-((5'-((4-methylcyclohexyl)ethynyl)-l',3'- A > 1 μΜ < 1 μΜ dihydrospiro[azetidine-3,2'-inden]-l- yl)methyl)cyclopropanecarboxylic acid

116 1 - ((5' - ((6- (cyclopentyloxy)pyridin - 3 -yl) ethynyl) - B > 1 μΜ > 1 μΜ l',3'-dihydrospiro[azetidine-3,2'-inden]-l- yl)methyl)cyclopropanecarboxylic acid

117 l-((5'-((6-((l,l,l-trifl.uoropropan-2-yl)oxy)pyridin- A < 1 μΜ > 1 μΜ 3-yl)ethynyl)-l',3'-dihydrospiro[azetidine-3,2'- inden] - l-yl)methyl)cyclopropanecarboxylic acid

118 l-((5'-((4-methoxy-2-methylphenyl)ethynyl)-l',3'- D > 1 μΜ < 1 μΜ dihydrospiro[azetidine-3,2'-inden]-l- yl)methyl)cyclopropanecarboxylic acid

119 l-((5'-(2-(6-isopropoxypyridin-3-yl)ethyl)-l',3'- D > 1 μΜ > 1 μΜ dihydrospiro[azetidine-3,2'-inden]-l- yl)methyl)cyclopropanecarboxylic acid

120 l-((5 (4-ethoxy-3,5-difluorobenzyl)oxy)- r,3'- D > 1 μΜ < 1 μΜ dihydrospiro[azetidine-3,2'-inden]-l- yl)methyl)cyclopropanecarboxylic acid

121 l-((5'-((6-methoxy-2-methylpyridin-3- D > 1 μΜ > 1 μΜ yl)methoxy)-l',3'-dihydrospiro[azetidine-3,2'- inden] - l-yl)methyl)cyclopropanecarboxylic acid

122 l-((5 (4-ethoxy-2,6-difluorobenzyl)oxy)- r,3'- D > 1 μΜ < 1 μΜ dihydrospiro[azetidine-3,2'-inden]-l- yl)methyl)cyclopropanecarboxylic acid

123 l-((5 (4-ethoxy-2,3-difluorobenzyl)oxy)- r,3'- D > 1 μΜ < 1 μΜ dihydrospiro[azetidine-3,2'-inden]-l- yl)methyl)cyclopropanecarboxylic acid

124 l-CCB'-^^-dichloropyridin-S-y^methoxy)-!'^'- D > 1 μΜ < 1 μΜ dihydrospiro[azetidine-3,2'-inden]-l- yl)methyl)cyclopropanecarboxylic acid

125 l-CCB'-^^-dihydro-lH-inden^-y^methoxy)-!'^'- B > 1 μΜ < 1 μΜ dihydrospiro[azetidine-3,2'-inden]-l- yl)methyl)cyclopropanecarboxylic acid

126 l-((5'-(cyclohexylmethoxy)-l',3'- C > 1 μΜ < 1 μΜ dihydrospiro[azetidine-3,2'-inden]-l- yl)methyl)cyclopropanecarboxylic acid

127 l-CCB'-^^-dihydro-lH-inden^-y^oxy)-!'^'- D > 1 μΜ < 1 μΜ dihydrospiro[azetidine-3,2'-inden]-l- yl)methyl)cyclopropanecarboxylic acid

128 l-((5'-((4-(cyclopropylmethoxy)benzyl)oxy)-l',3'- D > 1 μΜ > 1 μΜ dihydrospiro[azetidine-3,2'-inden]-l- yl)methyl)cyclopropanecarboxylic acid

129 l-((5'-((7-chloro-2,3-dihydro-lH-inden-l-yl)oxy)- A > 1 μΜ < 1 μΜ l',3'-dihydrospiro[azetidine-3,2'-inden]-l- yl)methyl)cyclopropanecarboxylic acid

130 l-CCB'-^^-dihydro-lH-inden-l-y^oxy)-!'^'- D > 1 μΜ < 1 μΜ dihydrospiro[azetidine-3,2'-inden]-l- yl)methyl)cyclopropanecarboxylic acid

131 l-((5'-((2-cyclopropyl-6-£luorobenzyl)oxy)-l',3'- A > 1 μΜ < 1 μΜ Ex. Name S1P5 SlPl S1P3 S1P4

EC50 EC50 EC50 EC50 range

#

dihydrospiro[azetidine-3,2'-inden]-l- yl)methyl)cyclopropanecarboxylic acid

132 l-((5'-(2-cyclohexylethoxy)-l ^, ,3'- D > 1 μΜ < 1 μΜ dihydrospiro[azetidine-3,2'-inden]-l- yl)methyl)cyclopropanecarboxylic acid

133 l-((5'-((4-methylbenzyl)oxy)- r,3'- dihydrospiro[azetidine-3,2'-inden]-l- yl)methyl)cyclopropanecarboxylic acid

134 l-((5'-(2-methylphenethoxy)-l',3'- D > 1 μΜ < 1 μΜ dihydrospiro[azetidine-3,2'-inden]-l- yl)methyl)cyclopropanecarboxylic acid

135 1 - ((5' - (4- methoxyphenethoxy) - 1 ' , 3' - D > 1 μΜ > 1 μΜ dihydrospiro[azetidine-3,2'-inden]-l- yl)methyl)cyclopropanecarboxylic acid

136 l-((5 ^, -(2-fluorophenethoxy)-l ^, ,3'- D > 1 μΜ < 1 μΜ dihydrospiro[azetidine-3,2'-inden]-l- yl)methyl)cyclopropanecarboxylic acid

137 l-((5 ^, -(4-fluorophenethoxy)-l ^, ,3'- D > 1 μΜ < 1 μΜ dihydrospiro[azetidine-3,2'-inden]-l- yl)methyl)cyclopropanecarboxylic acid

138 l-((5'-((2-methylbenzyl)oxy)- r,3'- D > 1 μΜ < 1 μΜ dihydrospiro[azetidine-3,2'-inden]-l- yl)methyl)cyclopropanecarboxylic acid

139 l-((5'-((4-methoxybenzyl)oxy)-l',3'- D > 1 μΜ > 1 μΜ dihydrospiro[azetidine-3,2'-inden]-l- yl)methyl)cyclopropanecarboxylic acid

140 l-((5 (2-fluorobenzyl)oxy)-l',3'- D > 1 μΜ > 1 μΜ dihydrospiro[azetidine-3,2'-inden]-l- yl)methyl)cyclopropanecarboxylic acid

141 l-CCS'-^-chlorobenzy^oxy)-!'^'- D > 1 μΜ < 1 μΜ dihydrospiro[azetidine-3,2'-inden]-l- yl)methyl)cyclopropanecarboxylic acid

142 1 - ((5'- ((4-cyanobenzyl)oxy) - V, 3'- D > 1 μΜ > 1 μΜ dihydrospiro[azetidine-3,2'-inden]-l- yl)methyl)cyclopropanecarboxylic acid

143 l-((5'-(benzo[d] [l,3]dioxol-5-ylmethoxy)-l ^, ,3'- D > 1 μΜ < 1 μΜ dihydrospiro[azetidine-3,2'-inden]-l- yl)methyl)cyclopropanecarboxylic acid

144 l-((5'-(2-(lH-indol-3-yl)ethoxy)-l ^, ,3'- D > 1 μΜ > 1 μΜ dihydrospiro[azetidine-3,2'-inden]-l- yl)methyl)cyclopropanecarboxylic acid

145 l-((5'-(2-(2-chlorophenoxy)ethoxy)-l',3'- D > 1 μΜ < 1 μΜ dihydrospiro[azetidine-3,2'-inden]-l- yl)methyl)cyclopropanecarboxylic acid

146 l-((5'-(3-(6-methylpyridin-2-yl)propoxy)-l',3'- D > 1 μΜ > 1 μΜ dihydrospiro[azetidine-3,2'-inden]-l- yl)methyl)cyclopropanecarboxylic acid

147 l-^'-CCS-cyanobenzy^oxy)-!'^'- C > 1 μΜ < 1 μΜ dihydrospiro[azetidine-3,2'-inden]-l- Ex. Name S1P5 SlPl S1P3 S1P4

EC50 EC50 EC50 EC50 range

#

yl)methyl)cyclopropanecarboxylic acid

148 l-((5'-(3-fluorophenethoxy)-r,3'- D > 1 μΜ < 1 μΜ dihydrospiro[azetidine-3,2'-inden]-l- yl)methyl)cyclopropanecarboxylic acid

149 2-(6'-((4-chlorophenyl)ethynyl)-3'H- D > 1 μΜ > 1 μΜ spiro[azetidine-3,2'-benzofuran]-l-yl)acetic acid

150 2-(6'-(cyclohexylethynyl)-3'H-spiro[azetidine-3,2'- A > 1 μΜ < 1 μΜ benzofuran]-l-yl)acetic acid

151 2-(6'-(phenylethynyl)-3'H-spiro[azetidine-3,2'- A > 1 μΜ < 1 μΜ benzofuran]-l-yl)acetic acid

152 2-(6'-((3-chlorophenyl)ethynyl)-3'H- A > 1 μΜ < 1 μΜ spiro[azetidine-3,2'-benzofuran]-l-yl)acetic acid

153 2-(6'-((2-chlorophenyl)ethynyl)-3'H- A > 1 μΜ < 1 μΜ spiro[azetidine-3,2'-benzofuran]-l-yl)acetic acid

154 2-(6'-((4-ethoxyphenyl)ethynyl)-3'H- B < 1 μΜ > 1 μΜ spiro[azetidine-3,2'-benzofuran]-l-yl)acetic acid

155 2-(6'-((4-methylcyclohexyl)ethynyl)-3'H- C > 1 μΜ < 1 μΜ spiro[azetidine-3,2'-benzofuran]-l-yl)acetic acid

156 l-((6'-((2-chloro-6-ethylbenzyl)oxy)-3'H- A > 1 μΜ < 1 μΜ spiro [azetidine- 3,2' -benzofuran] - 1 - yl)methyl)cyclopropanecarboxylic acid

157 4-(6'-((2-chloro-6-ethylbenzyl)oxy)-3'H- A > 1 μΜ < 1 μΜ spiro [azetidine- 3,2' -benzofuran] - 1 -yl) - 3- methylbutanoic acid

158 2-(6'-((2-chloro-6-ethylbenzyl)oxy)-3'H- A < 1 μΜ < 1 μΜ spiro[azetidine-3,2'-benzofuran]-l-yl)acetic acid

159 2-(5-((2-ethyl-6-fluorobenzyl)oxy)-l,3- A > 1 μΜ > 1 μΜ < 1 μΜ dihydrospiro [indene-2,4'-piperidin]-l'-yl)acetic

acid

160 2-(5-((2,6-dichlorobenzyl)oxy)-l,3- A > 1 μΜ > 1 μΜ < 1 μΜ dihydrospiro [indene-2,4'-piperidin]-l'-yl)acetic

acid

161 2-(5-((2-chloro-6-ethylbenzyl)oxy)-l,3- A > 1 μΜ > 1 μΜ < 1 μΜ dihydrospiro [indene-2,4'-piperidin]-l'-yl)acetic

acid

D: 1 μΜ EC50 < EC50 < 10 μΜ